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A I M  
Blinding disorders are estimated to affect 1 in 2000 individuals world-wide and can be seriously 
debilitating if progressed into an advanced stage. Due to recent advancements in molecular biology 
and genotyping, several of these ocular dystrophies have been linked to genetic defects in the retinal 
cells. Therefore, gene therapy could offer a curative treatment for these hereditary diseases. The 
major hurdle in gene therapy, however, remains the delivery of intact nucleic acids (NAs) to the 
target tissue. The most successful way of achieving this to date is the use of recombinant viral 
vectors that can deliver the therapeutic NAs into the target cells. However, several limitations have 
prompted the development of nonviral alternatives, which should be cheaper to produce, less 
immunogenic, more versatile and with a higher NA loading capacity. A particular advantage of these 
nonviral delivery vectors is that their surface can be easily modified either with polyethylene glycol 
(PEG) to prevent unwanted interactions with constituents of the extracellular matrix, or on the other 
hand with ligands for specific cellular targeting to diseased cells. 
Delivery of these nonviral gene nanomedicines to the retina poses some additional problems. 
Intravenous administration is not an efficient option, since the eye is isolated from systemic 
circulation by the blood-retinal barrier (BRB), blocking transport of high molecular weight 
therapeutics from the bloodstream to the retina. Topical instillation of nanoparticles is also known to 
result in highly inefficient delivery to the retina, due to the limited residence time on the corneal 
surface and the barriers posed by the corneal epithelium and conjunctiva. Therefore, intraocular 
administration routes are preferred. To date, subretinal injection has proven to be most efficient at 
transgene delivery, however, the complexity and invasiveness of this procedure limit its use on a 
large scale. Intravitreal injection on the other hand, represents an attractive alternative route of 
administration as it is a widely-used approach in the clinic for treatment of retinal and choroidal 
neovascularization.  
In this thesis, the aim is to investigate whether intravitreal injection of gene nanomedicines can be a 
suitable route of administration for retinal gene therapy. A representative ex vivo model system will 
be developed to investigate the mobility of nanoparticles in the vitreous humor. The influence of 
nanoparticle size and surface functionalization on their mobility in vitreous humor will be 
investigated. This will initially be done by employing model nanoparticles, followed by actual 
polymeric and lipid gene nanocarriers. Special attention will go to finding a suitable surface coating 
of gene complexes that provides them with excellent intravitreal mobility while retaining the 
capability to transfect retinal pigment epithelium (RPE) cells.  
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O U T L I N E  
Chapter 1 provides an overview of the anatomy of the eye and the application of nanomedicines to 
retinal gene therapy. The potential targets for retinal gene therapy are highlighted, followed by an 
overview of the different barriers that need to be overcome in order to deliver the therapeutic NAs 
to the retinal target cells. A final section will motivate the use of intravitreal injection as a suitable 
administration route for gene therapy for hereditary ocular disorders. In Chapter 2, we propose a 
novel ex vivo eye model to measure the mobility of nanoparticles in intact vitreous humor. By using 
excised bovine eyes and only removing the anterior components of the eye, we are able to use high-
resolution video microscopy to visualize the mobility of fluorescently labeled nanoparticles in intact 
bovine vitreous humor. By applying single particle tracking (SPT) analysis, detailed information can be 
obtained regarding the mobility of the nanoparticle population. In Chapter 3, an introduction is 
provided on the use of hyaluronic acid (HA) in the context of drug delivery. This is because in 
Chapter 4 we will evaluate the use of HA as a potential electrostatic surface coating of polymeric 
gene complexes, to ensure excellent mobility of the nanoparticles in vitreous humor while retaining 
the capacity to transfect RPE cells in vitro. In Chapter 5 the suitability for intravitreal injection is 
compared between an electrostatic and covalent HA coating of lipid gene nanomedicines. Again, 
complexation efficiency, intravitreal mobility and in vitro transfection and uptake efficiency are 
investigated. Furthermore, an in vivo experiment is carried out with these gene complexes to study 
retinal permeation after intravitreal injection in mice. Finally, in Chapter 6 we turn our attention to 
the intracellular processing of gene complexes. One of the major barriers for gene therapy is the 
endosomal sequestration, where nucleic acids are prevented from exerting a therapeutic effect due 
to the inability to escape from the endosomes into the cytoplasm. A major difficulty in the rational 
development of nanomedicines with improved endosomal escape properties is the lack of methods 
to investigate this particular intracellular barrier. Therefore, in Chapter 6 we provide a thorough 
review on methods that can be used to study endosomal escape. In Chapter 7, a brief outlook is 
given on the future and potential applications of retinal gene therapy. 
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N A N O M E D I C I N E  
Delivery of therapeutics remains a challenging endeavor. For example, cytotoxic chemotherapeutics 
are still being delivered systemically, effectively ‘poisoning’ the entire body, only to treat a relatively 
small diseased tissue. It has been established that efficient delivery of therapeutics contributes 
 
Figure 1.1 | Size range of nanoparticles for biomedical use 7 
 
Chapter 1 
Page 4   
significantly to the overall outcome of therapeutic treatment. Already in the beginning of the 20th 
century, Paul Ehrlich coined the term ‘magic bullet’, by which he meant a pharmaceutical entity, able 
to deliver toxins in a specific and targeted manner to disease-causing pathogens, without affecting or 
interfering with the patient’s healthy tissue. The first realizations of this concept were published in 
the 1970s 3, 4, where small molecule therapeutics were packaged in submicron sized lipid 
nanoparticles.  
This has led to a surge of various kinds of nanoparticulate systems for drug delivery, such as 
liposomes 5, 6, polymers 10, as well as fullerenes and carbon nanotubes 12 (Figure 1.1). These 
discoveries are further backed by continued advances in the field of nanomedicine, situated at the 
crossroads of different fields such as engineering, (bio)chemistry, physics, cell and molecular biology, 
pharmaceutics and medicine. By smart engineering, nanomedicines can be tuned to fulfill various 
needs: they can be used to (i) increase the solubility of hydrophobic drugs, (ii) increase residence 
time in systemic circulation by evading the complement system or renal clearance, (iii) deliver 
therapeutics specifically to diseased tissues by passive or active targeting, (iv) provide a 
sustained/controlled drug release profile, (v) increase stability of large molecular weight 
(bio)pharmaceuticals such as enzymes and nucleic acids (NAs) in extracellular matrices, (vi) increase 
cellular uptake of large hydrophilic therapeutics and (vii) respond to external stimuli and triggers to 
deliver therapeutics in a spatiotemporal controlled manner. 
G E N E  T H E R A P Y  
SHORT HISTORY AND GENERAL INTRODUCTION 
After the postulation of the double-helix structure of DNA in the 1950s by Watson & Crick, the idea 
of gene replacement for the treatment of hereditary disorders followed suit. Advancements in 
molecular biology, such as the development of virus-based systems for transforming mammalian 
cells in the 1960s and the advent of recombinant DNA technology in the 1970s, encouraged 
researchers to advance gene therapy into clinical trials as soon as possible 13, 14. The first successful 
gene therapy clinical trial in 1990 reported increased levels of immune reconstitution in several 
children with X-linked severe combined immunodeficiency (SCID) after gammaretroviral delivery of 
adenosine deaminase into T-lymphocytes. The unbridled enthusiasm and optimism, however, soon 
made way for caution when two patients were later on diagnosed with leukemia 15. Gene therapy 
was regarded as even more dangerous in the public eye after the death of Jesse Gelsinger due to 
fatal systemic inflammatory response to the viral delivery vector in a clinical trial for ornithine 
  Chapter 1 
  Page 5 
transcarbamylase deficiency 16. These events raised ethical and safety concerns about the use of viral 
vectors and gene therapy in general, and after that, advances have been slow and cautious. 
Nevertheless, nearly 15 years later, hope for the clinical application of gene therapy is again firmly 
established in the scientific and medical communities. Indeed, although 3 gene therapy products 
have already been approved in China (Gendicine, 2003 17 and Oncorine, 2005 18) and Russia 
(Neovasculgen®, 2011), it was the European Commission’s approval for clinical use of Glybera® in the 
EU in 2012 that has been regarded as a first major success for gene therapy. Glybera®, the brand 
name for alipogene tiparvovec, is designed to treat patients suffering from lipoprotein lipase 
deficiency, by introducing a functional lipoprotein lipase protein by viral transduction. The fact that 
already four gene therapy products have been approved by regulatory agents world-wide, does 
indeed bode well for the future of gene therapy.  
Gene therapy offers the ability to cure those dystrophies with known genetic causes, that otherwise 
could only be managed by symptomatic treatment. The genetic mutations resulting in such 
dystrophies, however, can be very diverse and appropriate gene therapy strategies should be applied. 
When functionality of a protein is lost due to mutations in a recessive gene or by a dominant 
negative mutation such as haploinsufficiency, gene supplementation therapy is the preferred 
method of treatment. By supplementing a functional transgene and restoring functional protein 
levels in the target tissue, the diseased phenotype could be reverted to a healthy state. Gene 
supplementation therapy can be achieved by delivering the therapeutic NA via viral vectors, stably 
integrating the gene in the target genome for long-term expression, or leaving the therapeutic gene 
in the target cells as episomes for a transient expression. Alternatively, therapeutic genes can be 
cloned in bacterial plasmid DNA (pDNA), which can be delivered to the target cells with nonviral 
methods (see further on). The treatment becomes more complicated when a diseased phenotype 
arises due to a dominant toxic gain-of-function mutation. In this case, the mutated gene product 
should be silenced by using single-stranded antisense oligonucleotides (AONs) or RNA interference 
(RNAi). AONs can silence gene expression by sequence-specific binding to mRNA and inhibiting 
translation by steric hindrance as well as inducing degradation of the formed duplex by RNAse H 19. 
RNAi rather relies on the innate cellular system responsible for degrading double stranded RNA by 
the RNA induced silencing complex (RISC). When double-stranded small interfering RNA (siRNA) is 
delivered to the cell cytosol, it is recognized by RISC, denatured and used as a template for the 
degradation of sequence-similar mRNA. In some cases, a combination of both gene supplementation 
and silencing is required, where a toxic mutated protein should be silenced and a functional copy of 
said protein supplemented. Additional complexity in this scenario arises from allelic heterogeneity of 
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some mutated proteins and the fact that the supplemented transgene should be resistant to the 
silencing therapeutic 20.  
VECTORS 
The efficacy of gene therapy is largely dependent on the delivery of functional NAs to the correct 
target tissue. Since naked NAs have difficulty reaching the target cells and crossing the cellular 
membrane alone, they are guided to their target destination by NA delivery vectors or methods, 
which are highlighted in the next section.  
Viral vectors 
Adeno-viruses are non-enveloped viruses with an icosahedral capsid. They contain a large, linear 
double-stranded DNA genome which provides the vector, when stripped, with a potential cargo 
capacity of 37 kb. However, the advantage of this large cargo capacity is countered by its relatively 
large (+/- 100 nm) size, possibly affecting its distribution by steric hindrance 21. Adeno-viruses can 
transduce both dividing and non-dividing cells. As the transgene is not integrated in the host genome 
but rather exists as an extragenomic episome, there is a decreased risk of insertional mutagenesis. 
However, adeno-viruses are highly immunogenic and cause tissue inflammation 16. Furthermore, 
though gene expression has a relatively fast onset (+/- 48 hours after administration), it is very 
transient and usually only lasts several weeks. This transient gene expression is thought to result in 
part by the T-cell mediated Th2 humoral response 22. 
Adeno-associated viruses (AAVs) are small (25 nm in size), non-enveloped  icosahedral parvoviruses 
which have a linear single-stranded DNA genome of ~4.7 kb. There are several different AAV 
serotypes known, differing from each other based on capsid protein. These capsid proteins can 
interact with different cell receptors, ultimately determining their cell tropism and transduction 
efficacy. They are the favoured choice for retinal gene therapy, as it has been shown that several AAV 
serotypes (2/5/8) are very efficient at transducing retinal cells 23. Furthermore, they exhibit very low 
immunogenicity and are capable of transducing both dividing and non-dividing cells. Similar to 
adeno-viruses, their cargo does not integrate but rather exists as extragenomic circular episomes, 
resulting in a decreased risk of insertional mutagenesis. (some AAVs do integrate, but at specified 
locations, not random. Recombinant AAVs are tailored not to integrate whatsoever.) 
Lentiviruses are enveloped retroviruses with a single-stranded RNA genome, e.g. the human 
immunodeficiency virus type 1 (HIV-1). They have a cargo capacity of about 8 kb, though they have a 
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rather large diameter of +/- 100 nm, possibly affecting tissue distribution by steric hindrance 22. They 
are very versatile since pseudotyping of the capsid proteins greatly enhances their tropism potential 
and because they can infect both dividing and non-dividing cells. They are known to integrate their 
cargo in the host genome, which can result in long-term expression of the transgene, but also 
increases the risk of random insertional mutagenesis.  
The herpes simplex virus is a DNA virus which has a natural tropism for neurons, explaining its use for 
transduction of the neural retina. It has a very large cargo capacity of +/- 30 kb and does not require 
cell division to integrate in the host genome. This implies long-term expression in non-dividing cells, 
though also an increased risk of random insertional mutagenesis. Also, these vectors are usually 
associated with significant tissue inflammation and cytotoxicity 24. 
Nonviral nanocarriers 
Even though most clinical success has been achieved with viral vectors, several limitations dictate the 
need for safer alternatives. The limited cargo capacity of the most efficient viral vectors and the risk 
of insertional mutagenesis are major concerns for their use in a clinical setting 24. Also, viral vectors 
have been associated with (severe) immunogenic responses 16, and systemic dissemination via the 
optic nerve after intraocular injection has been documented 25. Furthermore, the production of viral 
vectors requires controlled environments, and is thought to be expensive and very difficult to realize 
on a larger scale 24. Therefore, research is being focused on nonviral delivery methods of therapeutic 
NAs. Naked NAs can be delivered to target tissues but cellular uptake will be limited. Physical 
methods can be employed to aid in this cellular delivery, either forcing the NAs in the cell interior 
(e.g. gene gun 26, 27, iontophoresis 28) or by inducing temporary pores in the cell membrane, allowing 
the passive diffusion of the therapeutics in the cell interior (e.g. sonoporation 29, hydroporation 30,  
electroporation 31 or optoporation 32).  By using these physical stimuli, spatially controlled delivery 
can be attained in the target tissues. The field of nanomedicine and advanced drug delivery also 
greatly supported the evolution of nonviral nucleic acid delivery methods. Naked NAs are quickly 
broken down in the extracellular environment and have difficulty reaching and entering the target 
cells. Inspired by the viral vectors, therapeutic NAs are packaged in nanosized particles to protect 
them from degradation and aid in their cellular entry using endocytosis, the cell’s native endocytic 
uptake pathway 33. Even though these nonviral gene nanomedicines are at the moment not as 
efficient as viral vectors and lack inherent tropism for specific cell types, their safety profile, 
versatility and easy production on a large scale promote further research.  
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Liposomal gene delivery 
Liposomes are formed by self-assembly of amphiphilic lipid molecules dispersed in aqueous media. 
As the lipids each contain a hydrophilic head group and a hydrophobic tail, spherical bilayered 
structures are formed where the hydrocarbon tails face each other and the head groups face 
outward associating with the aqueous solution 34. The use of liposomes for the delivery of NAs, 
lipofection, was first introduced in 1987 35. Cationic liposomes, obtained by a mixture of lipids 
containing amine groups in the hydrophilic head group and helper lipids (e.g. cholesterol) were 
shown to form electrostatic complexes with negatively charged NAs. Commonly used cationic lipids 
are 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-di-O-octadecenyl-3-
trimethylammonium propane (DOTMA) (Figure 1.2). In these lipid/NA complexes, called lipoplexes, 
NAs are attached to the surface of the liposomes via electrostatic interactions, or possibly 
intercalated between different lipid bilayers 36. The cationic charge of the resulting lipoplexes enables 
them to attach to the negatively charged cell membrane, enhancing cellular uptake. However, the 
therapeutic cargo has to escape from the endosomes in order to exert their effect (also see Chapter 
6). To this effect, the neutral lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (Figure 1.2) 
is frequently included in the liposome composition, as it is thought to induce membrane 
destabilization at lower pH and promote endosomal escape 37. This versatility of lipoplexes is one of 
their major advantages, where different functionalities can be bestowed on the lipoplexes by adding 
modified lipids in the lipid bilayer. PEG chains attached to phosphatidylethanolamine-lipids (PE) can 
be incorporated to prevent unwanted interactions and endow the lipoplexes with so-called “stealth”-
 
Figure 1.2 | Chemical structure of DOTMA, DOTAP and DOPE. 
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characteristics. Additionally, lipids with covalently attached ligands can be used to target the 
lipoplexes to specific cell types and enhance cellular uptake. 
Polymeric gene delivery 
As an alternative for lipoplexes, cationic polymers have emerged as a second class of nonviral gene 
vectors. Similar to lipoplexes, the cationic polymers spontaneously form electrostatic complexes with 
anionic NAs, aptly called polyplexes. They can be designed to be biocompatible and are easy to 
produce on a large scale. The first polymer used for gene delivery was the linear polypeptide poly-L-
lysine (PLL). Its cationic charge ensured complexation with NAs and efficient uptake of the polyplexes 
in the cellular environment via endocytosis. However, escape from the acidifying endosomes 
towards the cellular environment was limited. Polyethylene imine (PEI) was introduced to circumvent 
the problem of endosomal entrapment. Its secondary amines ensure a cationic charge at neutral pH, 
and an additional buffering capacity over the physiological pH range found in the endosomal 
compartments, leading to a more efficient release due to the proton sponge effect (see Chapter 6). 
Initially, branched PEI (bPEI) was introduced because of its high buffering capacity, though it was 
soon discovered to be quite cytotoxic. Therefore, bPEI was modified into oligo-PEIs, also showing 
high endosomal release and high transfection efficiency with less cytotoxic effects. Other well-
studied gene delivery polymers are poly(amido amine) (PAMAM) dendrimers 38 and cyclodextrins 39. 
In order to improve on the biocompatibility of polymeric gene vectors, biodegradable polymers and 
natural polysaccharides, such as chitosan, dextran and hyaluronic acid have been introduced 40. 
Bioreducible polymers have also been proposed to decrease cytotoxicity.  Linear disulfide-based 
poly(amido amine)s (SS-pAAs) are synthesized by Michael-type poly-addition of 
cystaminebisacrylamide (CBA) monomers and amine-containing functional groups (Figure 1.3) 41. The 
disulfide bond is cleaved by reductive reactions in the cytosol due to high concentrations of 
glutathione (5 mM) and the presence of thioredoxine reductases 42. The synthesis of these 
bioreducible SS-pAAs is very simple and versatile, seeing as virtually any amine-containing monomer 
 
Figure 1.3 | General synthesis of bioreducible linear poly(amido amines) (SS-pAAs) by a Michael-
type poly-addition of cystaminbisacrylamide and amine-group containing functional group. 
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can be attached to the CBA backbone as a functional group. Upon addition of 4-aminobutal (ABOL), 
the polymer is endowed with buffering capacities around pH 6.5, resulting in high transfection 
efficiencies, possibly by enhanced endosomal escape.  
R E T I N A L  G E N E  T H E R A P Y  
ANATOMY OF THE EYE 
The eye is one of the most highly specialized organs in the human body, frequently heralded by 
creationists as proof that ‘such an elaborate and specialized organ could not have been created by 
evolution’. Even Charles Darwin wrote in his The Origin of Species that such evolution by natural 
selection would seem, at first glance, ‘absurd in the highest possible degree’, though he does 
continue with ‘the difficulty of believing a perfect and complex eye could be formed by natural 
selection, though insuperable by our imagination, should not be considered as subversive of the 
theory’. Though we have still not elucidated the full mechanism behind vision, nowadays we are able 
to appreciate the different complex structures that form the eye (Figure 1.4), and the advanced 
interplay between these different structures resulting in our ability to perceive the world around us.  
 
Figure 1.4 | Schematic representation of the anatomy of the eye. 
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Anterior segment 
The anterior part of the eye functions as a barrier for the outside environment, as well as the first 
steps in the optical cascade that enables us to see. The sclera, known as ‘the white of the eye’, 
provides the general structure and rigidity to the eye, as well as a firm barrier against outside 
pathogens or blunt force damage. The cornea is the transparent part of the sclera that lies in front of 
the lens and is connected to the sclera by the limbus. The cornea is the primary refractory element 
for focusing the incoming light on the retina. Indeed, it is estimated that two thirds of the light 
refraction necessary for focusing light on the retina occurs at the air-cornea interface. The lens, a 
crystalline gel like structure, accounts for the rest of the light refraction towards the retina. Its main 
objective is allowing our vision to focus on objects at varying distances. The ciliary muscles can 
change the shape of our lens, enabling us to focus on objects close to us (spherical lens), as well as 
objects further away (flattened lens). As we age, the hardening of the lens impairs our ability to focus 
at different distances. In front of the lens, the iris functions as a diaphragm, adjusting the amount of 
light entering the eyeball by opening and closing.  
Vitreous humor 
The vitreous humor is a transparent, hydrated biological matrix that occupies the largest part of the 
eye (approximately 80%). It is composed mainly of water (98 – 99%) with a 3-dimensional network of 
randomly spaced, non-branching collagen fibrils, of which collagen II is the most abundant 1. The 
collagen network provides mechanical strength to the eye. The distribution of collagen in the eye is 
not homogeneous (Figure 1.5), with the central vitreous comprising the lowest concentration of 
collagen, while the highest concentration is found in the periphery of the vitreous (called the vitreous 
cortex) 43. Interspersed between the collagen matrix are glycosaminoglycans (GAGs), with hyaluronic 
acid (HA) the predominant GAG in the mammalian vitreous humor. HA stabilizes the collagen 
network by ensuring hydration and inflation of the collagen fibrils. The spacing between the collagen 
fibrils is essential to minimize light scattering and provides the vitreous with its viscoelastic 
properties 44 . The vitreous humor is mostly acellular, except for some hyalocytes, which are usually 
found in the posterior vitreal cortex. Hyalocytes are phagocytic, spindle-shaped cells which are 
involved in synthesis of vitreal components such as collagen, HA and other macromolecules 1 . At the 
vitreoretinal interface, the inner limiting membrane (ILM) is formed by the basal lamina of the Müller 
cells (see further on), and is mainly composed of collagen type I and IV, fibronectin and laminin. The 
collagen fibrils of the vitreous are strongly adhered to this ILM, resulting in attachment of the 
vitreous to the retina. With age, the vitreous undergoes progressive liquefaction (synchysis) and 
aggregation (syneresis) of collagen 44, possibly as a result of changes in chemical or conformational 
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states of HA and its interactions with the vitreal collagen-fibrils. This liquefaction has been implicated 
in ocular disorders such as posterior vitreal detachment. Since the vitreous humor also keeps the 
retina in place, posterior vitreal detachment could result in tearing or detachment of the retina. 
Moreover, since the vitreous humor is frequently used as a drug depot for controlled release of 
therapeutics, vitreal liquefaction could also lead to changes in drug distribution 45.  
Neural retina 
The neurosensory retina is a highly organized, multi-layered cellular structure which captures 
incoming light and sends processed signals towards the brain via the optic nerve (Figure 1.6). It is 
approximately 0.5 mm thick, and lines the back/periphery of the eye. The cells responsible for 
capturing photons are the photoreceptor (PR) cells. Both rod and cone PRs  are found in the human 
retina, each with its own function. Whereas approximately 125 million rod PRs are located around 
the periphery of the retina, only 6 - 8 million cone PRs provide us with color vision and high acuity 
daylight vision. Most of the cone PRs are located in the macula lutea, or ‘yellow spot’ (Figure 1.7), 
named as such because of the high concentration of pigmented carotenoids lutein and zeaxanthin 
which filter out damaging blue light and act as biological sunglasses. Located in the center of the 
macula is the fovea. This part of the retina is highly enriched in cone PRs, and is responsible for our 
 
Figure 1.5 | The orientation of the heterotypic collagen fibrils in the vitreous humor, as well as 
the anatomy of the human eye and surrounding structures. Adapted from 1. 
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high acuity vision. Interesting to note is the dipped structure, where in the central part only PRs 
(mostly cone PRs) and Müller cells are located (Figure 1.8). Indeed, most downstream processing 
cells (bipolar, amacrine, horizontal) seem to be displaced, to offer an optimal amount of light to 
reach this part of the retina. Photons captured by the PRs are biochemically transformed into an 
electrical signal, which is passed on to the ganglion cells via bipolar, amacrine and horizontal cells. 
These ganglion cells then transport the electrical signal via the nerve fiber layer to the optic nerve, 
which transports the signal to the brain for image processing. At the location where all nerve fibers 
join together to form the optic nerve, no photoreceptors can be present, and is therefore referred to 
as the ‘blind spot’ of the retina.  
Another type of retinal cells are the Müller cells, which are radial, macroglial cells stretching through 
the entire retina. Their apical side protrudes out of the inner limiting membrane (ILM) into the 
vitreous humor. These protrusions are known as Müller cell endfeet. The basal side is located in the 
subretinal space between the neural retina and the RPE cell layer. In vertebrate retinas, they are the 
primary macroglial cells, with some 8 – 10 million Müller cells in the human retina. As they span the 
entire thickness of the retina, they are in contact with all neuronal cells, thereby forming an 
 
Figure 1.6 | Schematic diagram of the organization of the retina, with different retinal cell types 
and layers. Adapted from http://webvision.med.utah.edu/ 
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anatomical link between neuronal cells and the vitreous body, retinal blood capillaries and the 
subretinal space. They act as functional and metabolic support for the neuronal cells, providing 
neurotrophic compounds and removing metabolic waste. Furthermore, they guarantee the survival 
of PR cells and are key to the spatial buffering of ion concentrations, necessary for the excitability of 
PRs. Additionally, the Müller cells provide structural stabilization of the retina, being able to buffer 
mechanical deformations of the retinal tissue, as well as modulating retinal immune and 
inflammatory responses. Finally, it has recently been postulated that these radial glial cells act as 
living optical fibers, guiding the light from the vitreous body to the photoreceptors with minimal 
scattering due to differences in refractive index 46. A recent report suggests that they act as 
wavelength-dependent optical fibers focusing the green-red spectrum of light on the cone 
photoreceptors for day vision, while leaking purple-blue light onto the rods for night-vision 47. It 
offers a possible explanation to the counterintuitive inverted structure of the retina with respect to 
its optical function 46. Every Müller cell is though to guide light to 1 cone photoreceptor cell  46. In the 
fovea, this gives rise to a very high concentration of Müller cells, exactly the same density as the cone 
PRs 48, coined as the foveal Müller cell cone (Figure 1.8B) 11. It suffices to conclude that Müller cells 
are integral parts of the retina with a myriad of functions and responsibilities. 
Retinal pigment epithelium 
The retinal pigment epithelium (RPE) is made up of hexagonally arranged cuboidal cells with pigment 
granules, which are packed together with tight junctions in a cobblestone pattern 9. Generally not 
 
Figure 1.7 | View of a healthy retina, as seen through an ophthalmoscope. The optic nerve, also 
known as the blind spot, is devoid of cone photoreceptor cells, while the macula lutea, or yellow 
spot, contains high densities of cone photoreceptors. In the center of the macula lies the fovea. 
From http://webvision.med.utah.edu/ 
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regarded as a part of the neurosensory retina, it is located between the choroid and the outer neural 
retina and serves several different functions. The basal area is in close contact with the Bruch’s 
membrane, and functions as a selective barrier between the neural retina and the choroid by tight 
junctions. The RPE closely regulates transepithelial transport of water, ions and metabolic waste 
products towards the choroidal blood vessels, and glucose and nutrients toward the subretinal space, 
while preventing entry or systemic dissemination of unwanted pathogens. The apical area is closely 
associated with photoreceptor cells by a network of long apical microvilli (Figure 1.9), allowing close 
interactions with the PRs. The RPE is responsible for the continuation of the visual cycle by (i) 
reisomerization of retinoids, (ii) phagocytosis of shed PR outer segment discs, (iii) and by maintaining 
ion homeostasis in the subretinal space 9. Furthermore, excess and scattered light is absorbed by 
melanins to protect the retinal cells from photo-oxidation. Additionally, the RPE is known to secrete 
growth factors required for maintenance of PRs. Also, the RPE guarantees the immune-privileged 
state of the inner eye, on the one hand by blocking access to components of the adaptive immune 
 
Figure 1.8 | The central part of the macula, called the fovea, shows a dipped structure, where 
ganglion cells and bipolar cells are displaced from the center, allowing for minimal light scattering 
and maximum exposure of the cone PR cells. (A) Optical coherence tomography shows the dipped 
foveal structure of a healthy, adult retina 2. (B) Interpretation of the structure of the fovea, with 
the Müller cell cone (Mcc) located in the center of the fovea 11. The base is thought to correspond 
with the inner limiting membrane (arrows).  
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system, and on the other hand by secretion of immunosuppressive agents. Also, the RPE serves an 
important role in maintaining the water balance in the retina. There is a general convective flow of 
water from the vitreous body towards the retina 49, which has to be disseminated in order to 
maintain intraocular pressure. Müller cells are known to transport this water to the subretinal space, 
where it is removed by the RPE towards the choroidal blood vessels. 
OCULAR DYSTROPHIES AS POTENTIAL TARGETS FOR RETINAL GENE THERAPY 
The ability to see is one of our most valued senses and more than any of the other four, we rely on it 
to function in our daily lives. Unfortunately, it is estimated that nearly 1 in 2000 people suffer from 
blinding disorders, greatly reducing their comfort of life 21. Given the complex structure of the eye, 
loss of vision can be attributed to different causes. Whereas some blinding dystrophies are acquired 
during the lifetime by multifactorial causes, single genetic aberrations in retinal cells also represent a 
significant causative factor. The first genetic defects linked to ocular dystrophies have been 
documented in the 1980s 50, 51. In a field where ocular disease types were usually ranked by observed 
phenotypes, the extensive genetic heterogeneity of the ocular disorders soon became apparent 
(Figure 1.10). To date, several dystrophies are known to be caused by a large amount of genetic 
defects 52: around 260 disease gene loci and 220 disease-relevant genes have been identified for 
retinal disorders (RetNet™: Retinal Information Network: https://sph.uth.edu/retnet/).  
 
 
Figure 1.9 | Summary of RPE functions and structure 9. 
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Caused by these hereditary disorders, loss of vision is usually attributed to the degeneration and 
progressive loss of photoreceptors. Dominantly inherited retinal disorders, such as retinitis 
pigmentosa resulting from mutations in the gene encoding for rhodopsin (RHO), require a 
combination therapy of gene suppression and supplementation. However, gene suppression of the 
dominantly expressed mutated protein might prove difficult due to allelic heterogeneity of the 
mutated RHO gene 52. For recessive mutations, suppression of the mutated protein is no longer 
required and therefore gene supplementation could prove sufficient to restore a healthy phenotype. 
 
Figure 1.10 | Schematic of target cells for retinal gene therapy, highlighting the known genetic 
defects and their retinal location 8.  
MC: Müller cells; ONL: Outer nuclear layer; IS: inner segments (of the photoreceptors) ; CC: 
connecting cilium; OS: outers segments (of the photoreceptors); RPE: retinal pigment epithelium 
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This substantially increases the feasibility of the gene therapy approach, and indeed, most clinical 
trials as of yet have focused on treatment of autosomal recessive RPE65-Leber Congenital Amaurosis 
53, 54, 55. Other factors influencing the potential of ocular dystrophies as targets for gene therapy are 
the size of the mutated gene and the target cells where these genes are located. Firstly, Stargardt 
disease should be fairly straightforward to treat as it is caused by a recessive mutation, however, the 
large size of the mutated ABCA4-gene (~6.7kb) renders delivery by the favored AAV vectors difficult. 
Secondly, as loss of vision is caused by degeneration of the PRs, gene therapy can only be beneficial if 
the therapeutic gene is supplemented to the retina when it is still able to process light signal, i.e. 
when the PRs are still intact. Achromatopsia is an ideal target in this respect, as it is an autosomal 
recessive dystrophy where PR function is lost but they are nonetheless present and usually fairly 
intact 52. In X-linked juvenile retinoschisis, loss of vision is attributable to a recessive mutation in the 
RS1-gene encoding the 24 kDa retinoschisin protein, causing splitting of the retina 56. Nevertheless, 
PR morphology and function is relatively preserved. Finally, in Leber Hereditary Optic Neuropathy, 
loss of vision is thought to occur by a mutation in the mitochondrial DNA of the ganglion cells, 
therefore photoreceptors are not affected and remain fairly intact. 
Aside from the known hereditary single-gene defects, several blinding malignancies are a result of a 
complex interplay between polygenic mutations and environmental causes. Examples of such 
multifactorial retinal dystrophies are diabetic retinopathy and age-related macular degeneration 
(AMD). The latter accounts for the highest fraction of people suffering from blinding disorders. 
Exudative (or wet) AMD is characterized by the presence of drusen and altered pigmentation in the 
macular region together with a neovascularization of the retina and choroid. Therefore, the 
preferred treatment for wet AMD is anti-VEGF therapy 57. Intravitreal injection of anti-VEGF 
antibodies (Lucentis®/ranibizumab and Avastin®/bevacizumab) has to be repeated on a monthly 
basis. Alternatively, studies are now focusing on the delivery of anti-VEGF-shRNA via gene therapy 58. 
Furthermore, Genzyme/Sanofi has recently started a clinical trial where AAV2 vectors are 
intravitreally injected to deliver a persistent expression of sFLT-01, a soluble VEGF-receptor. 
ADMINISTRATION ROUTES AND BARRIERS FOR RETINAL GENE THERAPY 
The eye is a small, compartmentalized organ. As it is in direct contact with the environment, different 
barriers are in place to protect entry of harmful pathogens. These barriers cause the eye to be an 
isolated organ, impeding the delivery of therapeutics to its tissues. To deliver therapeutics to the 
posterior segment of the eye, i.e. the retina, different routes of administration are employed. A 
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discussion is provided below on each of these administration routes, along with the advantages and 
barriers that need to be overcome. 
Systemic delivery 
When delivering therapeutics of any kind via intravenous injection (Figure 1.11A), the major 
disadvantage is the high dilution and rapid clearance of the therapeutic agent from the bloodstream. 
 
Figure 1.11 | Potential routes of administration for therapeutics destined for the retina, with the 
most notable barriers highlighted. (A) Systemically administered therapeutics are blocked by the 
blood-retina barrier (BRB), composed organized monolayers with complex tight junctions of RPE 
cells (outer BRB) and retinal vascular endothelial cells (inner BRB). (B) Topically instilled 
therapeutics are quickly removed by blinking and nasolachrymal drainage. When travelling 
towards the retina via the anterior segment, corneal and conjunctival epithelial layers limit 
transport. Furthermore, the therapeutics have to cross the vitreous humor and the inner limiting 
membrane, before reaching the retina. (C) Subretinal injection delivers the  therapeutics directly 
at their target site, though the procedure is very invasive and is limited to the injection spot. (D) 
Intravitreal injection delivers the therapeutics in the vicinity of the retina, in the vitreous humor, 
which can act as a drug depot. However, it is known that the vitreous humor itself might act as a 
barrier for nanoparticle transport towards the periphery of the eye. Transport to the retinal tissue 
is further hampered by the presence of the inner limiting membrane (ILM) at the vitreoretinal 
interface. 
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This necessitates the delivery of high concentrations of the drug to reach minimal active 
concentrations at the target site. Such high concentrations might result in unwanted systemic side 
effects. Delivery of therapeutics to the retina via systemic administration is furthermore hampered 
by the blood-retina barrier (BRB). The BRB functions as a selective barrier between the ocular 
environment and systemic circulation, allowing transport of nutrients and glucose in the blood-to-
retina direction and eliminating metabolic waste products in the retina-to-blood direction. It is 
formed by tight monolayers of retinal cells with complex tight junctions, limiting non-specific 
paracellular transport  across the monolayer. The inner BRB that is formed by the retinal vascular 
endothelial cells (RVECs) in the inner retina can be distinguished from the outer BRB that is formed 
by the RPE. 
Topical delivery 
Topical instillation (e.g. eye-drops, Figure 1.11B) has the advantage of delivering the therapeutics 
directly near the ocular environment. Furthermore, the application is non-invasive, easy and can be 
performed by the patients themselves. It is commonly applied for the treatment of corneal ailments, 
notwithstanding that delivery to the back of the eye via topical administration is very inefficient. This 
is attributed to (i) the distribution of the drugs across the surface of the eye in tear and periocular 
fluids, (ii) clearance from tear fluid by blinking and nasolachrymal drainage, (iii) impermeability of the 
corneal and conjunctival epithelia to macromolecules, (iv) the efflux of compounds by these epithelia, 
(v) enzymatic metabolism of the drug in the anterior segment, (vi) drug dilution in the anterior fluid 
and vitreous humor. 
Intravitreal delivery 
Intravitreal administration delivers the therapeutics in the vitreous humor of the eye (Figure 1.11D). 
By delivery directly in the ocular environment, the toughest ocular barriers (anterior barriers and BRB) 
are bypassed, and a high concentration of the therapeutics is delivered near the target site. 
Furthermore, though the procedure does involve an injection and contains a risk of endophthalmitis 
and retinal detachment, it is relatively easy to perform by trained personnel, making it feasible on a 
large scale. Indeed, antibodies (Lucentis®) and aptamers (Macugen) for the treatment of retinal or 
choroidal neovascularization are already frequently administered via intravitreal injection in a clinical 
setting, spurring research to decrease the risk of previously mentioned unwanted side effects. 
Nonetheless, these drugs still have to move towards the retina to exert their intended effect. 
Mobility of compounds injected in the vitreous is thought to be driven by 2 major forces, diffusion 
and a convective anterior-posterior flow 49. Nevertheless, it has been shown that the vitreous humor 
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itself might pose a barrier for transport of large molecular weight drugs, owing to the 3D network of 
collagen fibrils. Furthermore, the ILM at the vitreoretinal interface, formed by the basal lamina of 
Müller cells, has also been suggested to form a barrier for retinal permeation of intravitreally injected 
therapeutics 59. 
Subretinal delivery 
Subretinal administration of therapeutics delivers the cargo between the photoreceptors and RPE 
cell layer, in the subretinal space (Figure 1.11C). In clinical trials, subretinal injection is the preferred 
method of choice, given its high delivery potential 60, 61. As most anatomical barriers are bypassed 
and therapeutics are delivered directly in the vicinity of the photoreceptor cells and RPE, this 
administration route remains to date the most efficient way of delivering therapeutic genes to the 
outer retinal layers. Though most clinical success in gene therapy has been achieved this way, the 
therapeutic efficacy is mostly localized to the injection spot. Furthermore, subretinal injection is a 
very invasive procedure which causes a temporary ‘bleb’ formation between the photoreceptors 
cells and the RPE, with an increased risk of complete retinal detachment.  
Periocular delivery 
Aside from those listed above, other administration routes can also been employed to try and deliver 
therapeutics to the retina, e.g. subconjunctival, peribulbar, retrobulbar, etc. 62. Advantageous for 
these type of injections are the reduced complexity of the procedure and the higher volumes that 
can be administered. Nevertheless, additional barriers are imposed by the sclera, conjunctiva and 
choroid, and it is assumed there is an increased risk of systemic spreading of the therapeutics. 
M O T I V A T I N G  I N T R A V I T R E A L  A D M I N I S T R A T I O N  O F  
N O N V I R A L  R E T I N A L  G E N E  T H E R A P E U T I C S  
WHY THE EYE? 
20 years have passed since the first documented successful results on gene transfer to different 
retinal cells using adeno-viral 63, 64, adeno-associated viral 65 and lentiviral vectors 66. As discussed 
before, gene therapy is gaining attention in recent years, as demonstrated by the approval of four 
different gene therapy products for use in clinical settings. Gene therapy for ocular disorders is 
especially booming, as these disorders are easily recognized and a considerable amount of research 
has focused on ocular disease gene discovery, creating a vast database of blinding disorders linked to 
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known genetic defects. Ocular dystrophies, while seriously affecting the quality of life, are not life-
threatening and persist in the human population. This results in a large morbidity, creating a large 
demand and encouraging major investments to further research by big pharmaceutical companies. 
Delivery of gene nanomedicines to the eye is attractive given its small, compartmentalized and 
isolated characteristics, preventing unwanted systemic side effects upon local delivery. Furthermore, 
the eye is easily accessible and is an immune-privileged site, which decreases the risk of 
immunogenic reactions to the delivered therapeutics. The first successful clinical trials documented 
Table 1.1 | Completed and ongoing clinical trials for ocular gene therapy (ClinicalTrials.gov, 
august 2014) 
Ocular dystrophy Therapeutic 
Clinical trial 
phase 
Clinical trial 
number 
Leber congenital 
amaurosis 
rAAV2-CBSB-hRPE65 Phase I NCT00481546 
AAV2-hRPE65v2 Phase I NCT00516477 
tgAAG76 (rAAV 
2/2.hRPE65p.hRPE65) 
Phase I / Phase II NCT00643747 
rAAV2-CB-hRPE65 Phase I / Phase II NCT00749957 
rAAV2-hRPE65 Phase I NCT00821340 
AAV2-hRPE65v2 Phase III NCT00999609 
AAV2-hRPE65v2 Phase I / Phase II NCT01208389 
rAAV2/4.hRPE65 Phase I / Phase II NCT01496040 
Age-related macular 
degeneration 
AdGVPEDF.11D Phase I NCT00109499 
AAV2-sFLT01 Phase I NCT01024998 
RetinoStat® (Sanofi) Phase I NCT01301443 
rAAV.sFlt-1 Phase I / Phase II NCT01494805 
Stargardt disease StarGen™ (Sanofi) Phase I / Phase II NCT01367444 
Choroideremia 
rAAV2.REP1 Phase I / Phase II NCT01461213 
rAAV2.REP1 vector Phase I NCT02077361 
MERTK-related 
autosomal recessive 
RP 
rAAV2-VMD2-hMERTK Phase I NCT01482195 
Usher syndrome UshStat® (Sanofi) Phase I / Phase II NCT01505062 
Leber’s Hereditary 
Optic Neuropathy 
GS010 (GenSight; rAAV2/2_ND4) Phase I / Phase II NCT02064569 
rAAV2-ND4 Phase I NCT01267422 
scAAV2-P1ND4v2 Phase I NCT02161380 
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the safety and efficacy of RPE65 delivered by AAV vectors to patients affected with RPE65-LCA 60, 61, 67, 
68. In the meantime, several other clinical trials involving gene therapy for ocular disorders have 
followed (Table 1.1).  
WHY INTRAVITREAL ADMINISTRATION? 
Although subretinal injection of gene nanomedicines has shown to be most efficient at delivering 
transgenes to the PRs and RPE, this procedure is very invasive and not without risks. Subretinal 
injection is accompanied by the formation of a ‘bleb’ in the subretinal space causing a temporary 
disconnection between the RPE and the neural retina, possibly leading to permanent retinal 
detachment. Also, subretinal injection usually only leads to transgene expression at the injection site. 
For dystrophies where the fovea or macula has to be targeted for transfection of the cone PRs, such 
as achromatopsia, it could be argued that the risk of permanent damage to the PRs is not worth the 
benefit of the gene therapy 52. Intravitreal delivery, on the other hand, could guarantee a 
homogeneous concentration of gene nanomedicines reaching the entire retinal surface area, without 
the need for a subretinal bleb. Intravitreal injection of therapeutics is already abundantly used in a 
clinical setting for the treatment of retinal or choroidal neovascularization by anti-VEGF therapeutics 
(Lucentis®, Macugen). This abundant use has resulted in continued effort to increase patient 
compliance and reduce adverse side-effects, such as endophthalmitis. Previously, it has been argued 
that nanoparticles will not reach the PRs or RPE cells intravitreal injection and that transgene 
expression will be limited to the ganglion cell layer 69. Nevertheless, intravitreally injected gene 
nanomedicines might still be of use for treating those targets located in the inner retinal layers close 
to the vitreous humor. Delivery of therapeutic NAs to the mitochondria of ganglion cells would be a 
possible therapeutic avenue for LHON. Müller cells can also be reached after intravitreal injection, 
expanding the therapeutic potential to mutations in those cells as well. For example, a recent study 
documents that RS1-expression in Müller cells was sufficient to revert an X-linked juvenile 
retinoschisis phenotype, to a healthy phenotype 56. In any case, the continued effort for the 
optimization of NA delivery vectors has resulted in recent studies showing that intravitreally injected 
gene nanomedicines can in fact transfect RPE cells 70 (see also Chapter 5). 
WHY NONVIRAL GENE NANOMEDICINES? 
As it is a known fact (and further demonstrated in Chapter 2) that the vitreous humor contains 
nucleases capable of degrading naked NAs, protecting these therapeutic NAs by means of 
encapsulation in gene vectors is necessary to guarantee optimal gene delivery efficiency. Gene 
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therapy has proven most successful by using viral vectors. Indeed, these have evolved over millions 
of years to be efficient at delivering NAs to their target cells. By screening the tropism of different 
viral vectors, vast libraries are documented for a multitude of target cell types. In retinal gene 
therapy, recombinant AAVs appear to be most common in clinical studies and trials due to their 
tropism for retinal cell types and low immunogenicity. Two disadvantages of using AAVs for retinal 
gene therapy are the relatively long lag in gene expression and the limited cargo capacity of 
~4.7 kb 21. The slow onset of gene expression is thought to result from the need for second strand 
synthesis, before transcription can occur. This problem has been circumvented by the use of self-
complementary AAVs (scAAVs), which contain both the sense strand and the reverse complement of 
a certain gene. Unfortunately, packaging of a double-stranded genome further limits the already 
limited cargo capacity of the AAVs 21. This poses a limit to which ocular dystrophies can be treated 
with AAV vectors. For instance, Stargardt disease is caused by a mutation in the ABCA4 gene, which is 
6.8 kb in size. Vision loss due to Usher Syndrome is caused by a mutation in the MYO7A gene, 9 kb in 
size. To counter this, recent studies have shown that larger genes can potentially be delivered by so-
called dual AAV vectors. Large transgenes are trans-spliced and delivered by two different AAV 
vectors, one containing a splice donor site and the other a splice acceptor site, which are joined by 
recombination once released in the nucleoplasm. Nonetheless, the dependence on recombination 
and the increased difficulty in vector design limit the use of dual-AAVs, and an easier and more 
straightforward approach would be to deliver these therapeutic NAs as pDNA via nonviral gene 
nanomedicines. Additionally, as previously highlighted, viral vectors are more difficult to produce on 
a larger scale, and are associated with immunogenic responses 24. Finally, it has been shown that viral 
vectors have a risk of neurotropic dissemination after intraocular injection 25. 
POSSIBLE AVENUES FOR RETINAL GENE THERAPY 
Gene therapy can be used as therapeutic avenue for vision-debilitating disorders in several different 
ways, classified by Sahel and Roska 53 as mutation dependent and mutation independent. The most 
straightforward application of retinal gene therapy is a mutation dependent approach, when 
therapeutic NAs are delivered to the retina to supplement a loss-of-function mutation, or silence a 
toxic gain-of-function mutation. Nevertheless, it must be noted that mutation dependent gene 
therapy approaches are only relevant when the inherent visual machinery is still functional, i.e. the 
degeneration of photoreceptor cells has not progressed too far. Achromatopsia, GUCY2D-LCA and X-
linked juvenile retinoschisis are retinal dystrophies where visual function is lost, yet the PR cells are 
still anatomically intact, making them ideal candidates for retinal gene therapy. The same goes for 
most PR-degenerative diseases when treated early on.  
  Chapter 1 
  Page 25 
However, a recently published study 71 shows that, even though human patients treated for RPE65-
LCA with gene therapy showed an increase in visual response, the degeneration of photoreceptor 
cells continued unabated. The authors support the need for combinatorial therapeutic approaches of 
both mutation dependent and mutation independent interventions. These mutation independent 
interventions involve the protection of the visual cascade, either by slowing down degeneration of 
PRs, or, if degeneration has progressed too far, restoring photosensitivity by creating new 
photosensors. Since PR degeneration usually results from immune responses to diseased phenotypes, 
a possible therapeutic avenue to slow down degeneration could be by regulating these immune 
responses by secretion of neurotrophic or anti-apoptotic proteins in the neural retina. The small size 
of these compounds ensured their diffusive capabilities throughout the retina, meaning transduction 
of ganglion cells or Müller cells to produce these factors should be sufficient to promote PR cell 
survival. Alternatively, if PR degeneration has progressed too far, a proposed strategy is to 
implement novel photosensors in the neural retina, taking over the function of the degenerated PRs. 
This can be achieved by electronic implants or stem cells, or via a gene therapeutic approach with 
optogenetics, where the aim is to express photosensitive proteins, such as channelrhodopsin-2 and 
halorhodopsin in the remaining, intact neuroretinal cell types.  
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A B S T R A C T  
Aims: The aim of this study was to develop a robust assay to evaluate and compare the intravitreal 
mobility of nanoparticles in the intact vitreous body. Materials & methods: Excised bovine eyes were 
prepared to preserve the fragile structure of the vitreous humor, while permitting high-resolution 
fluorescence microscopy and single particle tracking analysis of intravitreally injected nanoparticles. 
This assay was validated by analyzing polystyrene beads and further employed to evaluate gene 
nanomedicines composed of poly(amido amine)s and plasmid DNA. Results: Our assay was able to 
distinguish immobilized cationic nanoparticles from mobile PEGylated nanoparticles. PEGylation of 
the polyplexes resulted in a drastic improvement of their mobility. Conclusions: An ex vivo eye model 
was presented here for studying nanoparticle mobility in intact vitreous humor by single particle 
tracking microscopy. These results give important guidelines for developing gene and drug delivery 
nanomedicines that are compatible with intravitreal administration. 
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I N T R O D U C T I O N  
Several chronic and progressive retinal disorders which ultimately cause blindness do not yet have 
curative treatments. Examples of these are retinitis pigmentosa (RP), Leber congenital amaurosis 
(LCA), X-linked juvenile retinoschisis and age-related macular degeneration (AMD) 1-4. Since several of 
these dystrophies have been found to be caused by genetic aberrations, they are potential 
candidates for treatment by gene therapy 5, 6. In gene therapy, intracellular delivery of nucleic acids 
(NAs) to the diseased cells can either block a dysfunctional gene or introduce a functional one 6, 7. In 
ocular gene therapy, the target cells are usually located in the neuroretina or the retinal pigment 
epithelium (RPE), both located at the periphery of the eye 8. Because of potential systemic side-
effects and the impermeability of the blood-retina barrier to large hydrophilic molecules like NAs, 
intravenous injection is not an ideal route of administration. Several barriers also limit the efficacy of 
topical administration, such as the corneal epithelium (limited diffusion of high-molecular weight 
drugs) and the low residency time of the drugs due to the tear film and blinking 9-11. Instead, 
intraocular administration is an attractive alternative delivery route of both drug delivery systems 
and NAs, because the eye is an easily accessible, immune privileged organ and several barriers 
prevent the therapeutics from getting out into the body 5. 
Subretinal injection of naked NAs, in combination with electroporation, has led to successful 
transfection of photoreceptors and RPE cells in mice 12-15. However, subretinal injection is technically 
demanding and invasive with the risk of retinal detachment from the RPE, which may impair a 
complete restoration of vision 15, 16. Repeated subretinal injections are hence strongly discouraged 
and in any case not feasible on a large scale. A less invasive and safer way of ocular NA 
administration is direct injection into the vitreous chamber of the eye, referred to as intravitreal 
injections. These are performed routinely in the clinic for the administration of monoclonal 
antibodies such as Lucentis® or Avastin® to treat wet AMD 17. However, intravitreal injection of naked 
NAs exposes these biomacromolecules to enzymatic degradation by vitreal nucleases 18. Therefore, 
to protect them from intravitreal hydrolysis 19 and to facilitate NA uptake and processing by the 
retinal target cells, NAs are formulated in viral or nonviral nanocarriers 20, 21. Viral carriers have 
shown to be effective for retinal NA delivery, both after subretinal injection 22 or intravitreal injection 
23-25. However, these viral vectors can induce severe complications due to their immunogenicity and 
oncogenicity 26-29 or elicit the risk of their neurotropic spreading after intraocular administration 30. 
As a safer alternative, nonviral vectors for retinal gene transfer are being developed 19, 31-34. 
When developing nanomedicine formulations for intravitreal injection, the first requirement is that 
the nanoparticles should have optimal mobility inside the vitreous humor. The vitreous of the eye is a 
strongly hydrated transparent extracellular matrix that fills the intraocular cavity between the lens 
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and the retina. It consists mainly of water (>98 %), negatively charged hyaluronic acid (HA), 
hydrophobic collagen fibrils and few peripheral hyalocytes (i.e. phagocytic mononuclear cells) 35. The 
vitreous humor could present an important barrier to intravitreally administered nanomedicines, 
both for drug delivery and gene delivery. Indeed, in several previous reports, both in vitro and in vivo, 
it was reported that the interference of the vitreal network on the mobility of the particles is 
dependent on both size and surface characteristics 36-40. Therefore, a robust method which can 
rapidly and easily analyze and compare the mobility of nanoparticles in vitreous humor is essential in 
the field of nanomedicines for intravitreal injection.  
In this study, we established a robust method to assay the mobility of nanoparticles in intact vitreous 
humor, providing reliable quantitative data for optimizing ocular drug and gene delivery vectors. 
Indeed, previous studies investigating in vitro the intravitreal mobility of nanoparticles have used 
manipulated vitreous humor, which is known to have an altered network of collapsed collagen fibrils. 
In this study, we focused on keeping the vitreal structures as intact as possible. Fluorescence video 
microscopy and single particle tracking (SPT) analysis 41, allow real-time tracking of individual 
fluorescently labeled nanoparticles. SPT provides information on the mobility and interactions of 
single nanoparticles and can therefore discriminate heterogeneous behavior within a large 
population. Since SPT was demonstrated to be an excellent tool to investigate nanoparticle mobility 
in mucus samples and blood 42-44, here we use this methodology to investigate the mobility of 
fluorescently labeled nanoparticles inside the vitreous humor and their interaction with vitreous 
components. More specifically, we quantitatively validated the established relation between 
nanoparticle size and surface characteristics and their diffusive properties inside the vitreous body. 
To do so, model polystyrene nanospheres with different size and surface modifications were 
intravitreally injected inside excised bovine eyes and their intravitreal diffusion was then investigated. 
To specifically study the role of HA in the extracellular matrix, we also evaluated diffusion of the 
model nanoparticles in HA-solutions. Finally, we assessed the intravitreal behavior of DNA-polyplexes, 
composed of bioreducible, linear poly(amido amine)s 45 and plasmid DNA (pDNA), which were 
previously shown to efficiently transfect RPE cells 46.  
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M A T E R I A L S  A N D  M E T H O D S  
Nanospheres.  
Fluorescent, yellow-green polystyrene nanospheres of different sizes (0.1 µm, 0.2 µm, 0.5 µm and 1 
µm, referred to as PS100, PS200, PS500 and PS1000, respectively) were purchased from Invitrogen 
(FluoSpheres®, Invitrogen, Merelbeke, Belgium) with carboxylated surface. The fluorophores in these 
particles are located in the inner core, thus minimizing the possibility of altering the interaction with 
the vitreous humor due to the presence of fluorescent labels. Charge reversal of the surface carboxyl 
groups was obtained by covalent linkage with N,N-dimethylethylenediamine (DMEDA) (Sigma, 
Bornem, Belgium) as described previously 47. In short, 1 ml of the stock solution of nanospheres was 
first sonicated for 10 minutes. Then, 8 mg of coupling agent N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC) (Fluka, Bornem, Belgium) and 16.7 mg DMEDA was added, 
after which the mixture was vortexed and incubated overnight on a shaker (200 rpm) to establish the 
coupling (see Figure 2.1 for a schematic overview of the reaction). The next day, the nanospheres 
 
Figure 2.1| Surface modification of carboxylated polystyrene fluospheres with DMEDA or mPEG 
amine. Carboxyl groups on the green fluospheres were first activated with EDC and addition of 
DMEDA or mPEG amine led to the covalent coupling of the primary amine of DMEDA or mPEG 
amine to the carboxyl group by a stable amide bond. 
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were washed with HBS-buffer through centrifugation (12 minutes at 14000 x g) on an Amicon 
Ultracel™ 100 kDa centrifugal filter (Millipore, Brussels, Belgium) to remove the excess of DMEDA 
and EDC products. The nanospheres were then recollected after inversion of the filter in a new 
microcentrifuge tube (3 minutes at 1000 x g) and finally resuspended in HEPES buffer. To modify the 
surface of the carboxylated nanospheres with methoxypolyethylene glycol amine (mPEG amine, 2 
kDa) (PLS-269, Creative PEGworks, Winston Salem, USA), a similar protocol was employed. After 
sonication, 1 ml of the carboxylated nanospheres was mixed with 8 mg of EDC and 20 mg mPEG 
amine, vortexed and incubated overnight on a shaker (200 rpm). The next day, the PEGylated 
nanospheres were also purified on an Amicon Ultracel™ 100 kDa centrifugal filter and resuspended in 
HEPES buffer. 
Dynamic light scattering (DLS) was employed to characterize the size and surface charge of all 
nanoparticles, by measuring the hydrodynamic diameter, polydispersity index (PDI) and zeta 
potential (Table 2.1) on a NanoZS zetasizer (Malvern Instruments, Hoeilaart, Belgium). The surface 
amine-modification of the PS500 nanospheres led to some aggregation, as reflected in the increase 
of the PDI and the average size. Strong aggregation was observed in case of the cationic 
PS1000DMEDA spheres, which prevented them for further use in this study. As expected, surface 
Table 2.1 | Characterization of size and surface charge of the different batches of nanospheres in 
HEPES buffer measured by dynamic light scattering.  
Nanoparticle Z-averaged hydrodynamic 
diameter (nm) 
Zeta potential (mV) 
PS100COOH 106 ± 3 - 51 ± 1 
PS100DMEDA 107 ± 5 + 39 ± 3 
PS100PEG 121 ± 6 - 6 ± 2 
PS200COOH 216 ± 7 - 49 ± 2 
PS200DMEDA 229 ± 7 + 40 ± 0 
PS200PEG 239 ± 11 - 8 ± 1 
PS500COOH 533 ± 33 - 60 ± 6 
PS500DMEDA 601* ± 57 + 41 ± 4 
PS500PEG 575 ± 20 - 10 ± 5 
PS1000COOH 1228* ± 135 - 85 ± 3 
PS1000DMEDA NAv NAv 
PS1000PEG 1189* ± 70 - 11 ± 3 
Polydispersity index < 0.10 unless indicated otherwise. The mean value and standard 
deviation are shown of three independent measurements. 
(*) 0.10 < PDI < 0.15; PDI: polydispersity index;  
DMEDA: N,N-dimethylethylenediamine; NAv: Not available owing to aggregation during 
surface functionalization; PEG: Polyethylene glycol; PS: Polystyrene. 
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PEG-modification of the carboxylated nanospheres led to a strong shielding of the surface potential 
of these nanospheres.  
Polyplexes. 
The polyplexes were made using the bioreducible polymer vector p(CBA-ABOL), which is a linear 
poly(amido amine) with repetitive disulfide linkages in the main chain, prepared by Michael-type 
polyaddition of 4-aminobutanol (ABOL) to N,N′-cystaminebisacrylamide (CBA) 45. p(CBA-ABOL)/DNA 
complexes were obtained by adding a polymer solution of 0.6 mg/ml to a pGL4.13 plasmid (Promega, 
Leiden, The Netherlands) solution of 0.05 mg/ml in a final mass ratio of 48/1 in 25 mM HEPES buffer 
pH 7.2 and vortexing the mixture for 10 s, after which they were allowed to stabilize for 
approximately 15 minutes. These gene complexes have a Z-averaged hydrodynamic diameter in 
HEPES buffer of 108 ± 6 nm (PDI < 0.10) and an average zeta potential of +38 ± 1 mV. For the 
PEGylated polyplexes, p(CBA-ABOL/DMEDA’/PEG) was used as polymer vector, obtained by Michael-
type polyaddition of mPEG amine (2250 Da, Sigma, Bornem, Belgium), N,N’-dimethylethylenediamine 
(DMEDA’) and ABOL to CBA in a CBA/ABOL/DMEDA’/PEG molar ratio of 50/35/11/4. The same 
protocol was used for the characterization of these polyplexes, which have a Z-averaged 
hydrodynamic diameter of 85 ± 1 nm (PDI < 0.30) in HEPES buffer and an average zeta potential of 
+10 ± 0 mV. Fluorescently labeled polyplexes were obtained by labeling the plasmid with the nucleic 
acid stain YOYO-1™ (λex = 491 nm, λem = 509 nm, Molecular Probes, Merelbeke, Belgium). YOYO-
1 (1 mM in DMSO) iodide was added to the plasmid at a mixing ratio of 0.15:1 (v:w), resulting in a 
theoretical labeling density of 1 YOYO-dye molecule per 10 bp. The mixture was incubated at room 
temperature for 4 hours in the dark. To remove the DMSO and free YOYO-1, the labeled plasmid was 
precipitated by adding 2.5 volumes of ice-cold ethanol and 0.1 volume of 5 M NaCl. After incubation 
for 30 minutes at -80°C, centrifugation (17000 g, 30 minutes) and washing with clean 70 % ethanol, 
fluorescently labeled plasmid was finally resuspended in 25 mM HEPES, pH 7.2. The concentration of 
the plasmid was again determined by UV absorption at 260 nm. The plasmid was labeled instead of 
the vector, to minimize the influence of the labeling on the particle surface characteristics. 
Hyaluronic acid solutions. 
170 kDa hyaluronic acid (HA) (Sigma, Bornem, Belgium) was diluted with HEPES buffer (25 mM, pH 
7.2) to reach a concentration of 1 mg/ml. Afterwards, 20 µl of a solution containing polystyrene 
nanospheres was added to 20 µl of the HA-solution, reaching a final HA concentration of 500 µg/ml 
and an appropriate nanosphere concentration for single particle tracking. 
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Intravitreal injection in bovine eyes. 
Fresh bovine eyes were obtained from the local slaughterhouse, subsequently disposed of 
extraocular material and incised along the limbus (Figure 2.2). Then, the cornea and lens were 
removed, exposing the anterior part of the hyaloid membrane that holds the vitreous body. This 
“window” was juxtaposed to the glass cover slip of a MatTek glass bottom dish (35 mm, No. 1.5, 
MatTek Corporation, MA, USA). Finally, to avoid drift of the eye inside the glass bottom dish, the eye 
was gently fixed with parafilm. For all vitreous experiments, the sclera was punctured laterally with a 
21 G guard needle, after which 10-20 µl of nanoparticle suspension was injected in the vitreous 
humor with the help of a syringe and 25 G needle (0.5 mm).  
The nanoparticles were expunged from the syringe near the cover slip to allow visualization within 
the working distance of the objective lens, though far enough to avoid punctuation of the anterior 
hyaloid membrane and subsequent outflow of vitreous liquid (Figure 2.2). Next, the sample was 
  
Figure 2.2| (Left) Ex vivo model of intravitreal injection of nanoparticles in bovine eyes for single 
particle tracking (SPT) microscopy. (A, B) Cornea, anterior chamber and lens are removed from a 
fresh bovine eye, leaving the large vitreous chamber, surrounded by the hyaloid membrane, 
intact. (C) A glass bottom dish is positioned against the anterior hyaloid membrane, providing an 
imaging window into the vitreous humor. The glass bottom dish is gently fixed to the eye with 
parafilm, after which the 21G guard needle is used to puncture the sclera laterally. The fluorescent 
nanoparticles are expunged into the vitreous from a 25G needle at a small distance (± 500 µm) 
from the coverslip to avoid damage to the anterior hyaloid membrane. (Right) Illustration of the 
intravitreal injections, as performed in this study. Fluorescent nanoparticles are expunged from 
the needle, close to the part of the anterior hyaloid membrane that is juxtaposed to the coverslip 
of the glass bottom dish to allow high-resolution SPT. During the injection, attention is given not 
to damage the hyaloid membrane. 24 hours after the injection, SPT microscopy is performed 
sufficiently far from the cover slip.  
HM: hyaloid membrane 
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stored for 24 hours at room temperature before performing the microscopy experiments, thus 
allowing the nanoparticles to diffuse from the injection site into the surrounding vitreous and within 
the working range of the objective lens. 
3-D confocal microscopy. 
Z-stacks of the fluorescent nanoparticles at the injection site in the vitreous were acquired with a 
Nikon C1 confocal laser scanning microscope (Nikon Belux, Brussels, Belgium) equipped with a Plan 
Apo 10x 0.45 numerical aperture air objective lens. Nanospheres were excited with the Ar-ion 488 
nm laser line and emission light was collected using a 500–530 nm band pass filter. 3-D visualization 
was obtained using an alpha-blend surface rendering in NIS elements software (Nikon Belux, Brussels, 
Belgium). 
FLIM microscopy and SHG imaging. 
The excitation was by a MaiTai tuneable ultrafast laser (Spectra Physics, Mountain View, CA) 
operating at 900 nm yielding two-photon excitation of the fluospheres and the SHG signal from the 
collagen. The objective used was an LD C-Apochromat 40x/1.1 W Korr UV-VIS-IR. The fluorescence 
and SHG signals were simultaneously detected through a broad band pass filter HG 405 – 455 with a 
sensitive photon counting detector (Hamamatsu Photonics HP7422P-40, Hamamatsu City, Japan), 
and acquired by a Becker & Hickl (Berlin) FLIM system (SPC-830) based on time-correlated single 
photon counting. To discriminate SHG from fluorescence, the instrument response function was 
obtained from a KDP crystal yielding only the SHG signal. For the pixels with a resulting decay time 
shorter than 600 ps (represented in red) the signal was assumed to originate from backward SHG or 
from forward SHG scattered on the inside of the eye (see vitreous model). For pixels with longer 
decay times (represented in green) the signal was assumed to come from fluorescence of the 
Fluospheres® (typically in the order of nanoseconds).  
SPT microscopy. 
For the diffusion measurements in HEPES buffer (25 mM, pH 7.2) or in HA-solutions, the 
nanoparticles were diluted to give a concentration suitable for SPT (typical concentrations of 108 to 
1010 particles per ml). 9 µl of these samples was then applied between a microscope slide and a cover 
glass with a double-sided adhesive sticker of 120 µm thickness in between (Secure-Seal Spacer; 
Molecular Probes, Leiden, The Netherlands). This creates a 3-D environment in which the particles 
can diffuse freely, while the sample is sufficiently thin to avoid drift from convection. The microscope 
was always focused at 5 to 10 µm above the cover glass to avoid deviations from free diffusion due 
to the presence of the cover slip. For each sample, typically 10 to 20 movies of about 200 frames 
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each were recorded at different locations within the sample. The fluorescent nanoparticles that were 
injected intravitreally were recorded under the same conditions, although sufficiently far in the 
bovine eye, beyond the anterior hyaloid membrane (Supplementary Movie 1, 2 and 3 available 
online: http://www.futuremedicine.com/doi/suppl/10.2217/nnm.12.202).  
All fluorescence video imaging of diffusing nanoparticles was performed on a custom-built laser wide 
field fluorescence microscope setup, here referred to as the “SPT-microscope” 43. The SPT-
microscope is composed of a TE2000-E inverted microscope equipped with a Plan Apo VC 100x 1.4 
numerical aperture oil immersion objective lens, with a working distance of 130 µm (Nikon Belux, 
Brussels, Belgium), except when imaging PS500 and PS1000 nanospheres, where a Plan FL 40x 0.75 
numerical aperture objective was employed with a working distance of 720 µm (Nikon Belux, 
Brussels, Belgium). Both nanospheres and YOYO-1-labelled polyplexes were excited with a 491 nm 
laser line (Cobolt, Stockholm, Sweden) and fluorescence emission was captured through a 500-600 
nm band-pass filter (AHF Analysentechnik, Tubingen, Germany) on an electron-multiplying CCD 
(EMCCD) camera (Cascade II:512, Roper Scientific, Nieuwegein, The Netherlands). The EMCCD 
camera was synchronized with an acousto-optical tunable filter (AOTF) to minimize photobleaching 
by only illuminating the sample during the actual camera exposure time. Videos were acquired in NIS 
Elements. 
Trajectory analysis. 
Diffusion analysis of the videos was performed off-line using in-house developed software, as 
described before 41 (Figure 2.3). Briefly, background removal is first performed on all frames using an 
unsharp mean filter, followed by a median smoothing filter for suppression of high-frequency noise. 
These processed images are automatically thresholded and converted to binary images on which the 
contours of individual fluorescent objects are automatically identified. The intensity-weighted 
centroid location of these objects is determined with a center of mass algorithm. The motion 
trajectories of the identified objects are calculated using a nearest neighbor algorithm, a common 
approach in SPT 48, 49 (see Supplementary Movie 1, 2 and 3, available online: 
http://www.futuremedicine.com/doi/suppl/10.2217/nnm.12.202). Short tracks, often being a result 
of noise or strong axial movement of the particle, were omitted by defining a minimum track length 
of 9 steps for PS100, PS200 and polyplexes, and 15 steps for PS500 and PS1000.  
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For each trajectory, the mean squared displacement (MSD) was calculated for the available time lags 
t, 2t, …, Kt, where t is the time between the steps (i.e. the time between the images) and K is the 
total number of steps in the trajectory 50. In case of free diffusion, the MSD is described by 51, 52: 
  2
4
4 4 ,
3
MSD Dt D t D t      (1) 
with D the diffusion coefficient, ∆t the image acquisition time, and σ the localization precision (a 
function of D and ∆t). In case of anomalous diffusion, D in the first term of Eq. 1 is often replaced by a 
time-dependent parameter 53:  
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with Γ the transport coefficient. The anomalous exponent α is a measure for the mode of diffusion. 
For nanoparticles undergoing free diffusion α=1, while α<1 and α>1 are indicative of anomalous sub- 
and superdiffusion, respectively. The width of the α-distribution is explained by the fact that per 
trajectory only a limited number of steps are available, which results in an inherent limited precision 
with which α can be determined. For α=1, Γ reduces to the time-independent diffusion coefficient: 
Γ = 4D. Since ∆t << t in our experiments, diffusion during illumination can be considered to be free 
(α=1) so that D in the second and third term in Eq. (1) is simply replaced by 4D   . Thus, Eq. (1) 
becomes:  
 
Figure 2.3 | Principle of diffusion measurements with SPT. Movies of diffusing fluorescent 
nanoparticles were recorded on the SPT-microscope. Individual trajectories of the nanoparticles 
were calculated off-line and analyzed to obtain distributions of diffusion coefficients or the mode 
of motion. The black dashed line indicates the minimal observable diffusion coefficient Dmin, which 
is a measure for the minimum diffusion coefficient that can be measured for a given time-lag t. 
Particles that move slower than Dmin are perceived as being immobile. 
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For each sample, the MSD vs. t plots of 100’s to 1000’s of individual nanoparticle trajectories were 
analyzed by a weighted fit of this anomalous diffusion model (with only Γ and α as free fitting 
parameters) as described before 54. In that way, a distribution of α-values can be obtained that is 
representative for the nanoparticle population. In addition, the apparent diffusion coefficient Da 
corresponding to the first time-lag t was calculated using the formula: 
 
4
a
MSD
D
t
  (4) 
The distribution of Da values was finally refined with the previously published maximum entropy 
analysis method (MEM) to filter out sampling noise and statistical broadening resulting from finite 
trajectory lengths. MEM analysis improves the precision of the distributions and removes features 
(noise) from the distributions that are not statistically warranted by the data 43. 
Since in Eq. (4) the localization precision  is not explicitly taken into account, there will be an offset 
in the Da values, such that stationary particles (D=0) will have the following apparent diffusion 
coefficient:  
 
 2
min
0, t
D
t
 
  (5) 
This Dmin is a measure for the minimum diffusion coefficient that can be measured for a given time-
lag t. Particles that move slower than Dmin are perceived as being immobile.  
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R E S U L T S  
MOBILITY OF NANOPARTICLES IN BOVINE VITREOUS HUMOR 
The effect of particle size and surface characteristics has already been investigated in a number of 
studies 36-40. However, the methods employed were either ensemble-techniques, such as 
Fluorescence Recovery After Photobleaching (FRAP), yielding the average diffusional behavior, or 
were just qualitative based on imaging the distribution of nanoparticles in the vitreous. To be able to 
discriminate heterogeneous mobility behavior of the nanoparticle population, here we have applied 
single particle tracking microscopy to quantitatively analyze the diffusion coefficient and mode of 
motion (free vs. anomalous diffusion) on a particle by particle basis, thus yielding unprecedented 
detailed information on mobility of the entire particle population. We injected model polystyrene 
nanospheres of different sizes and surface characteristics in the vitreous of isolated, intact bovine 
eyes and after 24 hours their diffusion was monitored on the SPT-microscope. Distributions of 
 
Figure 2.4 | The relative retardation of different nanospheres in 170 kDa hyaluronic acid (HA)-
solution and vitreous humor, calculated as the quotient of the average Da in HEPES buffer (Dh) 
and the average Da in HA-solution or vitreous humor (Dm). Values depicted here are calculated 
from average apparent diffusion coefficients obtained from single particle tracking (SPT) analysis 
(n = 3 experiments, typically 500 – 1000 trajectories).   
Dh: Da in HEPES buffer; Dm: Da in a biological matrix (e.g. HA or vitreous humor); (*): Average 
value of a bimodal distribution 
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apparent diffusion coefficients (Da’s) were obtained from SPT analysis and average Da’s are listed in 
Table 2.2. The relative retardation of the nanoparticles, compared to their free diffusion in HEPES 
buffer, is visualized in Figure 2.4, from which it is clearly noticeable that cationic charge has a 
profound effect on mobility in vitreous humor.  
Due to practical considerations, SPT analysis of the diffusion of cationic nanoparticles in bovine 
vitreous was only performed for the PS100DMEDA nanospheres (see Discussion). 24 hours after 
intravitreal injection it was observed that a large fraction of the cationic particles were not able to 
penetrate into the vitreous and remained primarily in the injection spot (Figure 2.11). Indeed, a 
confocal z-stack through the injection spot revealed strong accumulation of the 0.1 µm cationic 
nanospheres at the edges of the cylindrical opening that was created by the needle (Figure 2.5A). In 
the region of the vitreous adjacent to the injection spot, a rapid decrease in nanosphere 
concentration was observed (Figure 2.5B). Nevertheless, the distribution of Da’s in this region 
revealed a bimodal behavior, which suggests that apart from the large immobile fraction, some 
mobile nanoparticles are also present (Figure 2.5C). This also implies that the average value in Figure 
2.4 and Table 2.2 should be interpreted with care. It was noticed that the immobilized nanospheres 
in that region were mostly aligned along fibril-like structures of the vitreous (Figure 2.5B inset). We 
Table 2.2 | Average apparent diffusion coefficient Da of the different nanospheres in HEPES 
buffer, 170 kDa hyaluronic acid (HA)-solution and vitreous humor, as obtained with single particle 
tracking (SPT) (n = 3). The relative retardation of the nanospheres in the HA-solution and in 
vitreous is calculated as the quotient of the average Da in HEPES buffer and the average Da in HA-
solution or vitreous. 
Nanoparticle 
HEPES HA (170 kDa) Vitreous humor 
Da (µm²/s) Da (µm²/s) Relative 
retardation 
Da (µm²/s) Relative 
retardation 
PS100COOH 4.12 ± 0.08 3.05 ± 0.19 1.3 ± 0.1 1.38 ± 0.15  3.0 ± 0.3 
PS100DMEDA 4.01 ± 0.12 2.22 ± 0.18 1.8 ± 0.2 0.31 ± 0.02 * 12.9 ± 1.0 * 
PS100PEG 3.21 ± 0.15 2.57 ± 0.13 1.3 ± 0.1 2.52 ± 0.56 1.3 ± 0.3 
PS200COOH 1.92 ± 0.02 1.56 ± 0.12 1.2 ± 0.1 0.73 ± 0.03 2.6 ± 0.1 
PS200DMEDA 1.94 ± 0.06 1.21 ± 0.08 1.6 ± 0.1 NAv NAv 
PS200PEG 1.88 ± 0.00 1.34 ± 0.06 1.4 ± 0.1 0. 84 ± 0.13 2.2 ± 0.3 
PS500COOH 0.82 ± 0.00 0.68 ± 0.03 1.2 ± 0.1 0.39 ± 0.03 2.1 ± 0.2 
PS500DMEDA 0.77 ± 0.04 0.51 ± 0.04 1.5 ± 0.1 NAv NAv 
PS500PEG 0.79 ± 0.01 0.63 ± 0.03 1.3 ± 0.1 0.59 ± 0.11 1.3 ± 0.3 
PS1000COOH 0.41 ± 0.00 0.29 ± 0.03 1.4 ± 0.1 0.14 ± 0.09 3.0 ± 1.8 
PS1000DMEDA NAv NAv NAv NAv NAv 
PS1000PEG 0.39 ± 0.01 0.31 ± 0.02 1.3 ± 0.1 0.23 ± 0.02 1.7 ± 0.2 
Da: apparent diffusion coefficient; NAv: not available because of aggregation after intravitreal injection 
(positive particles) or during surface functionalization (PS1000DMEDA); *: Average value of a bimodal 
distribution 
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speculated that these fibril-like structures are in fact collagen-fibrils. This hypothesis was further 
supported by fluorescence lifetime microscopy (FLIM), where images were produced using the 
fluorescence of the cationic nanospheres and the second harmonic generating (SHG) properties of 
collagen (Figure 2.6). 
In contrast to the cationic nanospheres, the anionic and PEGylated nanoparticles were able to diffuse 
out of the injection site. A 3-D rendering of the injection site for PS200PEG is shown in Figure 2.7A 
(similar data for anionic nanospheres not shown). The fluorescence image in Figure 2.7B of the 
region near the injection site shows a gradual spreading of the nanospheres throughout the vitreous. 
Analysis of the particle diffusion coefficients showed that all PEGylated nanoparticles remained 
mobile (Figure 2.7C). Also, because SPT-analysis shows a monomodal distribution for these particles, 
the average values in Table 2.2 can be interpreted as such. 
Interestingly, the anionic nanospheres were slowed down more than the PEGylated ones (Figure 2.4). 
This can also be seen from the results in Figure 2.8, where the distributions of Da in vitreous are 
 
Figure 2.5 | Injection of cationic PS100DMEDA nanospheres in the vitreous humor of bovine eyes 
led to poor diffusion and high retention at the injection spot. (A) Confocal sectioning through the 
injection spot after 24h with low magnification and 3-D reconstruction revealed a high 
accumulation of the cationic nanoparticles at the edges of the cylindrical opening, created by the 
needle (direction of injection is indicated with the black arrowhead) (scale box: X,Y: 1.27 mm; Z: 
0.73 mm). (B) Fluorescence microscopy image of the region in the vitreous humor adjacent to the 
injection site. The black arrowhead points towards the injection site. Most of the cationic 
nanospheres remain trapped in the injection site. The few nanospheres that are able to diffuse 
into the vitreous are rapidly becoming immobilized by binding to fibril-like structures (see inset). 
Scale bars are 100 µm. (C) Distribution of apparent diffusion coefficients of the nanospheres that 
were monitored in the region depicted with the white rectangle in B, as obtained by SPT-analysis. 
The black dashed line indicates Dmin. 
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shown for the different 0.1 µm nanospheres. Also when comparing fluorescence microscopy movies 
of the diffusing particles (Supplementary Movies 1 and 2), the difference between anionic particles 
(Supplementary Movie 1) and PEGylated particles (Supplementary Movie 2) is obvious. Finally, we 
note that no clear trend could be observed for the relative retardation on a short time scale in 
function of the size for the anionic and PEGylated nanospheres in vitreous (Table 2.2).  
TRAJECTORY ANALYSIS TO INVESTIGATE ANOMALOUS DIFFUSION 
So far we analyzed nanosphere mobility in terms of their apparent diffusion coefficient Da as derived 
from the MSD at the first time lag (see Materials & Methods). However, by analyzing the MSD for 
longer time lags, SPT diffusion theory dictates that an exponent α can be obtained for every 
trajectory, which is a measure of anomalous diffusion 50.  The distributions of α-values were derived 
 
Figure 2.6 | PS100DMEDA fluospheres (green) immobilized on collagen fibrils (red), obtained by 
fluorescence lifetime imaging microscopy (FLIM) based on the fluorescence of the fluospheres 
and the second harmonic generated (SHG) signal from the type II collagen. The scale bar indicates 
10 µm. The image shows that the majority of the fluorescent nanospheres are colocalized on 
fibril-like structures. It is known that the vitreous of the eye contains type II collagen, capable of 
generating SHG. This supports our hypothesis that the positively charged PS100DMEDA 
nanospheres are indeed immobilized on collagen-fibrils, possibly by electrostatic interactions with 
anionic glycosaminoglycans which are covalently attached to the collagen. 
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from the same sets of trajectories that were obtained earlier for the Da measurements. Figure 2.9 
shows the overlay of the α-distributions for the different sizes of PEGylated nanospheres in HEPES 
buffer (solid lines), representative of free diffusion, and in bovine vitreous humor (dashed lines). As 
expected, the α-distributions in HEPES buffer were centered around a value of 1. The distributions 
show that PEGylated nanoparticles up to a size of 1 µm diameter exhibit free diffusion in the vitreous 
humor within the time-scale of the SPT measurements, indicating these do not experience steric 
hindrance from e.g. the collagen network.  
MOBILITY OF NANOPARTICLES IN A HA-SOLUTION 
HA is the main component of the vitreal anionic glycosaminoglycans, filling up the space between the 
collagen fibrils and possibly acting as a molecular sieve 35. To investigate the effect of HA on the 
mobility of nanoparticles, the same model polystyrene nanospheres were mixed with a pure HA-
solution of 0.05 % 170 kDa HA in HEPES buffer. The nanosphere diffusion was monitored with SPT-
microscopy. A molecular weight of 170 kDa and concentration of 500 µg/ml was chosen for the HA 
because these values are reported in adult bovine vitreous 35. The average Da’s in HEPES buffer and 
 
Figure 2.7 | Injection of PS200PEG in the vitreous humor of bovine eyes. (A) Confocal sectioning 
through the injection spot with low magnification and 3-D reconstruction revealed efficient 
diffusion of the nanospheres from the injection spot into the surrounding vitreous (scale box: X,Y: 
1.27 mm; Z: 0.73 mm). (B) Fluorescence microscopy image of the region in the vitreous adjacent 
to the injection spot revealed a smooth nanosphere gradient. The black arrowhead points 
towards the injection site. Scale bar is 100 µm. (C) Distribution of apparent diffusion coefficients 
of the nanospheres that were monitored in the region depicted with white rectangle in B, as 
obtained by SPT-analysis. The black dashed line indicates Dmin.  
HM: hyaloid membrane 
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HA-solution are shown in Table 2.2. The relative retardation of the nanospheres in the HA-solution is 
calculated from the ratio of Da in HEPES buffer to Da in HA, and is visualized in Figure 2.4. 
All PEGylated nanospheres (PSPEG) were slowed down in the HA-solution by approximately the same 
factor, independent of their size, indicating that all nanospheres experienced a purely viscous drag at 
the shortest measured time lag. It was also found that the average retardation of the anionic 
PSCOOH nanospheres was similar to that of the PSPEG nanospheres. This indicates that there is no 
significant interaction of the anionic nanospheres with the HA polymers. In comparison, PSDMEDA 
nanospheres were slowed down the most in HA-solution, likely due to electrostatic interactions 
between the cationic nanospheres and the anionic charges in the HA network.  
THE DIFFUSIVE PROPERTIES OF GENE NANOMEDICINES AFTER INTRAVITREAL INJECTION 
Finally, we investigated the diffusive behavior of p(CBA-ABOL)/pDNA polyplexes in the bovine 
vitreous model.  These gene nanomedicines were shown to have high in vitro transfection efficiency 
in RPE cells with very low cytotoxic effects 46. To investigate whether these polyplexes are suitable 
 
Figure 2.8 | Diffusive properties of 0.1 µm nanospheres with different surface modifications in 
bovine vitreous humor, as obtained with SPT-analysis. The black dashed line indicates Dmin. A 
bimodal distribution is obtained for the cationic nanoparticles (PS100DMEDA, black squares), 
indicating a mobile and immobile fraction, while the monomodal distributions of anionic 
(PS100COOH, light grey crosses) and PEGylated particles (PS100PEG, dark grey diamonds) indicate 
only a mobile fraction. PEGylated particles show an increased mobility over anionic particles, 
indicating that hydrophobic interactions might also be contributing to the overall delay of 
nanoparticles in vitreous humor. 
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for intravitreal injections, their stability and mobility in the vitreous matrix was examined. Since our 
nanosphere results show that PEGylation improves mobility of nanoparticles in vitreous humor, we 
also evaluated p(CBA-ABOL/DMEDA’/PEG) as pDNA carrier, where mPEG amine (2 kDa) was 
copolymerized into the p(CBA-ABOL/DMEDA’)-carrier.  
Similar to the experimental setup with the nanospheres, fluorescently labeled polyplexes were 
injected into the vitreous model. 24 hours later, it was observed with fluorescence microscopy that 
p(CBA-ABOL)/DNA polyplexes formed large, immobile aggregates, which impaired their diffusion 
throughout the vitreous (data not shown). This was clearly reflected in the SPT-analysis of polyplex 
diffusion in vitreous, which revealed a large immobile fraction, as is evident from the Da -
distributions (Figure 2.10). Interestingly, analogous to the cationic nanospheres, the SPT analysis 
could still distinguish a small fraction of mobile polyplexes. In the case of the PEGylated polyplexes 
the vast majority remained mobile, as confirmed by diffusion analysis. The tail in the Da distribution 
towards lower values (Figure 2.10), representative of a less mobile fraction, could be due to 
heterogeneity in the PEGylation degree and thus the remaining cationic charge of the polyplexes. 
 
 
Figure 2.9 | Mode of motion of PEGylated nanospheres in vitreous humor and in HEPES buffer. 
The nanospheres were injected in the vitreous humor of bovine eyes and after 24 hours, particle 
trajectories were constructed with the help of SPT. For every trajectory, a corresponding α-value 
was derived and plotted in a distribution (dashed lines). As a comparison, the α-values were also 
measured for the same nanospheres, freely diffusing in HEPES buffer (solid lines).  
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Figure 2.10 | Distributions of apparent diffusion coefficients (Da) of both unPEGylated (blue line) 
and PEGylated (red line) polyplexes in vitreous humor, 24 hours after intravitreal injection, in 
comparison with their distribution of Da in HEPES buffer (green and purple lines). The black 
dashed line indicates Dmin. 
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D I S C U S S I O N  
Intravitreal injection of nanomedicines is an attractive approach to deliver therapeutics into the 
ocular environment. It is currently employed on a routine basis in the clinic to administer therapeutic 
antibodies and aptamers against (AMD-related) choroidal neovascularization (CNV) 17, and is 
constantly optimized and evaluated to minimize adverse effects such as pain and vitreal reflux 55. 
Many blinding dystrophies require delivery of the therapeutics to the retina or subretinal space, and 
therefore it is essential that optimal mobility of the intravitreally injected nanomedicines throughout 
the vitreous is guaranteed and that aspecific interactions with vitreal components are minimized. 
Indeed, previous studies have pointed out that the vitreous can strongly interfere with the stability 
and mobility of nanomedicines, limiting the delivery of their therapeutic payload to retinal cells 37, 38, 
40, 56. First of all, the collagen and HA network could act as a molecular sieve for larger nanoparticles 
and may thus impair diffusion throughout the vitreous 35, 57. Secondly, because nanomedicines for NA 
delivery are often positively charged, electrostatic interactions with anionic glycosaminoglycans in 
the vitreous may capture and immobilize them completely 37, 40. Nanoparticles can also become 
immobilized on the collagen fibrils of the vitreous, presumably because of hydrophobic interactions 
38. Thirdly, as it is known that many nonviral NA-carriers lack colloidal stability at physiological salt 
concentrations 58, the vitreous could induce aggregation of the nanomedicines. Taken together it is 
clear that the successful development of nanomedicines for intravitreal administration will depend 
on robust methods which can provide us with comprehensive knowledge on how nanoparticle 
properties influence their mobility and stability in the vitreous humor.  
In this study, we evaluated SPT microscopy as an analytical and quantitative method to monitor the 
diffusion of intravitreally injected nanoparticles for drug or gene delivery in real-time. Previous 
reports on the relationship between nanoparticle properties and intravitreal mobility employ 
ensemble-based methods such as FRAP to determine the average diffusion coefficient of a 
population of particles 38, or confocal microscopy to visualize the biodistribution of the nanoparticles 
in vivo after intravitreal injection 39, 40. While these methods both have their merits, the advantage of 
measuring diffusion on the single particle level is that this enables to discriminate heterogeneous 
behavior of a population. With SPT, it is also possible to gauge the anomaly of diffusion within a 
biological matrix, which can be used to gain an understanding in how the mesh size of the vitreal 
network might influence the mobility of larger particles. First of all, we provided an appropriate ex 
vivo bovine eye model that leaves the fragile network organization of the vitreous intact. This is in 
contrast to previous studies, where the vitreous humor was isolated from the eyecup and then 
pushed through a syringe for easy handling or mechanically mixed with the studied nanoparticles 37, 
38. It is known that isolation and mechanical manipulation of the vitreous induces outflow of HA, 
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leading to 50 % weight loss after 2 hours 59. This can cause a collapse of collagen fibrils and thus alter 
the collagen network mesh size and the original structure of the vitreous 35, 37. Here, all experiments 
were performed on isolated bovine eyes within 30 hours post mortem, which is an acceptable time 
frame as it is known that intact eyes can be stored for up to 60 hours post mortem without affecting 
the rheology of the eye 59. To minimize exudation while permitting high-resolution microscopy inside 
the vitreous, only a small window was excised above the limbus, without perforating the anterior 
hyaloid membrane. A guard needle was used to puncture the sclera, after which nanoparticles were 
injected with a smaller needle to minimize damage to the vitreous structure (Figure 2.2). Using this 
ex vivo model, we could ensure maximum vitreous integrity and additional support of the sclera to 
maintain vitreous rigidity during the microscopy investigations.  
Fluorescently labeled polystyrene nanospheres of different sizes and surface charges were evaluated 
with our assay to validate on a single particle level the established effect of nanoparticle properties 
on intravitreal diffusion. Because the fluorophores are located in the inner core of the particles, the 
fluorescent labeling is expected to only have a minimal effect on the particle surface characteristics 
and subsequent interactions with the biopolymer matrix. Carboxylate nanospheres were anionic, 
while amine-modified nanospheres were cationic. A covalent surface modification of the carboxylate 
nanospheres with the non-ionic hydrophilic polymer PEG shielded the negative charge. PEGylation is 
a well-known strategy to improve the colloidal stability of nanoparticles and to decrease aspecific 
interactions with biogels 60. 24 hours after injection of the model nanoparticles, strong retention of 
 
Figure 2.11 | Wide-field fluorescence images of the injection spots in the vitreous humor for 
PS100DMEDA (A), PS200DMEDA (B) and PS500DMEDA (C). Scale bars are 100 µm. These images 
were taken with a Plan Apo 10x objective lens with a numerical aperture of 0.45 and a working 
distance of 1.6 mm. The same effect for all particles is noticed, specifically that the cationic 
nanospheres are immobilized in the injection spot. Single particle tracking analysis was only 
performed for PS100DMEDA, due to practical difficulties. Based on the fluorescence images above 
we speculated that the diffusional data would show the same trend for the remaining cationic 
particles. 
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the cationic nanospheres at the injection spot was detected (Figure 2.11). When analyzing the 
diffusive characteristics of PS100DMEDA in vitreous humor with SPT, a bimodal distribution of Da’s is 
observed (Figure 2.5C) with a large fraction of the injected nanoparticles immobilized. Even though a 
small part of the nanospheres remains mobile, the loss of the immobilized fraction makes cationic 
nanoparticles very inefficient in terms of transport towards the retina. Only the PS100DMEDA 
nanospheres were analyzed with single particle tracking, due to the technical difficulty of injecting 
the nanoparticles within the limited working distance of the objective lens. To avoid puncture of the 
hyaloid membrane surrounding the vitreous humor, the nanoparticles are injected sufficiently far 
from this membrane (few 100 µm) and left for 24h to diffuse into the vitreous and toward the cover 
glass. Most of the cationic particles, however, are immobilized and remain within the vicinity of the 
injection spot, unable to diffuse within the working distance of the objective lens. This was imaged 
for all particle sizes with a low magnification long working distance objective lens (not suited for SPT 
measurements), as shown in Figure 2.11. Thus, it can be concluded for the cationic nanoparticles that 
a large part remains trapped within the injection spot, whereas a small fraction is still mobile. In 
contrast, intravitreal injection of anionic nanospheres led to their more or less efficient spreading 
throughout the vitreous. The differences between these findings suggest electrostatic interactions 
between nanoparticles and anionic vitreal components to be contributing to the intravitreal mobility. 
To investigate further, we have measured the diffusion of the polystyrene nanospheres in pure 
solutions of 0.05% HA, which are the predominant anionic glycosaminoglycans that fill up the space 
between the collagen fibrils in the vitreous humor. By entanglement, HA molecules can form flexible 
networks which might impede mobility of the nanoparticles. Nevertheless, SPT analysis revealed that 
all nanospheres remained mobile in a 170 kDa HA-solution with an average diffusion coefficient Da 
that was only slightly less than in HEPES buffer and independent of their size (Table 2.2). As expected, 
the cationic nanospheres were slowed down more than the anionic or PEGylated ones, which can be 
explained by electrostatic interactions with the anionic HA biopolymers. Nevertheless, the 
immobilized fraction of cationic nanoparticles as seen in the vitreous humor was absent, indicating 
that this immobilization cannot merely be attributed to interactions with free HA molecules. We 
hypothesize it is likely the result of electrostatic interactions with other glycosaminoglycans, which 
are bound to the vitreal collagen fibrils 35. This hypothesis is supported by our fluorescence 
microscopy images (Figure 2.5b inset) showing that immobilized cationic nanospheres were aligned 
along fibril-like structures. Further support was obtained from FLIM images showing clear 
colocalization of the beads with SHG-active structures, most likely being collagen fibrils (Figure 2.6). 
Interestingly, while we expect the electrostatic repulsion between the anionic nanospheres and the 
vitreal glycosaminoglycans to be defining for their increased mobility, SPT analysis showed that 
PEGylation of the anionic nanospheres increased their average diffusion rate even more. Thus it 
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seems that other non-electrostatic interactions with vitreous components contribute to the observed 
result of the anionic nanospheres, such as a hydrophobic interaction with collagen fibrils 38. 
To explore the effect of nanoparticle size on their diffusion through the vitreous matrix, we 
investigated the mobility of nanospheres with a PEG-surface, thereby minimizing the effect of 
potential electrostatic or hydrophobic interactions with the vitreal components. SPT diffusion 
analysis showed that the relative retardation of the PEGylated nanospheres in vitreous was 
practically the same as that in the HA-solutions (Figure 2.4). By analyzing the MSD of the trajectories 
for longer time lags, a distribution of α-values could be calculated for each size (Figure 2.9A to 2.9D). 
It was found that all α-distributions were centered around 1, indicating unhindered diffusion in the 
vitreous humor of PEGylated nanoparticles up to 1 µm. It should be noted, however, that the mesh 
size of the collagen matrix in the vitreous cortex, i.e. the vitreal region closest to the retina, is 
presumably smaller than that of the central vitreous because of the higher concentration of collagen 
present along the vitreal periphery. Future studies could focus on nanoparticle mobility in the 
vitreous cortex to see if there is a substantial difference with the results presented here for the 
central vitreous.  
Finally, we investigated the intravitreal behavior of bioreducible polyplexes for retinal gene therapy. 
To minimize the effect of the fluorescent labeling on the interactions with the biopolymer matrix, the 
pDNA was labeled rather than the carrier polymer. Because the polyplexes are formed by 
spontaneous electrostatic complexation the anionic vitreal environment could cause a disruption of 
the polyplexes leading to the degradation of pDNA by the vitreal DNAses 38 and influencing our SPT 
measurements. However, we verified the stability of the complexes by gel electrophoresis and 
showed that even after 24h both PEGylated and unPEGylated polyplexes were still intact (Figure 
2.12). After intravitreal injection of the unPEGylated polyplexes, a strong immobilization was 
observed in the vitreous matrix with the formation of large polyplex aggregates. This is in agreement 
with previous studies where intravitreal injection of cationic liposomes or polymeric nanoparticles 
also led to extensive aggregation and impaired mobility in vitreous 38-40. This effect was illustrated 
more accurately by diffusion analysis, where an immobilized fraction can clearly be distinguished in 
the distribution of Da’s (Figure 2.10). Interestingly, Gomes dos Santos et al. 61 investigated the 
transretinal migration and transfection efficiency of cationic PEI-polyplexes after intravitreal injection 
in rats, and showed that some nanoparticles could reach the retinal layers, indicative of their 
mobility in the vitreous humor. These seemingly contradictory results are nevertheless supported by 
our findings that cationic nanoparticles show a bimodal diffusional behavior in the vitreous humor: a 
small fraction remains mobile, yet the majority of nanoparticles is aggregated and immobilized. This 
leads to a very inefficient delivery of their cargo and makes cationic polyplexes incompatible with 
intravitreal injections. Nevertheless, aggregation and immobilization could be eliminated by using a 
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PEGylated variant of these polyplexes, which showed efficient spreading out of the injection spot in 
the vitreous. The diffusion data also demonstrated a substantial increase in the mobile fraction 
compared to the unPEGylated polyplexes (Figure 2.10). Yet, the PEGylated polyplexes exhibit a higher 
relative retardation in vitreous humor than similar sized PEGylated anionic nanospheres. This could 
be attributed to the remaining anionic or cationic surface charge (-6 mV for the nanospheres 
compared to +10 mV for the polyplexes). In any case, by altering the PEGylation degree or by 
incorporating different functionalizations in the polymer subunits, it should be possible to tailor the 
polyplexes in such a way that they are stable and monodisperse, with surface characteristics 
providing them with optimal mobility throughout the vitreous humor.  
In short, the proposed quantitative assay for intravitreal mobility promises to be a valuable tool for 
 
Figure 2.12 | pDNA and polyplex stability in the vitreous humor, verified with gel 
electrophoresis (a) and SPT microscopy (b).   
(a) To evaluate the stability of polyplexes compared to free pDNA in vitreous gel, 40 µl of YOYO-1 
labeled pDNA or polyplex mixture was mixed in vitro with vitreous gel. Afterwards, pDNA integrity 
in HEPES buffer and vitreous was checked after 2h, 16h and 24h with gel electrophoresis. First of 
all, it can be seen that labeling with YOYO-1 did not drastically influence pDNA integrity. 
Furthermore, naked pDNA in vitreous showed some degradation after 24 hours, as deduced by 
the increase in open circular (OC) pDNA (black arrow). Interestingly, this OC fraction is not spotted 
with the complexed pDNA in vitreous (not for the CBA-ABOL/pDNA complexes, nor for the CBA-
ABOL-DMEDA’-PEG/pDNA-polyplexes), indicating the polyplexes do indeed protect the pDNA 
from vitreal nucleases.   
(b) Single particle tracking microscopy was used to analyze the diffusion coefficients of naked 
YOYO-1 labeled pDNA after 24h in the vitreous humor. However, almost no fluorescent spots 
could be seen as could be expected since the gel electrophoresis experiments have demonstrated 
pDNA degradation at that time point. In contrast, intact polyplexes could still easily be found. 
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the screening and rational design of drug delivery vectors for intravitreal administration. By using 
cadaveric bovine eyes, the assay is cheap to perform and readily available, yet some general remarks 
should be made. For instance, it is known that the composition of vitreous humor differs between 
species 35, having differences in collagen concentration, HA concentration and HA molecular weight 
as well. Nevertheless, this assay can easily be adapted to evaluate intravitreal mobility in a human 
model, if such eyes are available. Another point of interest is the in vivo relevance of our ex vivo 
model, which only takes diffusional mobility into account when evaluating intravitreal mobility of the 
nanoparticles. With the empirically determined Da’s from our SPT-assay, a theoretical particle 
distribution in the vitreous humor could be calculated (Supplementary information, further on). Yet, 
it is known that in vivo an anterior-posterior convective flow is present in the vitreous humor, driven 
by a pressure drop between the hyaloid membrane and the retina 62. This also influences intravitreal 
particle mobility, and several papers have modeled or described the coupled convective-diffusive 
transport of particles in the vitreous humor 63, 64.  However, we feel that a particle showing optimal 
diffusional mobility in our ex vivo model (i.e. no interactions with the vitreal network), will also show 
optimal mobility in an in vivo situation, where convective movement towards the posterior of the 
eye will only assist in the retinal delivery of injected particles. Also, by implementing the obtained 
diffusion coefficients from our assay in the transport formulas describing coupled convective-
diffusive transport, a more relevant view of in vivo nanoparticle distribution in the vitreous humor 
can be obtained. A last important remark regarding the in vivo relevance of our assay relates to the 
liquefaction of the vitreous humor in elderly patients. This liquefaction entails a breakdown of the 
collagen network and a clustering of the remaining proteoglycans 65, thereby altering the vitreal 
network mesh size and influencing the results obtained by our assay. Nevertheless, as the 
disintegration of the collagen network should result in less steric hindrance, we believe this implies 
an increased mobility of the nanoparticles in liquefied vitreous humor and therefore a more efficient 
delivery to the back of the eye. To summarize, we believe the use of cadaveric bovine eyes  is not 
only beneficial for the cost and availability of the assay, we also feel the relevance to the in vivo 
situation is guaranteed for the most important parameters. 
C O N C L U S I O N S  
In this study, we developed a robust method to accurately evaluate the suitability of nanoparticles 
for intravitreal injection, which is crucial for the rational design of nanomedicines for intravitreal drug 
and gene delivery. More specifically, the mobility of nanomedicines in the vitreous humor can be 
quantitatively evaluated by using single particle tracking microscopy in an ex vivo bovine vitreous 
model. This new method was validated by further investigating the relation between nanoparticle 
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characteristics and intravitreal mobility. We found that positively charged nanoparticles show a 
heterogeneous diffusion profile in vitreous humor, where a small fraction remains mobile, but the 
majority is immobilized on what is presumed to be collagen fibrils. Aside from this electrostatic effect, 
we found indications that hydrophobic interactions with the vitreal matrix can also decrease 
nanoparticle mobility. Therefore, a PEGylated, negatively charged surface guarantees intravitreal 
mobility, independent of nanoparticle size in the sub-micron range. The results for polystyrene 
nanospheres were confirmed for cationic gene nanomedicines. By PEGylating the polyplexes, the 
mobile fraction could be maximized and optimal intravitreal mobility could be ensured. Taken 
together, the proposed assay can provide accurate intravitreal mobility data of single nanoparticles, 
essential for optimizing the drug delivery efficiency after intravitreal injection. We have clear 
evidence that cationic particles are inefficient in terms of intravitreal mobility, but that a negative 
surface charge and a hydrophilic coating could be useful strategies to ensure intravitreal mobility. 
F U T U R E  P E R S P E C T I V E S  
Ocular gene therapy has the potential to improve the comfort of life of millions of people suffering 
from blinding dystrophies. A major bottleneck in this field remains the delivery of gene 
nanomedicines to the retinal target cells. Intravitreal injection is preferred over subretinal injection 
due to the repeatability of the procedure and the feasibility of providing the treatment on a large 
scale, despite the possible barrier effect of the vitreous humor. Also, it is important to realize that 
intravitreally injected nanomedicines encounter other barriers as well, such as the retina itself or the 
inner limiting membrane that separates the retina from the vitreous humor. Indeed, most of the 
inherited blinding disorders affect either the RPE cells or the photoreceptor cells, both of which are 
located at the posterior part of the retina. Nevertheless, previous reports did reveal migration of 
intact nanoparticles to RPE cells following intravitreal injection, possibly via transcytosis through the 
Müller glial cells 39, 40, 66, 67, as well as recent publications showing transduction of RPE and 
photoreceptor cells after intravitreal injection of viral particles 25. Therefore, what happens with 
nanomedicines at the vitreoretinal interface and the evaluation of transretinal transport is also an 
aspect that should be further investigated. Advanced microscopy techniques are expected to play an 
important role in this. 
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Supplementary movies can be found online:  
(http://www.futuremedicine.com/doi/suppl/10.2217/nnm.12.202) 
Supplementary Movie 1 
Fluorescence movie acquired of anionic PS100COOH particles diffusing in the proposed vitreous 
model. On the left-hand side the original movie is displayed, on the right-hand side the particle 
trajectories are overlaid. These trajectories, typically between 20 – 50 in 1 movie, contain the 
mobility data of the nanoparticles from which the Da-distributions and α-distributions are derived. It 
can be seen for the PS100COOH particles that the majority remains mobile, however some 
immobilization is still noticed.  
Real-time speed; Scale bar = 10 µm 
Supplementary Movie 2 
Fluorescence movie acquired of cationic PS100DMEDA particles diffusing in the proposed vitreous 
model. On the left-hand side the original movie is displayed, on the right-hand side the particle 
trajectories are overlaid. These trajectories, typically between 20 – 50 in 1 movie, contain the 
mobility data of the nanoparticles from which the Da-distributions and α-distributions are derived. It 
can be seen for the PS100DMEDA particles that the majority of the nanoparticles is immobilized 
along fibril-like structures. However, a small fraction does retain some mobility.  
Real-time speed; Scale bar = 10 µm 
Supplementary Movie 3 
Fluorescence movie acquired of hydrophilic PS100PEG particles diffusing in the proposed vitreous 
model. On the left-hand side the original movie is displayed, on the right-hand side the particle 
trajectories are overlaid. These trajectories, typically between 20 – 50 in 1 movie, contain the 
mobility data of the nanoparticles from which the Da-distributions and α-distributions are derived. It 
can be seen for the PS100PEG particles that the mobility is drastically increased, and no 
immobilization is seen.  
Real-time speed; Scale bar = 10 µm 
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Nanoparticle distribution after intravitreal injection based on diffusion 
To calculate the distribution of nanoparticles after a certain amount of time after intravitreal 
injection, consider an amount of substance M that is deposited as a point source in 3-D space at time 
t=0 (assuming a central injection in an eye with a diameter of 20 mm). According to Fick’s second law, 
the concentration as a function of time and space is given by (Crank 1975): 
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where C is concentration, D is the diffusion coefficient, t is time and r is the distance after a certain 
time t. Integration yields the amount of substance m that has gone past a distance R at time t>0: 
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Thus it can be calculated that, for R = 1 cm and D = 1 µm²/s, 10% of the particles with a diffusion 
coefficient of 1 µm²/s has moved beyond 1 cm after ~92.6 days, while this is ~244.2 days for 50% of 
the particles and ~990.7 days for 90% of the particles. 
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A B S T R A C T  
Surface coating of nanomedicines with polyethylene glycol (PEG) can be beneficial to avoid 
unwanted interactions with  extracellular components. However, it is known to inhibit cellular 
interactions as well, drastically reducing therapeutic efficacy of PEGylated nanomedicines. In this 
work, hyaluronic acid (HA) is proposed as an alternative to PEG. Because of its biocompatible and 
non-immunogenic nature, HA has gained increasing attention by the advanced drug delivery 
community as an additive for the delivery of nanomedicines and gene therapeutics. In the following 
chapter, we will provide a general introduction to HA and its uses in drug delivery. Though HA is 
being used more frequently in ocular drug delivery approaches, the scope of this chapter specifically 
details its uses as an additive for the delivery of gene therapeutics. Finally, since it is known that 
native HA has a diverse array of functions depending on its molecular weight (MW), the final 
paragraph of this chapter is aimed at informing the reader that this variable should not be ignored 
when using HA in a drug delivery setting.  
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The field of nanomedicine and advanced drug delivery has benefited greatly from the use of 
polyethylene glycol (PEG) as a surface coating. PEGyaltion bestows nanomedicines with stealth 
properties, prolonging half-life in the blood circulation and preventing unwanted interactions with 
extracellular matrices. However, some problems associated with PEG are the decreased cellular 
uptake due to steric hindrance and shielding of surface charge, as well as putative immunogenic 
responses upon multiple administrations. Therefore, in the context of this thesis, we have proposed 
hyaluronic acid (HA) as an alternative coating strategy to PEGylation. Indeed, HA has been already 
frequently employed in a drug and gene delivery setting, as well be discussed in the following 
chapter. 
I N T R O D U C T I O N  T O  H Y A L U R O N I C  A C I D  
Hyaluronic acid (HA) is a nonsulfated glycosaminoglycan (GAG), composed of alternating disaccharide 
units of N-acetyl-D-glucosamine (GlcNAc) and D-glucuronic acid (GlcA), linked by alternating β-1,4 
glycosidic bonds and β-1,3 glucuronidic bonds (Figure 3.1) 6. Despite its plain appearance, its 
functions and interactions are extremely diverse depending on its size. In mammalian organisms, 
native HA is usually found as an unbranched, high molecular weight (HMW) (several million Daltons) 
linear polymer with exceptional physicochemical properties. In this HMW form, HA is one of the main 
constituents of the extracellular matrix (ECM) and is known to have a mechanical and structural role 
in the synovial fluid, the vitreous humor of the eye and in connective tissues of e. g. the umbilical 
cord and dermis 7. Aside from these extracellular functions conveyed by the physicochemical 
properties of HA, so-called HA binding hyaladherins extend the functionality of HA to the modulation 
of cellular fate by receptor-mediated intracellular signaling. For example, HA has been suggested to 
influence cell signaling to the cyclin D1 pathway 8, regulate the immune response 9 and influence 
 
Figure 3.1 | Chemical structure of hyaluronic acid. Reprinted from 5 
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both cell proliferation and migration 10, 11. Some hyaladherins play important roles in the degradation 
and uptake pathways of HA, mostly cell receptors in contact with the extracellular environment. To 
date, already several of these HA-specific cell receptors have been identified, such as cluster 
determinant 44 (CD44), receptor for hyaluronate-mediated motility (RHAMM), HA receptor for 
endocytosis (HARE) and lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), all with specific 
functions. More detailed information about these various HA binding proteins and their respective 
functions can be found in an extensive review recently published by Jiang et al. 12. 
Nowadays, HA is easily extracted from rooster combs or produced by microbial fermentation 13. In 
the medical field, non-immunogenic, highly viscous HA solutions are commercially available as a 
surgical aid in ophthalmology and as viscosupplementation for synovial fluids in patients with 
osteoarthritis 7. The ubiquitous distribution of HA throughout the body and its intrinsic properties 
such as hydrophilicity, biocompatibility, biodegradability and non-immunogenicity all endorse the 
use of HA for biomedical needs. Aside from these advantages, several other characteristics have 
encouraged the use of HA in drug delivery. The muco-adhesive properties of HA were exploited to 
increase the residence time of small molecule therapeutics on ocular mucosa or in topical wound 
healing 14, 15, whereas the hydrophilic nature of HA was employed to reduce unspecific interactions 
with proteins in the bloodstream and prolong in vivo circulation time 16. Nearly ten years ago, it was 
documented that the hydrophilic nature of HA could also serve as a cryoprotectant in the 
preparation of unilamellar liposomal formulations 17. When using liposomes for drug delivery, the 
unilamellar structure is of utmost importance. Upon rehydration after lyophilization, the emulsions 
usually revert back to multilamellar liposomes, yet it was found that the covalent attachment of HA 
on the unilamellar liposomes could preserve their structure after rehydration. Finally, one of the 
most promising advantages of HA is based on the previously mentioned interactions with HA-specific 
cell receptors such as CD44, rationalizing HA as a targeting strategy to CD44-(over) expressing tissues, 
such as tumors and diseased livers 18-20. This targeting strategy was elegantly documented in vitro by 
Surace et al. in HA receptor-expressing cells compared to control cells (Figure 3.2) 4. Taken together, 
it is widely acknowledged that HA can provide several advantages to drug delivery, and in the next 
section we would like to highlight the use of HA specifically for nucleic acid delivery vectors. 
H Y A L U R O N I C  A C I D - B A S E D  M A T R I C E S  
Since HA is advantageous in terms of biodegradability and non-immunogenicity, and given its use in 
drug delivery 7, 13, it would make sense to propose this biopolymer as a nucleic acid delivery vector. 
Unfortunately, due to the negative charge of both HA and nucleic acids, nucleic acid nanoparticles 
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(NPs) based solely on HA are not that common. Regardless, some groups have reported on the ability 
of HA matrices to incorporate therapeutic nucleic acids.  HA hydrogels and microspheres were 
evaluated for the sustained release of pDNA encoding for platelet derived growth factor (PDGF) 21 
and β-galactosidase 22, respectively. The HA matrices were formed by an adipic dihydrazide (ADH) 
crosslinking reaction, where pDNA and HMW HA are mixed together,  after which ADH and 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) are added to ensure crosslinking. Another group 
employed a film of ADH-crosslinked HA as a physical barrier to prevent post-operative peritoneal 
adhesions, where the film was also able to release previously incorporated pDNA encoding for 
hyaluronan synthase 2 in the peritoneal cavity over a prolonged period of time 23. In all three studies, 
the sustained release of the pDNA was confirmed in vitro by degradation of the matrices in a 
 
Figure 3.2 | In vitro targeting properties of HA towards the CD44 receptor, as demonstrated by 
Surace et al. Comparative transfection efficiency in MCF-7 (A) and MDA-MB231 (B) cells treated 
with DE:DOPE lipoplexes (black) and lipoplexes containing 0.10 mg/mL of HA-DOPE conjugate 
(white) in the presence of increasing amounts of anti-CD44 antibody Hermes-1 and anti-ErbB2 
antibody used as control. It is noticed that lipoplexes containing the HA-DOPE conjugate show an 
increased transfection efficiency in HA receptor-containing MDA-MB231 cells compared to MCF-7 
cells. This increase in transfection efficiency is downregulated by increasing amounts of anti-CD44 
antibody, indicating a CD44 receptor-specific uptake in MDA-MB231 cells. Reproduced with 
permission from ref 4. 
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hyaluronidase solution. The released pDNA was shown to be intact and bioactive by in vitro 
transfection assays using commercially available transfection agents. Consequently, aside from the in 
vivo data by Yun et al. 22, it must be emphasized that in these studies only the bioactivity of the 
released pDNA was assessed. This way, the macroscopic HA matrices are only evaluated in terms of 
their ability to protect therapeutic DNA, not to ensure its uptake in the target cells, one of the most 
difficult barriers to overcome in nucleic acid delivery. To do so, some groups have proposed the use 
of HA hydrogels not only for their biocompatible features, but also for their known interactions with 
HA-specific cell receptors. In contrast with the larger hydrogels discussed previously, Lee et al. 
reported using an emulsion method and ultrasonication to fabricate nano-sized biodegradable thiol-
crosslinked HA nanogels, with anti-GFP-siRNA physically entrapped during the emulsification process 
24. The disulfide-linkages in the hydrogels were incorporated to ensure cargo release in the reductive 
intracellular environment, as was demonstrated by the release of intact siRNA in a glutathione-
concentration dependent fashion. Compared to cationic polymers such as polyethylene imine (PEI) 
and poly-L-Lysine (PLL), the HA hydrogels showed much lower cytotoxicity and higher gene silencing 
capabilities in the presence of serum. Additionally, the purpose of HA to guarantee specific uptake of 
the hydrogels in HA receptor-positive cells was verified by a competitive binding assay in HCT-116 
cells, where the co-incubation of HA/siRNA-hydrogels with free HA drastically decreased the gene 
silencing effect, indicative of the specific uptake of the hydrogels by HA receptor-mediated 
endocytosis 24. 
H Y A L U R O N I C  A C I D  A S  A N  A D D I T I V E  I N  N U C L E I C  A C I D  
N A N O T H E R A P E U T I C S  
HYALURONIC ACID POLYELECTROLYTE COMPLEXES 
As mentioned before, HA on its own is not considered a good nucleic acid vector due to its negative 
charge. Therefore, HA is mostly used as an additive to an existing nucleic acid carrier to endow the 
latter with added advantages. As it is known that most nucleic acid vectors have a positive charge, 
anionic HA can be electrostatically complexed with these cationic polymers and the nucleic acids to 
form poly-electrolyte complexes (PECs) by supramolecular self-assembly. By mixing low molecular 
weight (LMW) HA with biodegradable poly-L-arginine, PECs capable of complexing siRNA were easily 
formed 25. The authors proposed to incorporate HA in the siRNA-vector to grant additional HA 
receptor-specific targeting capabilities. Besides an increased colloidal stability in physiological 
conditions, the proposed targeting advantage was confirmed by an in vitro uptake profile and in vivo 
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gene silencing effect which was positively correlated with CD44 receptor density. Crosslinked 
hyaluronic acid-chitosan oligomer (HA-CSO) PECs were synthesized by de la Fuente et al. to improve 
the gene delivery potential in the cornea by prolonging residence time of gene delivery NPs on the 
ocular mucosa due to HA’s muco-adhesive nature 26. The particles in this study were prepared by an 
ionotropic gelation technique, where CSOs were mixed with a solution containing HA, 
tripolyphosphate and the desired pDNA. Furthermore, the authors propose that HA might influence 
the intracellular trafficking of the gene carriers towards the perinuclear region of the cell, given 
previously published data by Tammi et al. 27 and Evanko et al. 28. This premise was further studied by 
Contreras-Ruiz et al. by visualizing the uptake of the same crosslinked HA-CSO hydrogels using live 
cell fluorescence microscopy 1. It was shown that the NPs were effectively taken up in an HA 
 
Figure 3.3 | Internalization pathway for hyaluronic acid (HA) – chitosan oligomer (CSO) NPs, as 
proposed by Contreras-Ruiz et al.. The HA on the particles interacts with CD44 receptors in the 
plasma membrane, triggering the caveolae-mediated internalization of the NPs. From the 
caveosome, NPs are sorted to the endoplasmic reticulum (ER) and then to the nucleus, bypassing 
the lysosomal degradation pathway. CD44 receptors and caveolin are then recycled and carried 
back to the membrane through the Golgi network. The authors therefore envision HA as a 
targeting ligand not only for the CD44 receptor, but also for the caveolae-mediated endocytic 
pathway. Reproduced with permission from ref 1. 
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receptor-specific process. Further experiments with chemical inhibitors of endocytic processes 
demonstrated that the particles were not taken up by clathrin-mediated endocytosis, but rather by 
caveolin-mediated endocytosis, which was confirmed by colocalization studies of NPs with caveolin 1. 
As it has previously been reported that caveolin-dependent endocytosis bypasses the lysosomal 
degradation pathway and delivers its cargo near the Golgi apparatus or in the perinuclear region 29, 
the authors postulate the idea of HA as a targeting ligand not only for HA-specific cell receptors, but 
also for intracellular compartments (Figure 3.3).  
HYALURONIC ACID-BASED CONJUGATES 
For a more stable and permanent availability of HA on the nucleic acid vector, some groups prefer to 
covalently attach an HA-molecule to the building blocks of the NP before the self-assembly. Several 
HA-conjugates have already been described in the literature. For example, Takei et al. conjugated 
LMW HA to PLL by a reductive amination reaction using sodium cyanoborohydride (NaBH3CN) as a 
reductant 30. The resulting copolymer was able to efficiently complex pDNA due to the cationic PLL. 
The HA bestowed the carrier with in vivo HARE receptor-specific targeting properties, as 
demonstrated by the enrichment of particles at liver sinusoidal endothelial cells after intravenous 
injection in animal models. Usually though, the carboxyl-groups on the HA are activated with EDC in 
acid buffer to form a highly reactive O-acylisourea, which can easily react in a basic medium with a 
free amine to form a covalent amide-linkage. These free amine groups are frequently encountered 
on most known nonviral polymeric nucleic acid vectors, such as PEI. By conjugating PEI on a HA 
backbone via amide-bonds, Jiang et al. envisioned a nonviral nucleic acid carrier with the target-
specific and biocompatible advantages of HA, whilst retaining the ability to escape the endosomes 
via the buffering effect of the amine-containing PEI 31. These conjugates were able to efficiently 
complex siRNA by means of electrostatic interactions with the amine groups of PEI. The authors 
demonstrated the HA receptor-specific binding in vitro with preferred uptake and enhanced silencing 
effects in LYVE-1-expressing cells (B16F1 cells) compared to HEK 293 cells, which do not express HA-
specific receptors.  
To determine how the chemical conjugation of PEI to HA would affect its receptor-specificity, the 
authors investigated in a follow-up study the receptor-mediated uptake of quantum dot (Qdot)-
modified HA in different mol %, and showed an increased accumulation of Qdot-HA conjugates in the 
liver up to 35 mol % modification, and a non-targeted systemic distribution with higher mol % 
modifications 31, 32. Less mol % modification with PEI resulted in the inability of the conjugates to 
form complexes with siRNA due to the shortage of positive groups, which was demonstrated in their 
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first study 31. To complement the in vitro targeting studies of the HA coated NPs, Jiang et al. further 
investigated the particles in terms of in vivo targeting. After injection in xenografted C57BL/6 mice, 
the authors note that the HA coated particles preferably accumulate in tissues with HA receptor-
expressing cells, such as the liver, kidneys and tumors, in agreement with in vivo data on the QD-HA 
conjugates 32. The siVEGF-PEI/HA particles were significantly better at suppressing tumor growth 
compared to uncoated siVEGF/PEI complexes 33. Aside from the main advantage of HA receptor 
specificity, the authors also noted that the HA-PEI conjugates showed less cytotoxicity in vitro 
compared to PEI alone, yet still more cytotoxic than HA alone. To further optimize the nucleic acid 
carrier, the group proposed to use LMW PEI crosslinked with cystamine bisacrylamide (CBA). This 
disulfide-linked PEI is known to be less cytotoxic because of its biodegradability in reductive 
environments, and Park et al. examined if an HA/SS-PEI conjugate would still show the same 
targeting abilities. These optimized particles were employed in in vivo studies for tumor therapy with 
anti-VEGF-siRNA and to treat liver cirrhosis with anti-transforming growth factor-β siRNA targeted to 
the liver 2, 34. In a first study, the authors demonstrated an enhanced therapeutic effect of the 
siVEGF/SS-PEI/HA-nanoparticles after intratumoral injection compared to siVEGF/SS-PEI-particles, 
indicating the preservation of tumor-specific targeting (Figure 3.4) 2. In a follow-up study, a 
therapeutic effect was noticed after intravenous injection, which they attribute in part to the 
maintained targeting effects towards cirrhotic livers, yet also to the decreased unspecific interactions 
with blood proteins and longer circulation time on the other. 
This enhanced biodistribution of HA-coated particles was correspondingly visualized in a study by 
Choi et al., where HA-NPs were intravenously injected in tumor-bearing mice and analyzed at 
different time-points (Figure 3.5) 3. In contrast to the HA/polycation-conjugates used by Park et al., 
the HA particles in the study of Choi and coworkers had a hydrophobic segment incorporated, such 
as 5β-cholanic acid, to further ensure the spontaneous self-assembly of core/shell-structured NPs. 
This has already been used in a drug delivery setting, where the authors hoped the HA-shell would 
confer colloidal stability and mobility in the vitreous humor, the extracellular matrix in the center of 
the eye 35. Here, hydrophobic small molecule drugs could easily be loaded in the hydrophobic core, 
but in the context of nucleic acid delivery the loading of hydrophilic nucleic acids could pose a 
problem. Nevertheless, there have been reports of hydrophobation of nucleic acids with CTAB 36, 
enabling its complexation in the hydrophobic core, although the possible toxic effects of CTAB 37 was 
not further investigated in this study.  
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A more elegant approach was proposed by Shen et al., who added a cationic spermine segment to 
the HA block copolymers for the complexation of siRNA 38. In their study, the authors wanted to 
elucidate the uptake mechanism of HA coated particles, and found that they were mostly 
endocytosed by caveolae-dependent endocytosis. These findings nicely concur with the proposed 
hypothesis of Contreras-Ruiz and colleagues to employ HA as a targeting ligand towards the 
caveosome 1. Nevertheless, a different study by Zaki et al. reported on the clathrin-dependent 
uptake mechanisms of both uncoated and HA-coated nucleic acid NPs 39. The differences between 
the findings of Zaki et al. on the one hand 39, and Shen et al. 38 and Contreras-Ruiz et al. 1 on the 
other, could be explained in part by the different cell types used or the size of the particles. Indeed, 
 
Figure 3.4 | Anti-tumoral therapeutic effect of anti-VEGF-siRNA (siVEGF)/(PEI-SS)-b-HA complex in 
female balb/c mice where CT-26 colon cancer cells were injected for tumor inoculation and 
growth. (A) Tumor volume change with increasing time after intratumoral injection of a control of 
5% glucose solution, siVEGF/PEI-SS, non-specific Luc siRNA (siLuc)/(PEI-SS)-b-HA, and siVEGF/(PEI-
SS)-b-HA complexes. The treatments were performed three times after 8, 11, and 14 days. The 
results represent mean ± SD (n = 3). (B) Photo-images of dissected tumor tissues after 20 days. 
Both in (A) and (B), the increased therapeutic effect of HA-containing particles is clearly seen. 
Reproduced with permission from 2. Copyright  Elsevier. 
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despite the fact that the findings of Contreras-Ruiz et al. 1 agree with those of Shen et al. 38, the latter 
authors attributed the caveolae-dependence to the size of the particles rather than claiming HA can 
be used as a targeting ligand to an intracellular compartment. It has been reported that particle size 
can influence the uptake pathway where larger particles around 200 – 500 nm in size would 
preferably be endocytosed in a caveolae-dependent manner 40. In short, the intracellular targeting of 
NPs can’t solely be attributed to the presence of HA and regarding the previously mentioned studies, 
some other remarks should also be taken in consideration. When interpreting data from chemical 
endocytosis inhibitor experiments, care should always be taken. Aside from the risk of eliciting 
cytotoxicity, the effects of these inhibitors are usually poorly characterized, non-specific and cell 
type-dependent 41, 42, all of which might influence the findings of the previously mentioned studies.  
 
Figure 3.5 | In vivo biodistribution of Cy5.5-labeled particles consisting of 5β-cholanic acid 
(CA)/hyaluronic acid (HA)-conjugates. 2, 6 and 10 denote the degree of substitution (DS), defined 
as the number of CA molecules per 100 sugar residues of HA. (A) In vivo non-invasive 
fluorescence imaging of HA-NPs in tumor-bearing mice. Time-dependent whole body images of 
athymic nude mice bearing SCC7 tumors after intravenous injection of HA-NPs. Arrows indicate 
the sites of tumors. (B) Ex vivo fluorescence images of normal organs and tumors collected at two 
days post-injection of HA-NPs. (C) Quantification of the ex vivo tumor targeting characteristics of 
HA-NPs in tumor-bearing mice. Error bars represent standard deviation (n = 3). Reproduced with 
permission from 3. Copyright  Elsevier. 
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HYALURONIC ACID CORE-SHELL PARTICLES 
The conflicting results between caveolae-dependent endocytosis 1, 38 and clathrin-dependent 
endocytosis 39 could also be attributed to a different particle structure. Instead of incorporating HA in 
a PEC or a covalently attached micelle-coat, Zaki et al. employed an electrostatic “post-coating” 
strategy, where HA is added to a preformed crosslinked chitosan/TPP core to ensure HA availability 
by means of an outer HA-shell. Indeed, this electrostatic complexation could prove beneficial, as it 
had been suggested by Kim et al. that chemical modification could disturb the functionalities of 
native HA 25. Moreover, because the negative charge density of HA is not high enough to displace the 
electrostatic bonds between the nucleic acids and the polymer, HA would be unable to displace the 
nucleic acids or even disturb supramolecular self-assembled PECs 43. Electrostatic coating of 
preformed cationic PEI/pDNA polyplexes was documented by Hornof et al. 44, who justified a LMW 
HA coating by facilitating uptake in human corneal epithelial (HCE) cells via CD44-mediated 
endocytosis. Wang et al. employed the same strategy to improve stability in physiological conditions 
and specifically target HA receptor-expressing cells 45. Again, HA was added to preformed PEI/pDNA 
binary polyplexes, resulting in negatively charged ternary complexes which displayed increased 
stability in physiological salt media compared to the uncoated polyplexes. Furthermore, shielding of 
the polyplexes with HA resulted in a significant increase in transfection efficiency in HA receptor-
expressing HepG2 cells, while a decreased transfection efficiency was observed in HEK 293T cells. 
Interestingly, the significant rise in transfection efficiency in the HepG2 cells could not be related to 
an increased uptake. The lack of correlation between uptake and transfection efficiency had already 
been reported by a previous study of Ruponen et al. 43, where it is suggested that downstream 
intracellular processing mechanisms might contribute more to the final transfection efficiency than 
uptake alone. Wang et al. attributed the increase in transfection efficiency to the relaxation of 
DNA/polycation interactions which would allow the gene transcription machinery to more easily 
reach the complexed DNA 45, a hypothesis previously postulated by Ito et al. 46. In their study, the 
authors describe the formation of ternary HA coated PEI/pDNA complexes and specifically 
investigate the influence of HA on transcription of complexed DNA. They observe with in vitro assays 
that HA increases both DNA transcription as well as DNA relaxation and conclude that HA might 
display high mobility group (HMG)-like properties, which enhance transcription by granting the 
transcription machinery easier access to the genes. Similarly, Xu et al. noticed an increase in 
transfection efficiency independent of uptake when evaluating ternary HA/CLPEI/pDNA complexes in 
NIH/3T3 cells 47. These polyplexes consist of pDNA complexed by LMW PEI-fragments crosslinked 
with disulfide linkages (CLPEI), which are electrostatically coated with HA for increased stability in the 
extracellular environment. The authors hypothesized that increase in transfection efficiency was 
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because of the HA which helps DNA unpacking triggered by the intracellular CLPEI degradation, by 
further loosening the interactions between complexed DNA and LMW polycations. Likewise, it was 
observed by de la Fuente et al. that the combination of HA and LMW CSOs in their hydrogels resulted 
in very high transfection efficiencies, which was also explained by the proposed role of HA as a 
transcription activator and facilitator of DNA unpacking 26. 
Instead of polymers, other commonly used NA vectors are cationic liposomes 48. The group of Dan 
Peer has focused on the use of HA by covalently attaching it to the surface of preformed liposomes. 
They have previously shown that liposomes with mitomycin D preferentially accumulate at CD44-
overexpressing tumor tissue when coated with HMW HA 16. They noticed that the effect of HA is two-
fold: (1) HA acts as a targeting ligand in vitro to cells overexpressing hyaluronan receptors; (2) HA 
provides the particles with a longer circulation time in vivo by eluding unspecific interactions with 
blood components. What is more, the authors discovered a new advantage of HA, being its use as a 
cryoprotectant 17. In a later study, the liposomes coated with HA are used for the in vivo delivery to 
leukocytes of siRNA against cyclin D1 49. The targeting to the leukocytes was not done by using the 
HA as a ligand, rather HA was used as an easily modifiable intermediate to graft targeting antibodies. 
Furthermore, HA was used for liposomal stability during rehydration after lyophilization and to 
prolong the circulation time in vivo. 
Some groups argue that a post-coating as described before, where HA is covalently attached to 
preformed liposomes, does not grant enough control over loading density which is deemed highly 
necessary for proper targeting 4. By conjugating HMW HA molecules on 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) lipids via an EDC-facilitated amide-bond, liposomes with an outer HA 
shell could be made with sufficient control of HA loading. These liposomes were evaluated in terms 
of delivery of both pDNA 4 and siRNA 50.  Surace et al. prepared liposomes consisting of cationic lipid 
[2-(2,3-didodecyloxypropyl)-hydroxyethyl] ammonium bromide (DE) and DOPE, complexed with 
pCMV-Luc plasmids 4. These lipoplexes were then evaluated in CD44-expressing MDA-MB-231 cells, 
as well as in MCF-7 control cells with very low CD44 expression (Figure 3.2). Taetz et al. used 
DOTAP:DOPE liposomes to validate HA receptor-targeted gene silencing of the HA coating in CD44-
expressing A549 cells and in non-hyaladherin-expressing Calu-3 cells 50. Both studies demonstrated a 
very low toxicity in all cell lines, attributed to the negative surface charge. Also, the targeting 
properties of the NPs were confirmed by an increased transfection efficiency in CD44-expressing 
cells, compared to a lower transfection in the control cell lines. 
In conclusion, the use and advantages of HA in the field of nucleic acid delivery are being actively 
investigated in combination with many known nucleic acid delivery vectors and in many different 
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particle structures. Therefore, it should be noted that every method has its own merits and pitfalls, 
yet a clear consensus on NP structure has not been found yet. 
I N F L U E N C E  O F  H Y A L U R O N I C  A C I D  M O L E C U L A R  W E I G H T  
In the wealth of literature concerning the use of HA as an aid in drug or nucleic acid delivery, a lot of 
contradictory findings have been documented. As previously stated, this could be explained in part 
by a different NP structure or the different cell types used. However, the MW of the HA molecules 
should also be taken into account, because it has been documented that the functions of free HA in 
the body is mostly determined by its MW 51. For example, HMW HA chains are non-immunogenic 
whereas LMW HA oligomers are suspected to elicit immune-responses. It has also been documented 
that HA oligomers have a tumor-suppressive ability 11, whereas HA of a different MW are thought to 
have a general stimulating effect of tumor growth 10. These effects are presumably modulated by HA-
binding receptors overexpressed in the tumors, indicating the interaction of HA with hyaladherins is 
also dependent on MW of the HA molecule 52. Yet, as a targeting ligand towards the CD44 receptor, 
HA has been used in its LMW form 25, 44, its HMW form 4, 50 and a middle MW form 24. Some groups 
acknowledge the alleged effect of MW on HA functions and have investigated accordingly. Hornof et 
al. have tried to optimize an electrostatically shielded particle with different MWs of HA (<10 kDa, 10 
– 30 kDa, 30 – 50 kDa) 44. The authors find that a LMW coating (<10 kDa) is most adept at providing 
the carriers both with colloidal stability in physiological media as with a targeting function. However, 
the HA fractions used in this study only cover a very small part of the entire range of MW, mostly in 
the LMW range. A more comprehensive study by Mizrahy et al. compared 5 different fractions, 
ranging from LMW 6.4 kDa HA to HMW 1500 kDa HA, for the effects on innate immune response and 
CD44 targeting 53. Contrary to the previous findings, they document that the binding affinity towards 
the CD44 receptor is increased with increasing HA MW. In conclusion, because it is generally 
accepted that the different functions of HA in the body are solely regulated by its MW, this factor 
should not be overlooked when employing HA in a drug or nucleic acid delivery setting. 
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A B S T R A C T  
Retinal gene therapy could potentially affect the lives of millions of people suffering from blinding 
disorders. Yet, one of the major hurdles remains the delivery of therapeutic nucleic acids to the 
retinal target cells. Due to the different barriers that need to be overcome in case of topical or 
systemic administration, intravitreal injection is an attractive alternative administration route for 
large macromolecular therapeutics. Here it is essential that the therapeutics do not aggregate and 
remain mobile in the vitreous humor in order to reach the retina. In this study, we have evaluated 
the use of hyaluronic acid (HA) as an electrostatic coating for nonviral polymeric gene 
nanomedicines, p(CBA-ABOL)/pDNA complexes, to provide them with an anionic hydrophilic surface 
for improved intravitreal mobility. Uncoated polyplexes had a Z-averaged diameter of 108 nm and a 
zeta potential of +29 mV. We evaluated polyplexes coated with HA of different MWs (22 kDa, 137 
kDa and 2700 kDa) in terms of size, surface charge and complexation efficiency and noticed their zeta 
potentials became anionic at 4-fold molar excess of HA-monomers compared to cationic monomers, 
resulting in submicron ternary polyplexes. Next, we used a previously optimized ex vivo model based 
on excised bovine eyes and single particle tracking microscopy to evaluate mobility in intact vitreous 
humor. It was confirmed that HA-coated polyplexes had good mobility in bovine vitreous humor, 
similar to polyplexes functionalized with polyethylene glycol, except for those coated with high 
molecular weight HA (2700 kDa). However, contrary to PEGylated polyplexes, HA-coated polyplexes 
were efficiently taken up in vitro in ARPE-19 cells, despite their negative charge, indicating uptake via 
CD44-receptor mediated endocytosis. Furthermore, the HA-polyplexes were able to induce GFP 
expression in this in vitro cell line without apparent cytotoxicity, where coating with low molecular 
weight HA (22 kDa) was shown to induce the highest expression. Taken together our experiments 
show that HA-coating of nonviral gene complexes is an interesting approach towards retinal gene 
therapy by intravitreal administration. To our knowledge, this is the first time electrostatic HA-
coating of polyplexes by different MWs has been evaluated in terms of their suitability for intravitreal 
delivery of therapeutic nucleic acids towards the retina. 
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I N T R O D U C T I O N  
Gene therapy has long been recognized as a promising therapeutic avenue to effectively treat 
dystrophies with a genetic cause. Especially retinal gene therapy has been identified as a favored 
candidate, as the eye is an easily accessible organ which is shielded from systemic circulation, thus 
minimizing potential unwanted side-effects. Furthermore, in recent years several blinding 
dystrophies have been linked to genetic aberrations in the retina, such as RPE65-Leber congenital 
amaurosis (RPE65-LCA), Leber Hereditary Optic Neuropathy (LHON) and X-linked juvenile 
retinoschisis. The promise of gene therapy was substantiated in different clinical studies in patients 
suffering from RPE65-LCA 1-4, which further spurred research on retinal gene therapy.  
To protect the therapeutic nucleic acids (NAs) from degradation during the delivery process and to 
aid in their transport towards the target cells, they are usually packaged into nano-sized particles. 
Even though most clinical successes so far have been achieved with viral vectors, cost and safety 
concerns dictate the need for cheaper and safer alternatives 5. Nonviral vectors, such as cationic 
liposomes and polymers, can be designed to be biocompatible and are more easily manufactured on 
a large scale 6.  When combined with negatively charged NAs, they spontaneously form binary 
polyelectrolyte complexes (PECs) of about 100 – 200 nm in size, with easily adaptable surface 
characteristics 7. In the case of retinal gene therapy, these NA/carrier complexes have to be delivered 
into the target cells in the neural retina or retinal pigment epithelium (RPE), located at the posterior 
part and the periphery of the eye (Figure 4.1). However, the impermeability to large macromolecular 
compounds of the blood-retina barrier (BRB) and the corneal epithelium discourage systemic 
administration and topical instillation, respectively 8. Therefore, intraocular administration routes 
which bypass these ocular barriers are frequently employed (Figure 4.1). While clinical success has 
been achieved primarily by subretinal injection of nanoparticles, this procedure is known to be very 
invasive, potentially associated with serious adverse effects and not feasible on a large scale 9. 
Therefore, intravitreal injection represents an attractive alternative route of administration, with the 
essential requirement that the therapeutics remain mobile in the vitreous humor in order to reach 
the retinal target cells. Indeed, we have previously shown that the vitreous humor poses a barrier to 
nanocarriers for retinal gene delivery 9, 10.  
Recently we reported on an ex vivo assay for measuring the mobility of fluorescent nanoparticles in 
intact vitreous humor on a single-particle level 9. By removing the anterior parts (cornea, iris, lens) of 
excised bovine eyes, an optical window was formed allowing us to use high-resolution fluorescence 
microscopy without damaging the fragile structure of the vitreous humor. This way, we were able to 
Chapter 4 
 
Page 94 
visualize diffusion of nanoparticles on a sub-resolution scale and analyze their behavior by using 
single particle tracking 9. We have shown that the mobility of gene nanomedicines in the vitreous 
body can be improved by shielding their cationic surface charge with a coating of polyethylene glycol 
(PEG). Unfortunately, however, PEGylation prevents successful cell transfection since the 
nanomedicines can no longer interact with the cell membrane and are not internalized by the target 
 
Figure 4.1 | Schematic illustration of different intra-ocular administration routes.   
Systemic and topical delivery of gene nanomedicines to the retina (shown in green) is hampered 
by different ocular barriers, such as the blood-retina barrier and the cornea, respectively (shown 
in red). Intra-ocular injections are used as an effective way to bypass these barriers. The upper 
syringe shows a subretinal injection, where the cargo is delivered in the subretinal space, 
between the neural retina and the RPE cell layer. The lower syringe shows an intravitreal 
injection, where the therapeutics are injected in the vitreous humor (central grey part). After 
intravitreal injection, the cargo has to migrate to the retinal target cells in the posterior part of 
the eye. 
 
  Chapter 4 
 
  Page 95 
cells 11, 12. Therefore, an alternative coating strategy is needed that combines excellent nanoparticle 
mobility in the vitreous humor with efficient cell uptake and transfection. 
In the present study we have evaluated hyaluronic acid (HA) for this purpose. HA is an anionic 
biodegradable, non-immunogenic biopolymer which is ubiquitously present in mammalian 
organisms. It is a nonsulfated glycosaminoglycan (GAG), composed of alternating disaccharide units 
of N-acetyl-D-glucosamine (GlcNAc) and D-glucuronic acid (GlcA), linked by alternating β-1,4 
glycosidic and β-1,3 glucuronidic bonds 13. Given its well-tolerated and biocompatible nature, HA has 
attracted a lot of interest in the field of drug delivery 13. HA was postulated as a cryoprotectant in the 
formulation of liposomal drug delivery vectors 14 and as a means of evading the complement system 
after intravenous injection 15, 16. Furthermore, it was used for targeting CD44-overexpressing tumor 
tissues 16-19, since it is known that HA is a ligand for receptors such as CD44, RHAMM, LYVE, etc. 13. HA 
might be an interesting molecule for ocular delivery as well since it is a major constituent of the 
vitreous humor, is found throughout the retina 20 and many retinal cell types have been shown to 
express CD44-receptors on their surface 21, 22.  
Here, we investigated the use of HA with different MWs (22 kDa, 137 kDa, 2700 kDa)  as an 
electrostatic coating of cationic polymeric pDNA gene complexes. These nonviral gene 
nanomedicines, composed of anionic plasmid DNA and the cationic N,N’-cystaminebisacrylamide-4-
aminobutanol (p(CBA-ABOL) vector), have shown promising gene transfection results in vitro with 
minimal cytotoxicity, owing to the repetitive disulfide linkages in the main poly(amido amine) 
backbone 9, 23. We demonstrate that electrostatic coating of the cationic polyplexes with HA results in 
negatively charged nanoparticles without compromising their ability to encapsulate pDNA. 
Furthermore, by comparing the intravitreal mobility of the nanoparticles in an ex vivo, single-particle 
based model, we show that coating with HA of 22 kDa and 137 kDa provides a marked increase in the 
mobile fraction of polyplexes. Finally, this study also documents the ability of these ternary PECs to 
interact with retinal pigment epithelial cells in vitro. With flow cytometry we show that the 
nanoparticles are still taken up by ARPE-19 cells and are able to induce GFP expression in the target 
cells, with minimal cytotoxic effects to the cells. 
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M A T E R I A L S  A N D  M E T H O D S  
Materials.  
Dulbecco's modified Eagle's medium supplemented with growth factor F12 (DMEM:F12 (1:1), 
OptiMEM™, Trypan Blue, L-glutamine, fetal bovine serum (FBS), penicillin-streptomycin solution 
(5000 IU/mL penicillin and 5000 μg/mL streptomycin) (P/S), and Dulbecco’s phosphate-buffered 
saline (DPBS 1x, with or without Ca2+/Mg2+) were supplied by GibcoBRL (Merelbeke, Belgium). 
Sodium hyaluronate of different molecular weights was purchased from LifeCore Biomedical 
(Minnesota, USA). All other reagents were purchased from Sigma-Aldrich (Bornem, Belgium) unless 
otherwise stated.  
Chromatographic analysis of hyaluronic acid. 
The molecular weights of hyaluronic acid (Figure 4.2A)  were determined with a Malvern Viscotek 
GPCmax (Pump and Injector) and a Malvern Viscotek TDA 302 detector (contains a refractive index , 
light scattering (RALS and LALS)  and viscosity detection). The eluent was PBS (pH = 7.4) at a flow rate 
of 1ml/min and 2 Agilent PL aquagel-OH Mixed 8µm columns were used in series. Columns and 
detectors were operated at 30°C. Calibration was done with a pullulan standard (180 kDa) also 
 
Figure 4.2 | Chemical structure of (A) hyaluronic acid, (B) CBA-ABOL and (C) CBA-ABOL-DMEDA’-
PEG 
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provided by Malvern. Data were recorded and the molecular weights were calculated with Malvern 
Omnisec software version 4.7. 
Plasmids.  
The plasmid constructs pGL4.13 and gwiz-GFP (Promega, Leiden, The Netherlands)were amplified in 
transformed E. Coli bacteria and isolated from a bacteria suspension with a Purelink™ HiPure Plasmid 
DNA Gigaprep kit K2100 (Invitrogen, Merelbeke, Belgium). Concentration and purity were 
determined by UV absorption at 260 nm and 280 nm on a NanoDrop 2000c (Thermo Fisher Scientific, 
Rockford, IL, USA). Finally, the plasmids were suspended at a concentration of 1 µg/µl and stored in 
25 mM HEPES, pH 7.2, at -20°C. Fluorescent labelling of pGL4.13 plasmids with YOYO-1™ (λex = 491 
nm, λem = 509 nm, Molecular Probes, Merelbeke, Belgium) was performed according to the 
manufacturer’s instructions and as previously published 9. Briefly, YOYO-1 iodide (1 mM in DMSO) 
was added to the plasmid at a mixing ratio of 0.15:1 (v:w), resulting in a theoretical labelling density 
of 1 YOYO-dye molecule per 10 base pairs. The mixture was incubated at room temperature for 4 
hours in the dark. To remove the DMSO and free YOYO-1, the labelled plasmid was precipitated by 
adding 2.5 volumes of ice-cold ethanol and 0.1 volume of 5 M NaCl. After incubation for 30 minutes 
at -80°C, centrifugation (14600 g, 30 minutes) and washing with clean 70 % ethanol, fluorescently 
labelled plasmid was finally resuspended in 25 mM HEPES, pH 7.2. The concentration of the plasmid 
was again determined by UV absorption at 260 nm, and adjusted to 1 µg/µl. 
Polyplexes.  
The polyplexes were made using the bioreducible polymer vector p(CBA-ABOL) (Figure 4.2B), which is 
a linear poly(amido amine) with repetitive disulfide linkages in the main chain, prepared by Michael-
type poly-addition of 4-aminobutanol (ABOL) to N,N’-cystaminebisacrylamide (CBA), yielding 
polymers with an average MW of 5.24 kDa 9, 23. p(CBA-ABOL)/DNA complexes were obtained by 
adding a polymer solution to a plasmid solution in a final mass ratio of 48/1 in 25 mM HEPES buffer 
pH 7.2, resulting in an N/P ratio of 45/1 .The mixture was vortexed for 10 s, after which they were 
allowed to stabilize for approximately 15 minutes at room temperature. Electrostatic coating of the 
previously prepared polyplexes was performed by adding HA-solution, with the appropriate amount 
of HA for the desired molar ratio, to an equal volume of polyplexes and vortexing 10 seconds, after 
which the ternary complexes were again allowed to stabilize for 10 minutes. For the PEGylated 
polyplexes, p(CBA-ABOL/DMEDA’/PEG) (Figure 4.2C) was used as polymer vector, obtained by 
Michael-type polyaddition of methoxyPEG amine (2250 Da), N,N’-dimethylethylenediamine 
(DMEDA’) and ABOL to CBA in a CBA/ABOL/DMEDA’/PEG molar ratio of 50/34/11/5, yielding 
polymers with an average MW of 7.3 kDa. The same protocol was used for the preparation and 
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characterization of these polyplexes. Fluorescently labelled polyplexes were obtained by using 
YOYO1-labeled plasmids, which has been described in the previous section. The plasmid was labelled 
instead of the vector, to minimize the influence of the labelling on the particle surface 
characteristics. 
Physical characterization of gene nanomedicines. 
Hydrodynamic diameter, polydispersity index (PDI) and zeta potential (ZP) were measured by 
dynamic light scattering with a NanoZS Zetasizer (Malvern Instruments, Hoeilaart, Belgium). All 
samples were measured in triplicate, diluted in 25 mM HEPES buffer pH 7.2 to evaluate the stability 
of nanoparticles.  
Gel electrophoresis. 
Polyplexes were prepared as previously described. Polyplexes (uncoated, HA-coated and PEG-coated) 
corresponding to 50 ng pDNA were diluted and incubated in HEPES, after which 5 µl of Ambion 
loading buffer (Ambion, Merelbeke, Belgium) was added to the suspension. The mixtures were 
loaded into a 1% agarose gel in 1 x TBE buffer, to which GelRed (Biotium, Hayward, CA) was added 
for visualization of the pDNA. The gel was run for 40 minutes at 100 V and imaged. 
Cell Culture.  
ARPE-19 cells (retinal pigment epithelial cell line; ATCC number CRL-2302) were cultured in 
Dulbecco's modified Eagle's medium supplemented with growth factor F12 (DMEM:F12 (1:1), 10% 
FBS, 2 mM L-glutamine and 50 µg/ml penicillin/streptomycin). Cells were incubated at 37 °C in a 
humidified atmosphere containing 5% CO2 and subcultured every 3 to 4 days. Cellular experiments 
were performed on cells in culture with passage number below 20.  
Detection of CD44-expression on ARPE-19 cells by immunohistochemistry. 
ARPE-19 cells were seeded in T25 cell culture flasks. When reaching +/- 70% confluency, they were 
detached with non-enzymatic cell dissociation buffer (Sigma-Aldrich, Bornem, Belgium) and counted. 
100000 cells were washed with flow buffer, after which they were incubated for 30 minutes with a 
primary anti-CD44 antibody produced in rabbit (Sigma, Bornem, Belgium). After washing, the cells 
were incubated with a green fluorescent bovine secondary anti-rabbit IgG-FITC antibody (Santa Cruz 
Biotechnology, Dallas, TX) for 30 minutes in the dark. After washing, the surface marker expression 
was evaluated with flow cytometry (FACSCalibur™, BD Biosciences Benelux N.V., Erembodegem, 
Belgium). 
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Uptake and transfection efficiency. 
ARPE-19 cells were plated in 24 well plates at 45000 cells/well and allowed to grow overnight. The 
next day, polyplexes were prepared with YOYO1-labeled pGL4.13 plasmids as described above, 
added to the cells in serum-free OptiMEMTM at a concentration of 1 µg pDNA / 45000 cells, and 
incubated for 2 hours at 37°C in an incubator. As a negative control, ARPE-19 cells were pre-
incubated on ice for 1 hour, and also incubated with the particles on ice. After incubation, the 
particles were removed and ice-cold Trypan Blue was added to each well to quench extracellular 
fluorescence from polyplexes attached to the cell membrane. After removal of Trypan Blue, the cells 
were washed with Dulbecco’s phosphate buffered saline (DPBS 1x without Ca2+/Mg2+), trypsinized 
and centrifuged for 7 minutes at 300 g, after which they were resuspended in flow buffer (1% bovine 
serum albumin and 0.1% sodium azide in PBS). The green fluorescence from the plasmids in the cell 
interior was measured by flow cytometry (FACSCalibur™, BD Biosciences Benelux N.V., 
Erembodegem, Belgium). For transfection experiments, cells were plated similar to the uptake 
experiments. One day after cell seeding, polyplexes were prepared with gwiz-GFP plasmid to 
measure transfection efficiency and pGL4.13 plasmid as a negative control, since luciferase 
expression does not produce a detectable fluorescence signal in GFP-emission spectrum. Incubation 
of the cells was done similar to the uptake experiments, where 1 µg pDNA was added to each well 
and incubated for 2 hours at 37°C. Afterwards, the polyplexes were removed, cells were washed with 
PBS and fresh medium was added for 22 hour incubation. 24 hours after the particles were added, 
the cells were trypsinized and GFP expression was examined by flow cytometry. 
Flow cytometry. 
After inhibition of trypsinization by cell culture medium, cells were centrifuged for 7 minutes at 300 g 
and supernatant was removed. Cells were resuspended in flow buffer (PBS+ / 0.1% sodium azide / 
1% bovine serum albumin) and cell-associated fluorescence was analysed with a FACS Calibur 
(BecktonDickinson, Erembodegem, Belgium) equipped with an Argon laser (excitation488 nm). For 
quantification, all experiments were performed in triplicate and for each sample, data were collected 
for 30 seconds consisting of side scatter, forward scatter and fluorescence emission of YOYO-1 dye 
(uptake experiments) or GFP (transfection experiments) with a 530/30 nm bandpass filter (FL1). 
Cellquest software (Beckton Dickinson, Erembodegem, Belgium) was used for analysis. Appropriate 
gating was applied to the forward/side-scatterplot of untreated cells to select for intact cells. A cell 
was considered positive for YOYO-1 or GFP fluorescence, if the average fluorescence was above the 
threshold T, defined as the 99.5 percentile of the negative control sample. 
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Uptake after saturation of HA receptors. 
ARPE-19 cells were plated in 24 well plates at 45000 cells/well and allowed to grow overnight. The 
next day, cells were pre-incubated for 1 hour with 2 mg/ml HA-solutions. After 1 hour incubation, 
polyplexes prepared with YOYO1-labeled pGL4.13 plasmids as described above, were added to the 
cells at a concentration of 1 µg pDNA / 45000 cells, and incubated for 2 hours at 37°C in an incubator. 
After incubation, cells were treated and analyzed as described above. 
Cytotoxicity. 
Cytotoxicity of the polyplexes was evaluated with an MTT assay. ARPE-19 cells were plated in 24 well 
plates at 45000 cells per well. Similar to the transfection protocol, pGL4.13-polyplexes, prepared as 
previously described, were added to the cells in serum-free OptiMEM™ and incubated for 2 hours at 
37°C. After removal of the polyplexes, fresh cell culture medium was added to the cells. 24 hours 
after addition of the nanoparticles, MTT reagent was added to full cell culture medium for 4 hours at 
37°C. Afterwards, cells were washed and lysed with cell lysis buffer (0.04N HCl and 1% Triton-X in 
isopropanol) for 1 hour on a shaker. Then, absorbance at 590 nm and 690 nm is measured with a 
plate spectrophotometer (PerkinElmer 2104 EnVision®), where A590 relates to the metabolic activity, 
and A690 is used as a reference wavelength.  
Statistical analysis. 
Statistical tests were performed in IBM® SPSS® Statistics version 22. Normality of all triplicates was 
verified with a Shapiro-Wilks test. Average values were further compared by means of an 
independent samples t-test or Welch’s t-test, based on the outcome of the Equality of Variances 
Levene test. The mean difference was considered significant at the p < 0.05 level. 
Single particle tracking microscopy. 
For the diffusion measurements in HEPES buffer (25 mM, pH 7.2), the nanoparticles were diluted to a 
concentration suitable for SPT (typical concentrations of 108 to 1010 particles per ml). 9 µl of these 
samples was then applied between a microscope slide and a cover glass with a double-sided adhesive 
sticker of 120 µm thickness in between (Secure-Seal Spacer; Molecular Probes, Leiden, The 
Netherlands). The microscope was always focused at 5 to 10 µm above the cover glass. For each 
sample, typically 10 to 20 movies of about 200 frames each were recorded at different locations 
within the sample, at a frame rate of 24 or 35 fps depending on the exposure time. All fluorescence 
video imaging of diffusing nanoparticles was performed on a custom-built laser wide field 
fluorescence microscope setup. Diffusion analysis of the videos was performed off-line using in-
house developed software, as described before 24, providing a distribution of apparent diffusion 
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coefficients from which hydrodynamic diameter could be calculated. For a more detailed description 
of both the SPT microscope and the trajectory analysis, the reader is referred elsewhere 9. 
Determining viscosity of different HA-ratios. 
Inert, green-fluorescent polystyrene nanospheres of 200 nm in size and a carboxylated surface, were 
imaged with SPT microscopy in different concentrations of HA22, HA137 and HA2700. These 
concentrations corresponded to the molar ratios used to electrostatically coat the polyplexes. With 
SPT analysis, trajectories of the diffusing nanoparticles were elucidated, from which a distribution of 
diffusion coefficients was obtained, as described in Materials & Methods. Since the size of the 
nanoparticles is known, the viscosity of the HA-solution can be determined via the Stokes-Einstein 
equation below, where D is the diffusion coefficient, k is the Boltzmann constant, T is the 
temperature, η is the viscosity and R the hydrodynamic radius of the particle.  
 
Ex vivo evaluation of intravitreal polyplex mobility. 
Intravitreal mobility of nanoparticles in vitreous humor was evaluated with single particle tracking 
microscopy in an ex vivo model as previously described9. In short, fresh bovine eyes were obtained 
from the local slaughterhouse, subsequently disposed of extraocular material and incised along the 
limbus. Then, the cornea and lens were removed, exposing the anterior part of the hyaloid 
membrane that holds the vitreous body. This optical “window” was juxtaposed to the glass cover slip 
of a MatTek glass bottom dish (35 mm, No. 1.5, MatTek Corporation, MA, USA). Finally, to avoid drift 
of the eye inside the glass bottom dish, the eye was gently fixed with parafilm. For all vitreous 
experiments, the sclera was punctured laterally with a 21 G guard needle (BD Microlance, BD 
Biosciences Benelux N.V., Erembodegem, Belgium), after which 10-20 µl of nanoparticle suspension 
was injected into the vitreous humor with the help of a syringe and 25 G spinal needle (BD 
Microlance, BD Biosciences Benelux N.V., Erembodegem, Belgium). The nanoparticles were 
expunged from the syringe near the cover slip to allow visualization within the working distance of 
the objective lens, though far enough to avoid punctuation of the anterior hyaloid membrane and 
subsequent outflow of vitreous liquid. Next, the sample was stored for 24 hours at room 
temperature before performing the microscopy experiments, thus allowing the nanoparticles to 
diffuse from the injection site into the surrounding vitreous and within the working range of the 
objective lens. Camera settings and SPT data analysis was similar as described for buffer 
measurements.  
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R E S U L T S  
CHARACTERIZATION OF HYALURONIC ACID 
Hyaluronic acid (HA) was purchased with three different molecular weights (MWs) of 20 kDa, 200 
kDa and >1.8 MDa according to the manufacturer. These samples were analysed with gel permeation 
(size exclusion) chromatography, and the measured MWs and PDI are presented in Table 4.1. Based 
on the weight-averaged MW distributions (MW), we will refer to the different samples as HA22, 
HA137 and HA2700. 
PHYSICAL CHARACTERIZATION OF CBA-ABOL/PDNA POLYPLEXES  
Gene complexes were prepared from CBA-ABOL polymers and pDNA at an N/P ratio of 45/1 
according to previously published data 9, 23, 25, with N and P representing the amine groups in the 
cationic polymer and phosphate groups in the NAs, respectively. Their hydrodynamic diameter, 
polydispersity index (PDI) and surface charge were measured in HEPES buffer with dynamic light 
scattering (DLS) (Table 4.2). CBA-ABOL/pDNA polyplexes had a size of +/- 108 nm and a positive zeta 
potential of + 29 mV. Also PEGylated polyplexes were prepared from CBA-ABOL-DMEDA-PEG/pDNA 9, 
26, resulting in slightly larger particles with a close to neutral surface charge.  
Preformed CBA-ABOL/pDNA polyplexes were electrostatically coated with HA at 45/1/100 and 
45/1/200 molar N/P/C ratios, where C refers to the anionic carboxyl groups of the HA monomers. To 
evaluate if pDNA is still retained in the polyplexes after HA coating, gel electrophoresis was 
performed of HA-coated polyplexes prepared in HEPES buffer. As can be seen from the results in 
Table 4.1 | Molecular weight characterization of the different HA samples by gel permeation 
chromatography. Shown are the number-averaged (Mn), peak-value (Mp), weight-averaged (Mw) 
and z-averaged (Mz) MWs of the different fractions in kDa, as well as the PDI. 
 Mn (kDa) Mp (kDa) Mw (kDa) Mz (kDa) PDI (Mw/Mn) 
LifeCore 
20 kDa 
14.86 ± 0.27 19.57 ± 0.12 22.64 ± 0.14 33.33 ± 0.41 1.52 
LifeCore 
200 kDa 
88.9 ± 7.7 126.7 ± 1.1 136.9 ± 3.3 213 ± 11 1.54 
LifeCore 
>1,8 MDa 
2606 ± 11 2510 ± 340 2764 ± 25 3038 ± 36 1.06 
PDI: polydispersity index 
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Figure 4.3, HA coating did not displace pDNA from the polyplexes. Only for the PEGylated polyplexes,  
a fraction of pDNA was not complexed, as apparent by the fluorescent smear from the well. In 
conclusion, electrostatic coating of CBA-ABOL/pDNA polyplexes with HA can result in stable gene 
nanomedicines with negative surface charge, which are still able to retain their pDNA cargo. In order 
to compare between different MWs of HA-coating, the N/P/C ratio should be kept constant. 
Therefore, we decided using the 45/1/200 ratio for all following experiments, seeing as HA22-coated 
polyplexes only stabilized around this ratio. 
Table 4.2 | Size, PDI and zeta potential of polyplexes in HEPES buffer, as measured by dynamic 
light scattering. 
 HEPES buffer, pH 7.2 
 
Z-averaged 
diameter 
(nm) 
PDI 
Zeta potential 
(mV) 
CBA-ABOL/pDNA 108 ± 3 0.134 ± 0.054 29 ± 3 
CBA-ABOL-DMEDA-PEG/pDNA 124 ± 5 0.381 ± 0.034 10 ± 1 
HA22-pplxs 45/1/100 1820 ± 150 0.878 ± 0.062 -20 ± 1 
HA22-pplxs 45/1/200 647 ± 19 0.401 ± 0.044 -22 ± 1 
HA137-pplxs 45/1/100 312 ± 2 0.209 ± 0.015 -26.6 ± 0.1 
HA137-pplxs 45/1/200 343 ± 4 0.214 ± 0.016 -29.9 ± 0.5 
HA2700-pplxs 45/1/100* 586 ± 44 0.546 ± 0.056 -28 ± 2 
HA2700-pplxs 45/1/200* 858 ± 67 0.825 ± 0.098 -37 ± 2 
(*) Clearly-observed flocculation during particle preparation in HEPES buffer  
PDI: polydispersity index; pplxs: polyplexes 
 
Figure 4.3 | Gel electrophoresis shows successful pDNA complexation of the different polyplexes 
in HEPES. Only the PEGylated polyplexes show some pDNA displacement, seen as a smear in the 
gel, though the majority of pDNA remains complexed, as evident from the fluorescence in the 
wells. 
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INTRAVITREAL MOBILITY OF HA-COATED POLYPLEXES 
In a next step we wanted to verify the crucial requirement that HA-coated polyplexes should be 
mobile in vitreous humor. Therefore, we injected the different nanoparticles in a recently optimized 
ex vivo model of intact bovine vitreous and visualized the movement of these nanoparticles with SPT 
microscopy. Examples of such movies can be found online as supplementary information for 
uncoated (Supplementary Movie 1), HA22-coated (Supplementary Movie 2), HA137-coated 
(Supplementary Movie 3) and HA2700-coated (Supplementary Movie 4) polyplexes. The diffusion 
coefficients were determined for individual polyplexes from their motion trajectories, the results of 
which are combined in a distribution and presented in Figure 4.4. The black line represents the 
distribution of diffusion coefficients of uncoated CBA-ABOL/pDNA polyplexes in vitreous humor, 
showing a bimodal distribution with the majority of polyplexes being immobilized, similar to what we 
have observed before for cationic polystyrene nanoparticles 9. We hypothesize that the small mobile  
 
Figure 4.4 | Single particle tracking analysis of the intravitreal mobility of HA-coated polyplexes. A 
bimodal distribution of diffusion coefficients can be seen for the uncoated, cationic polyplexes in 
vitreous humor (black, solid line). The highest increase in mobility was found for HA137-coated 
polyplexes, while no improvement was found for HA2700-coated polyplexes. The mobility of the 
HA-coated nanoparticles in HEPES buffer is also shown as a reference (dotted lines). 
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fraction of the nanoparticle population is a consequence of spontaneous electrostatic coating of 
native HA on the cationic polyplexes. The mobility of HA137-coated polyplexes has improved the 
most (solid purple line), followed by HA22 coated polyplexes (solid red line). Interestingly, the mobile 
fractions of HA22-and HA137-coated polyplexes show distributions of diffusion coefficients that are 
approximating those obtained in pure buffer solution, indicating close to maximum diffusional 
mobility within the vitreous body. HA2700-coated polyplexes, on the other hand, did not show any 
improvement. This is presumably due to the large size and aggregation of HA2700-coated polyplexes 
in buffer. Though this is not evident from DLS data (Table 4.2), SPT analysis reveals the size to be in 
the >3 µm range (Figure 4.4 and Table 4.3). Indeed, during preparation of the ternary PECs, 
flocculation of the nanoparticles was visually observed when high concentrations of high molecular 
weight HA (HMWHA) were added to the cationic polyplexes, presumably as a result of their high 
Table 4.3 | Size measurements by SPT in HEPES buffer (pH 7,2). 
 Hydrodynamic diameter (nm) 
CBA-ABOL/pDNA 140 ± 73 
CBA-ABOL-DMEDA-PEG/pDNA 150 ± 79 
HA22-pplx 45/1/200 601 ± 351 
HA137-pplx 45/1/200 499 ± 222 
HA2700-pplx 45/1/200* 3531 ± 4046 
(*) flocculation of particles was observed in buffer after adding HA-solution. 
 
 
Figure 4.5 | Micro-environment viscosity changes of different HA-ratios, calculated by analyzing 
diffusion of inert nanospheres with a known size by SPT. 
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viscosity (Figure 4.5 and Table 4.4). Alternatively, it could be hypothesized that the complete 
complexation of HMW HA to the polyplex surface would lead to an enormous loss of configurational 
entropy. Therefore, it seems likely that the HA chains only slightly bind to the polyplex and for the 
most part remain in their coiled form, leaving other binding sites available for binding to other 
particles resulting in aggregation. 
UPTAKE, TRANSFECTION AND CYTOTOXICITY OF HA-COATED POLYPLEXES IN RPE CELLS 
Following the observation that coating with HA22 or HA137 ensures good mobility of polyplexes in 
vitreous humor, we have evaluated if these HA-polyplexes can still transfect RPE cells. Seeing as 
electrostatic coating of CBA-ABOL/pDNA polyplexes with HA2700 does not further improve 
intravitreal mobility, we have excluded these particles in the following experiments. The results of 
cell uptake and transfection efficiencies quantified by flow cytometry are shown in Figure 4.6. 
Clearly, PEGylation of the polyplexes results in a lack of cell uptake (Figure 4.6A-B) and consequently, 
GFP expression (Figure 4.6C-D). On the other hand, both HA22-and HA137-coated polyplexes were 
taken up in close to 100% of the cells, most likely due to receptor mediated endocytosis (Figure 
4.6A). Nevertheless, whereas HA22-coating appears to result in more or less similar uptake to non-
functionalized polyplexes, HA137-coated polyplexes clearly show a lesser overall uptake efficiency 
Table 4.4 | Micro-environment viscosity changes of different HA-ratios, calculated by analysing 
diffusion of inert nanospheres with a known size by SPT. 
  Average 
diffusion 
coefficient 
(µm²/s) 
Average 
diameter 
 
(nm) 
Micro-
environment 
viscosity 
(mPa . s) 
HEPES buffer 2.28 204 0.95 
HA22 1/100 2.20 204 0.99 
HA22 1/200 2.12 204 1.02 
HA22 1/400 2.13 204 1.02 
HA22 1/600 2.11 204 1.03 
HA137 1/100 2.08 204 1.04 
HA137 1/200 1.91 204 1.13 
HA137 1/400 1.67 204 1.30 
HA137 1/600 1.50 204 1.45 
HA2700 1/100 1.57 204 1.38 
HA2700 1/200 1.10 204 1.97 
HA2700 1/400 0.67 204 3.21 
HA2700 1/600 0.49 204 4.42 
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when considering uptake on a per-cell basis (Figure 4.6B). Looking at the efficiency of GFP 
expression, both HA-coated polyplexes were able to transfect the RPE cells (Figure 4.6C-D), though 
not as efficiently as non-functionalized polyplexes, and again transfection efficiencies of HA137-
coated polyplexes were seemingly lower than HA22-coated polyplexes. 
 
Figure 4.6 | Uptake, transfection and cytotoxicity of HA-coated polyplexes in ARPE-19 cells. (A) 
Percentage of ARPE-19 cells which are positive for YOYO-1-labeled polyplexes, evaluated by flow 
cytometry. (B) Mean YOYO-1 fluorescence intensity of the ARPE-19 cell population, evaluated by 
flow cytometry. (C) Percentage of ARPE-19 cells that are positive for GFP fluorescence. (D) Mean 
GFP fluorescence intensity of the ARPE-19 cell population, evaluated by flow cytometry.(E) 
Metabolic activity of ARPE-19 cell population after treatment with different polyplexes, measured 
by MTT assay and normalized against untreated cells. All values are the mean of 3 repetitions and 
the error bars represent the standard deviation.  
(*) p < 0,05 with respect to non-functionalized polyplexes (independent samples t-test).  
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We additionally tested the toxicity of the different types of polyplexes by measuring the metabolic 
activity of cell populations with an MTT assay. The values shown in Figure 4.6E are normalized 
against untreated RPE cells. No cytotoxicity was observed for any of the polyplexes at the same 
concentrations employed for the uptake and transfection experiments. It can even be seen that the 
HA137 coating results in the cells being metabolically more active than the untreated cell population.  
INVOLVEMENT OF CD44-RECEPTOR IN UPTAKE OF HA-COATED POLYPLEXES 
Since the HA-coated particles are taken up despite their negative charge, it is likely that they are 
internalized through ligand-receptor interactions. As HA is a well-known ligand for the CD44-
receptor, we verified CD44-expression on the surface of ARPE-19 cells. This was confirmed by means 
of antibody-based surface marker expression analysis via flow cytometry (Figure 4.7A). To further 
verify the involvement of this receptor in HA-polyplex uptake, we pre-incubated the cells with HA of 
the respective MW in order to saturate the CD44 receptors and prevent interaction with HA-coated 
polyplexes. As shown in Figure 4.7B, a statistically significant decrease in polyplex uptake was seen in 
case of HA137-coating. Surprisingly, saturation of ARPE-19 cells with HA22 resulted in a statistically 
significant increase in uptake of HA22-coated polyplexes.  
  
 
Figure 4.7 | (A) CD44-expression on ARPE-19 cells is verified by flow cytometry (green curve). A 
representative distribution is shown selected from three replicates. (B) The influence on the 
cellular uptake of HA-coated polyplexes after saturation of the CD44 receptors with HA of the 
same MW.  
(*) Mean difference is significant at p < 0.05 level (independent samples t-test). 
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D I S C U S S I O N  
Intravitreal injection is generally regarded as a promising administration route for larger MW 
therapeutics or nanomedicines intended for retinal delivery, as it bypasses most of the natural 
barriers of the eyes. Nonetheless, the mobility of these therapeutics in the vitreous humor is of 
utmost importance in order to reach the retinal target cells. Indeed, we have previously reported 
that surface characteristics such as hydrophobicity and cationic charge can be detrimental for 
intravitreal mobility, inducing aggregation and immobilization of the nanomedicines in the vitreal 
matrix 9. The vitreous humor is composed of a random network of collagen-fibrils interspersed with 
anionic glycosaminoglycans, most notably hyaluronic acid (HA), stabilizing the network by ensuring 
hydration and inflation of the collagen fibrils 27. Due to the anionic nature of the vitreous humor, 
immobilization of cationic nanoparticles is to be expected 9, 10. Though PEGylation was previously 
shown to improve nanomedicine mobility 9, it almost entirely inhibits cell uptake and transfection, as 
shown in Figure 4.6.We hypothesized that HA could be a suitable alternative for PEG, due to the fact 
that it is one of the major constituents of the vitreous humor and that it is a ligand to the CD44 
receptor, which is expressed in RPE 21 and other retinal cells 22. Due to its ubiquitous and 
biocompatible nature, HA has also been frequently employed as a surface coating for nanomedicines 
in cancer therapy, acting as a natural stealth molecule and targeting ligand of CD44-overexpressing 
tumor-tissues 15, 16, 28, 29. HA is known to regulate a multitude of different cascades and processes in 
mammalian organisms, which are thought to be dependent on the MW of the HA chains 30, 31. In 
other words, the MW of HA influences its biological function and possibly the affinity towards the 
CD44-receptor and other hyaladherins. This aspect has remained overlooked in the majority of the 
literature concerning the use of HA as an additive in drug delivery vectors, resulting in contradictory 
findings being published 13. 
In our study, HA of different MWs was electrostatically coated on preformed binary PECs composed 
of anionic pDNA and cationic p(CBA-ABOL) polymers. A similar approach was previously reported for 
low molecular weight HA (LMWHA) and polyethylenimine (PEI)-polyplexes in the context of tumor-
targeting and corneal gene therapy, respectively 32, 33. Our method provided stable nanoparticles 
with a negative surface charge, that maintained efficient complexation of pDNA (Table 4.2 and Figure 
4.3). An approximately 4-fold higher molar ratio of HA negative charges compared to polymer 
positive charges was necessary to stabilize the nanoparticles, resulting in a molar N/P/C ratio of 
45/1/200. As the nanoparticles are formed by spontaneous complexation of cationic polymers and 
anionic pDNA, it is expected that a certain amount of free polymer will always be present in the 
solution. It could be argued that HA will form complexes with these free polymer molecules, affecting 
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the size distribution measured by DLS. Nonetheless, size measurements by fluorescence SPT showed 
similar size distributions (Table 4.3), leading us to believe that the contributions of such complexes to 
the results of DLS measurements are negligible. Interestingly, electrostatic coating with HA137 
appeared to require a lower amount of HA to provide stable complexes than HA22 or HA2700. 
Furthermore, it was noticed that electrostatic coating with HA2700 resulted in heavy flocculation of 
the gene nanomedicines. This can be attributed to the high viscosity of the suspension due to the 
high concentration of HA at 45/1/200 molar N/P/C ratio (Figure 4.5 and Table 4.4).  
Next we have evaluated the effect of coating cationic polyplexes with HA of various MWs on their 
mobility in the vitreous humor. For this we used our previously optimized ex vivo vitreal model that 
allows us to observe and analyze the mobility of the polyplexes by SPT microscopy 9. By analyzing the 
mobility of many individual polyplexes, potential heterogeneity of the population can be readily 
exposed. As before 9, a bimodal distribution was found for uncoated cationic polyplexes indicating 
that a large fraction is immobilized, likely by binding to collagen fibrils (Figure 4.4). By electrostatic 
coating of the polyplexes with HA of various MWs, a clear improvement in mobility was observed. 
Coating with HA137 resulted in the highest increase in fraction of mobile nanoparticles, followed by 
HA of 22 kDa. The smaller size of HA137-polyplexes should not be used as an explanation for this 
increase fraction of mobile nanoparticles, since in our previous study we have found that (PEGylated) 
nanoparticles up to 1 µm can diffuse freely through the vitreous humor 9. The fact that a small 
fraction of HA-coated polyplexes remains immobilized could indicate that the electrostatic coating is 
not perfect for all particles in the population. Especially for this type of polyplexes, where an excess 
of cationic polymer is added and free polymer might be available around the nanoparticles, it can be 
contended that the physical properties of PECs are influenced depending on their surrounding 
biological matrix or environment. For example, we have seen before that nanoparticle diffusion in 
bovine vitreous should be slowed down by a factor of 2 compared to diffusion in HEPES buffer 9. 
However, in Figure 4.4 we observe almost no difference in diffusion coefficient between HA-coated 
nanoparticles in HEPES buffer and those HA-coated nanoparticles that remain mobile in the vitreous 
humor. We suggest this is attributed to a reorganization of the ternary PECs in the vitreous humor 
due to the presence of several charged vitreal components, resulting in a decreased size and 
therefore higher diffusion coefficient in vitreous humor. In future research it would be interesting to 
evaluate a covalently attached HA-coating instead, or a coating of predefined gene nanomedicines. 
In any case, our findings are in line with recent in vivo reports where self-assembled amphiphilic 
polymeric nanoparticles (composed of a conjugate of HA and 5β-cholanic acid) and HA-modified 
core-shell liponanoparticles (composed of a chitosan core and cholesterol:DOPE)  were found in the 
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retina after intravitreal injection in rats, indicating intravitreal mobility of nanoparticles with an HA-
coated surface 34, 35.  
Apart from mobility in the vitreous humor, it is of equal importance that the polyplexes are capable 
of transfecting the target cells. Recently, uptake of HA-coated solid lipid nanoparticles in the ARPE-19 
cell line was reported, although the particles used in that study still had a cationic surface charge 36. 
In our study, cationic polyplexes were coated with HA until a negative surface charge was obtained as 
we have previously found that cationic particles are immobile in the vitreous body. We found that, 
despite their negative surface charge, our HA-coated polyplexes are still capable of being taken up by 
the ARPE-19 cells and induce transfection (Figure 4.6) without noticeable cytotoxicity. Likely this 
uptake is mediated by interaction with CD44-receptors, which we showed to be present on the cell 
surface (Figure 4.7A). HA22-coated polyplexes were highly efficient at transfecting ARPE-19 cells, 
almost to the same extent as uncoated polyplexes (Figure 4.6C), while HA137-coating resulted in less 
GFP expression. These differences were in line with the extent of polyplex uptake (Figure 4.6B). The 
lower transfection efficiency of HA137-coated polyplexes might additionally be due to increased cell 
proliferation, resulting in dilution of the transgene over a larger population of cells (Figure 4.6E). 
Indeed, we noticed that incubating ARPE-19 cells with HA137-coated polyplexes for 2 hours resulted 
in an increased metabolic activity 22 hours later. This can be related to previously published findings 
which indicate that LMWHA (20 – 500 kDa) is pro-angiogenic and stimulates proliferation of vascular 
smooth muscle cells, whereas HMWHA (several million Da) is supposed to have the opposite effect 37-
39. Indeed, Ferguson et al. 31 also documented a slight, though not statistically significant, increase in 
cell viability when normal fibroblasts were incubated with HA fragments of 120 – 360 kDa. A possible 
explanation for this increase in metabolic activity was postulated by Grishko and colleagues 40, who 
indeed noticed that free HA in the 500 kDa range typically increased mitochondrial reductase activity 
in chondrocyte primary cultures. 
Nevertheless, based on previously published studies trying to elucidate the optimal MW for 
interactions with CD44-receptors 41, 42 and uptake by CD44-expressing cells 15, 29, 35, we expected that 
HA137-coated polyplexes would be taken up more efficiently than HA22-coated nanoparticles. It is 
generally accepted that HMWHA leads to better uptake of HA-nanoparticles, presumably because it 
provides more multivalent interactions with the CD44-receptor 15, 41. The differences between our 
results and previously published research might be due to differences in CD44-receptor 
characteristics. Indeed, uptake and interactions were compared in different cell types, which could 
mean different CD44-receptor density, clustering and turn-over rate, leading to differences in 
interactions with HA-ligands. Interesting to note is a recent study by Almalik et al. 43, where it is 
hypothesized that a slow turn-over rate of CD44-receptors in RAW264.7 cells is the rate-limiting step 
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for HA-nanoparticle uptake. Ironically, a higher affinity to the CD44-receptor would thus result in a 
slower uptake of HA-coated nanoparticles. To investigate involvement of hyaladherins in HA-polyplex 
uptake, we also performed a competitive binding assay with free HA (Figure 4.7B), where cells were 
pre-incubated with free HA before addition of HA-coated nanoparticles. Interestingly, saturation of 
hyaladherins with HA137 significantly affects uptake of HA137-coated polyplexes, whereas a 
reversed effect was noticed for HA22-polyplexes. This could indicate that indeed, HA137 has a higher 
affinity for the hyaladherins, CD44 and others, present on the ARPE-19 cells and therefore free 
HA137 inhibits uptake of the HA-coated polyplexes. Likewise, HA22 has a much lower affinity for 
these hyaladherins, which could be why the uptake of HA22-coated particles is not diminished by 
free HA.  
C O N C L U S I O N  
Here we present an easy way of modifying cationic gene nanomedicines with HA for improved retinal 
drug delivery efficacy after intravitreal administration. Electrostatic coating of polyplexes with HA 
results in ternary gene polyplexes with an anionic, hydrophilic shell. The high viscosities inherent to 
high concentrations of HA2700 impeded the stabilization of HA2700-coated polyplexes. Using HA22 
and HA137 however, immobilization of therapeutics in the vitreal network is prevented. 
Furthermore, despite their negative charge, the HA-coated polyplexes are still taken up by retinal 
target cells, in this case ARPE-19 cells, presumably via CD44-mediated endocytosis. Together, these 
results demonstrate for the first time that using LMWHA as an electrostatic coating for cationic 
binary PECs is an easy, biocompatible method of enhancing the efficiency of gene nanomedicines to 
the retina via intravitreal administration.  
S U P P L E M E N T A R Y  I N F O R M A T I O N  
Supplementary movies available online upon publication of this manuscript. 
Supplementary Movie 1: non-functionalized polyplexes 
Example of diffusion analysis of non-functionalized polyplexes in vitreous humor. On the left-hand 
side, a typical movie of diffusing nanoparticles can be seen. On the right-hand side, the same movie is 
seen with the nanoparticle trajectories overlaid. In general, the majority of nanoparticles is 
immobilized in the vitreal network, though some mobility can still be spotted. The scale-bar denotes 
10 µm.  
  
  Chapter 4 
 
  Page 113 
Supplementary Movie 2: HA22-coated polyplexes 
Example of diffusion analysis of HA22-coated polyplexes in vitreous humor. On the left-hand side, a 
typical movie of diffusing nanoparticles can be seen. On the right-hand side, the same movie is seen 
with the nanoparticle trajectories overlaid. The bright fluorescence (in contrast to the non-
functionalized polyplexes) can be attributed to the larger size of the nanoparticles. Nonetheless, it 
can be seen that some nanoparticles are still mobile in the vitreal matrix. The scale-bar denotes 
10 µm.  
Supplementary Movie 3: HA137-coated polyplexes 
Example of diffusion analysis of HA137-coated polyplexes in vitreous humor. On the left-hand side, a 
typical movie of diffusing nanoparticles can be seen. On the right-hand side, the same movie is seen 
with the nanoparticle trajectories overlaid. The majority of HA137-coated nanoparticles is mobile in 
the vitreous humor. The scale-bar denotes 10 µm.  
Supplementary Movie 4: HA2700-coated polyplexes 
Example of diffusion analysis of HA2700-coated polyplexes in vitreous humor. On the left-hand side, 
a typical movie of diffusing nanoparticles can be seen. On the right-hand side, the same movie is 
seen with the nanoparticle trajectories overlaid. Most of the HA2700-nanoparticles, similar to the 
non-functionalized polyplexes, are immobilized in the vitreal matrix. The scale-bar denotes 10 µm.   
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A B S T R A C T  
Intravitreal administration of nanomedicines could be valuable for retinal gene therapy, if their 
intravitreal mobility and therapeutic efficacy in the target cells can be guaranteed. Hyaluronic acid 
(HA) as an electrostatic coating of polymeric gene nanomedicines has proven to be beneficial for 
both intravitreal mobility and in vitro transfection efficiency. Though electrostatic coating is 
considered an easy way of coating cationic particles, the stability of the electrostatic complexes in 
vivo can be questioned, especially in extracellular matrices and tissues. In this study, we compare the 
behavior of DOTAP:DOPE/plasmid DNA lipoplexes coated with HA either by electrostatic or covalent 
attachment. Specifically, by using a previously optimized ex vivo model to investigate intravitreal 
mobility of nanomedicines in intact bovine vitreous, we have determined that both approaches 
considerably improve the mobility of the lipoplexes in the vitreous humor of excised bovine eyes. 
Afterwards we determined that, in contrast to PEGylated liposomes, in vitro uptake and transfection 
efficiency in ARPE-19 cells are not hampered by the HA-coating. On the contrary, covalent HA-coating 
resulted in a 8-fold increase of transgene expression compared to the uncoated lipoplexes. Finally, 
preliminary in vivo data in mice suggests that covalent HA-lipoplexes were able to induce GFP 
expression in cells surrounding the subretinal space 72 hours after intravitreal injection, whereas 
transfection of uncoated lipoplexes was limited to the inner retina. In conclusion, covalent HA-
coating of gene nanomedicines appears to be a promising approach for the intravitreal 
administration of retinal gene therapeutics.  
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I N T R O D U C T I O N  
A wide variety of retinal disorders, often leading to blindness or severely affecting vision, are 
potential therapeutic targets for retinal gene therapy 1. While most clinical success has been 
achieved by subretinal injection of viral vectors, this procedure is often too invasive and requires the 
expertise of vitreoretinal surgeons, limiting its application on a large scale. Especially for those 
hereditary disorders affecting the cone photoreceptor cells, subretinal injection is very dangerous, 
and injection might be more detrimental than the intended effect of the treatment (e.g. 
achromatopsia 2). Furthermore, viral vectors are expensive to produce, and are associated with 
potential immunogenic reactions 3 and neurotropic dissemination 4. Therefore, intravitreal injection 
of nonviral vectors could be a suitable alternative for the delivery of therapeutic nucleic acids (NAs) 
to the retina. Intravitreal injection of therapeutics is being performed on a routine basis in the clinic, 
for the treatment of wet AMD with ranibizumab (Lucentis®) and aptamers (Macugen). It can be 
performed by trained personnel, and entails less risk than subretinal injection. Additionally, nonviral 
vectors offer several advantages over viral vectors, being (i) cheaper to produce on a large scale, (ii) 
less immunogenic, (iii) and with higher cargo capacity 5. Especially the latter is important for gene 
therapy as some hereditary disorders would require delivery of a therapeutic gene larger than the 
cargo capacity of AAV vectors (e.g. MYO7A for Usher syndrome; ABCA4 for Stargardt syndrome) .  
Nonviral delivery methods for therapeutic NAs to the retina are numerous, ranging from physical 
methods such as electroporation and iontophoresis 6, to chemical methods encompassing polymeric 
and lipid nanocarriers 7. Such polymeric and lipid nanocarriers usually have a positive charge, which 
allows them to spontaneously complex with anionic NAs. This results in the formation of spherical 
particles in the 100 nm size range, with versatile surface characteristics depending on the 
functionalization of the nonviral vector used 8. We have previously shown that intravitreally injected 
 
Figure 5.1 | Chemical structure of hyaluronic acid. 
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nanoparticles can be hampered on route to the retina by the vitreous humor itself 9, 10. Especially 
cationic charge and hydrophobicity were shown to be detrimental for intravitreal mobility. We 
demonstrated that this impaired mobility can be alleviated by surface decoration with polyethylene 
glycol (PEGylation), though it is also known to be detrimental for cellular interactions 11, 12. Therefore, 
we have previously proposed to use hyaluronic acid (HA) as an alternative coating strategy for PEG 13. 
HA (Figure 5.1) is a glycosaminoglycan ubiquitously found in mammals and a major component of the 
vitreous humor, with a myriad of functions depending on its molecular weight (MW). In recent years, 
its use in drug delivery has surged due to its biocompatible and non-immunogenic nature, combined 
with its inherent anionic and viscoelastic properties 14. HA molecules have several sites appropriate 
for chemical modification (e.g. hydroxyl, carboxyl, N-acetyl), further endorsing their use in drug 
delivery 15. Since HA is a ligand for different cell receptors, most notably CD44, HA-conjugation is 
abundantly used for drug targeting to CD44-overexpressing (tumor) tissues 14. Also in the field of 
ocular drug delivery, HA is gaining attention as a drug delivery additive 13, 16-18. Indeed, we have 
previously shown that an electrostatic coating of HA was able to increase intravitreal mobility of 
cationic polymeric gene complexes and to maintain cellular uptake and transfection efficiency 13. Our 
proposed use of HA as a coating strategy for improved retinal gene therapy has been supported by 
recent reports employing electrostatic HA-coating to improve in vitro transfection efficiency of gene 
polyplexes 18. However, electrostatic coating of HA could be considered unstable in extracellular 
matrices or tissues. Covalent HA-coated liposomes and amphiphilic polymeric nanoparticles with an 
HA-shell have been proposed to deliver small molecular therapeutics to the retina after intravitreal 
injection 16, 17, though with conflicting results. It is known that HA function is influenced by its MW 
and subsequent presentation to HA-receptors, and we believe that the approach used for coating HA 
to nanoparticles can also influence this HA presentation.  
In the present study, we compared electrostatic and covalent HA-coated lipid gene nanomedicines 
on their efficacy for transfection of retinal cells, in vitro and in vivo. Lipid gene nanomedicines  
containing plasmid DNA (pDNA) were composed of the cationic lipid 1,2-Dioleoyl-3-
trimethylammonium-propane (DOTAP) and the fusogenic lipid 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE). First, we evaluated the intravitreal mobility of both HA-coated 
lipoplexes using our previously published ex vivo eye model, using cadaveric bovine eyes and single 
particle tracking microscopy 10. Afterwards, we investigated whether different efficacies could be 
noted for both nanoparticles in terms of cellular uptake and transfection of an in vitro ARPE-19 cell 
line, representative for the retinal pigment epithelium (RPE) cell layer 19. Finally, we assessed the in 
vivo retinal permeation efficacy of the most promising HA-coated lipoplexes in mice. 
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M A T E R I A L S  A N D  M E T H O D S  
Materials. 
Dulbecco's modified Eagle's medium supplemented with growth factor F12 (DMEM:F12 (1:1), 
OptiMEM™, Trypan Blue, L-glutamine, fetal bovine serum (FBS), penicillin-streptomycin solution 
(5000 IU/mL penicillin and 5000 μg/mL streptomycin) (P/S), and Dulbecco’s phosphate-buffered 
saline (DPBS 1x, with or without Ca2+/Mg2+) were supplied by GibcoBRL (Merelbeke, Belgium). 1,2-
Dioleoyl-3-trimethylammonium-propane (DOTAP) chloride salt was obtained from Avanti Polar Lipids 
(Alabaster, AL, USA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) from Lipoid GmbH 
(Ludwigshafen, Germany), 1-ethyl-3-[3-dimethyl)aminopropyl] carbodiimide hydrochloride (EDC) 
from Sigma-Aldrich (Saint-Quentin Fallavier, France) and high-molecular- weight HA (1,600,000 Da) 
from Fluka (Sigma-Aldrich Chemie, Buchs, Switzerland). All other reagents were purchased from 
Sigma-Aldrich (Bornem, Belgium), unless otherwise stated.  
Plasmids. 
The plasmid constructs pGL4.13 and gwiz-GFP (Promega, Leiden, The Netherlands) were amplified in 
transformed E. Coli bacteria and isolated from a bacteria suspension with a Purelink™ HiPure Plasmid 
DNA Gigaprep kit K2100 (Invitrogen, Merelbeke, Belgium). Concentration and purity were 
determined by UV absorption at 260 nm and 280 nm on a NanoDrop 2000c (Thermo Fisher Scientific, 
Rockford, IL, USA). Finally, the plasmids were suspended at a concentration of 1 µg/µl and stored in 
25 mM HEPES, pH 7.2, at -20°C. For fluorescent labelling of pGL4.13 plasmids with YOYO-1™ (λex = 
491 nm, λem = 509 nm, Molecular Probes, Merelbeke, Belgium), YOYO-1 iodide (1 mM in DMSO) was 
added to the plasmid at a mixing ratio of 0.15:1 (v:w), resulting in a theoretical labelling density of 1 
YOYO-dye molecule per 10 base pairs. The mixture was incubated at room temperature for 4 hours in 
the dark. To remove the DMSO and free YOYO-1, the labelled plasmid was purified with ethanol 
precipitation and the fluorescently labelled plasmid was finally resuspended in 25 mM HEPES, pH 7.2. 
The concentration of the plasmid was again determined by UV absorption at 260 nm, and adjusted to 
1 µg/µl. 
Conjugation of DOPE to hyaluronic acid. 
The HA-DOPE conjugate was synthesized as reported by Surace et al. 20 based on a modified reaction 
described by Yerushalmi and Margalit 21. In brief, HA was dissolved in water overnight and 
preactivated for 2 hours at 37°C by incubation with EDC at pH 4, which was adjusted by titration with 
0.1 N HCl. Afterwards, DOPE suspension was added to the HA solution and pH was adjusted to 8.6 
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with 0.1 M borate buffer. The reaction was allowed to proceeded for 24 hours at 37°C. The conjugate 
was purified by ultrafiltration using a membrane with a molecular weight cutoff of 100000 Da 
(Amicon Ultrafiltration, Millipore, Billerica, MA). Purity of the conjugate was proven by thin layer 
chromatography. The successful conjugation was shown by 1H-NMR. The conjugate was lyophilized 
and stored at -25°C until further use. The coupling degree was determined to be 1.081% w/w (weight 
DOPE/weight conjugate). 
Liposomes and lipoplexes . 
To prepare uncoated liposomes, a thin lipid film was obtained by evaporation under vacuum of a 
chloroformic solution of an equimolar mixture of DOTAP and DOPE using a rotary vacuum 
evaporator. This lipid film was rehydrated with 1 ml pure ethanol, for a final molar concentration of 
15 mM, and liposomes were further prepared via the ethanol injection method (Figure 5.2). For 
liposome preparation, 400 μL of ethanolic lipid solution was rapidly injected into 2.6 mL MilliQ water 
under stirring with a magnetic bar to obtain a final lipid concentration of 2 mM. HA-modified 
liposomes were prepared by diluting an aqueous stock solution of the HA-DOPE conjugate (1 mg/mL) 
to different concentrations in MilliQ water before injection of the ethanol-lipid mixture. The content 
of HA-DOPE conjugate is expressed in percentage molar ratio HA-DOPE/DOTAP lipids (see Table 5.1). 
For the removal of ethanol, liposome suspensions were dialyzed against distilled water overnight in 
Slide-A-Lyzer dialysis cassettes with a molecular weight cutoff of 10000 (Thermo Fisher Scientific, 
 
Figure 5.2 | Schematic protocol showing the preparation of uncoated or HA-coated liposomes, for 
subsequent use in preparing covalent HA-lipoplexes. 
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Inc., Rockford, IL). Hydrodynamic diameter, polydispersity index (PDI) and zeta potential (ZP) were 
measured by dynamic light scattering with a NanoZS Zetasizer (Malvern Instruments, Hoeilaart, 
Belgium). All samples were measured in triplicate, diluted in 25 mM HEPES buffer pH 7.2. The size 
and zeta potential results for the liposomes can be found in Table 5.1. 
For the preparation of uncoated and PEGylated lipoplexes, a diluted pDNA solution was added to a 
liposome solution in HEPES buffer at an N/P ratio of 4/1, as described previously 9, with N 
representing the number of the positive charges (originating from DOTAP) and P the number of the 
negative charges (originating from the pDNA). This mixture was vortexed for 10 seconds and left to 
stabilize at room temperature for 15 minutes to allow complexation. 
To prepare lipoplexes with a covalent HA-coating, a similar protocol was applied where pDNA was 
added to HA-coated liposomes, while maintaining the N/P ratio of 4/1. Given the concentrations of 
HA in each liposomes, the resulting lipoplexes had N/P/C ratios ranging from 4/1/0 (uncoated 
lipoplexes) to 4/1/8 (200 mol% HA-liposomes), where C represent the number of negative charges 
originating from the carboxyl-group of the HA-monomer (Figure 5.3 right). For the preparation of 
Table 5.1 | Composition and physical characterization of the different liposomes evaluated in this 
study. Z-average size and zeta potential were measured in HEPES buffer by dynamic light 
scattering. Shown are average values and standard deviations of three measurements. It should 
be emphasized that these data concern the liposomes, without pDNA complexed. Therefore, no 
distinction can be made as to the electrostatic or covalent coupling of HA to the lipoplexes. 
 
Concentration 
DOTAP:DOPE 
Concen-
tration 
DOTAP 
lipids 
Concen-
tration 
HA-DOPE 
conjugate 
or DSPE-
PEG 
Size 
(nm) 
Zeta potential 
(mV) 
Uncoated 
liposomes 
 
2 mM 1 mM 0  mM 362 ± 106 54 ± 1 
5% DSPE-PEG 
liposomes 
2 mM 1 mM / 95 ± 0 14 ± 3 
10 mol% HA-
liposomes 
2 mM 1 mM 0.1  mM 104 ± 15 37 ± 5 
25 mol% HA-
liposomes 
2 mM 1 mM 0.25  mM 113 ± 1 36 ± 2 
50 mol% HA-
liposomes 
2 mM 1 mM 0.5  mM 178 ± 6 25 ± 1 
100 mol% HA-
liposomes 
2 mM 1 mM 1  mM 847 ± 210 -2 ± 0 
200 mol% HA-
liposomes 
2 mM 1 mM 2  mM 227 ± 8 -20 ± 0 
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electrostatically coated HA-lipoplexes, uncoated lipoplexes with the standard 4/1 ratio were 
prepared. After 15 minutes stabilization, HA diluted in HEPES was added to the lipoplexes 
corresponding to the previously mentioned N/P/C ratios. These were vortexed for 10 seconds and 
left to stabilize at room temperature for 15 minutes to allow complexation (Figure 5.3 left). 
Gel electrophoresis. 
Lipoplexes corresponding to 50 ng pDNA were prepared as previously described, after which 5 µl of 
Ambion loading buffer (Ambion, Merelbeke, Belgium) was added to the suspension. The mixture was 
loaded on a 1% agarose gel in 1 x TBE buffer, to which GelRed (Biotium, Hayward, CA ) was added for 
visualization of the pDNA. The gel was run for 40 minutes at 100 V and imaged. 
Cell Culture.  
ARPE-19 cells (retinal pigment epithelial cell line; ATCC number CRL-2302) were cultured in 
Dulbecco's modified Eagle's medium supplemented with growth factor F12 (DMEM:F12 (1:1), 10% 
FBS, 2 mM L-glutamine and 50 µg/ml penicillin/streptomycin). Cells were incubated at 37 °C in a 
humidified atmosphere containing 5% CO2 and subcultured every 3 to 4 days. Cellular experiments 
were performed on cells in culture with passage number below 20.  
 
Figure 5.3 | Different approaches of preparing of HA-coated, resulting in an electrostatic HA-
coating (left) and a covalent HA-coating (right). 
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Uptake and transfection efficiency. 
ARPE-19 cells were plated in 24 well plates at 45000 cells/well and allowed to grow overnight. For 
uptake studies, lipoplexes were prepared the next day with YOYO1-labeled pGL4.13 plasmids as 
described above, added to the cells in serum-free OptiMEMTM at a concentration of 1 µg pDNA / 
45000 cells, and incubated for 2 hours at 37°C in an incubator. As a negative control, ARPE-19 cells 
were pre-incubated on ice for 1 hour, and also incubated with the particles on ice. After incubation, 
the particles were removed and ice-cold Trypan Blue was added to each well to quench extracellular 
fluorescence from lipoplexes attached to the cell membrane. After removal of Trypan Blue, the cells 
were washed with DBPS, trypsinized and the green YOYO1-fluorescence from the plasmids in the cell 
interior was measured by flow cytometry (FACSCalibur™, BD Biosciences Benelux N.V., 
Erembodegem, Belgium).  
For transfection experiments, cells were plated similar to the uptake experiments. The next day, 
lipoplexes were prepared with gwiz-GFP plasmid to measure transfection efficiency and pGL4.13 
plasmid as a negative control, since luciferase expression does not produce a detectable fluorescence 
signal in GFP-emission spectrum. Incubation of the cells was performed similar to the uptake 
experiments, where 1 µg pDNA was added to each well and incubated for 2 hours at 37°C. 
Afterwards, the particles were removed, cells were washed with DPBS and fresh cell culture medium 
was added for 22 hour incubation. 24 hours after the particles were added, the cells were trypsinized 
and GFP expression was examined by flow cytometry. 
Flow cytometry. 
After inhibition of trypsinization by cell culture medium, cells were centrifuged for 7 minutes at 300 g 
and supernatant was removed. Cells were resuspended in flow buffer (DPBS / 0,1% sodium azide / 
1% bovine serum albumin) and cell-associated fluorescence was analyzed with a FACS Calibur 
(BecktonDickinson, Erembodegem, Belgium) equipped with an Argon laser (excitation 488 nm). For 
quantification, all experiments were performed in triplicate and for each sample, data was collected 
for 30 seconds consisting of side scatter, forward scatter and fluorescence emission of YOYO-1 dye 
(uptake experiments) or GFP (transfection experiments) with a 530/30 nm bandpass filter (FL1). 
Cellquest software (Beckton Dickinson, Erembodegem, Belgium) was used for analysis. Appropriate 
gating was applied to the forward/side-scatterplot of untreated cells to select for intact cells. A cell 
was considered positive for YOYO-1 or GFP fluorescence, if the average fluorescence was above the 
threshold T, defined as the 99.5 percentile of the negative control sample. 
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Cytotoxicity. 
Cytotoxicity of the lipoplexes was evaluated with an MTT assay. ARPE-19 cells were plated in 24 well 
plates at 45000 cells per well. Similar to the transfection protocol, pGL4.13-lipoplexes, prepared as 
previously described, were added to the cells in serum-free OptiMEM™ and incubated for 2 hour at 
37°C. After removal of the particles, fresh cell culture medium was added to the cells and 22 hour 
afterwards, MTT reagent (with a final concentration of 1 mg/ml) was added to full cell culture 
medium for 4 hour at 37°C. Finally, cells were washed and lysed with DMSO for 15 minutes on a 
shaker. Then, absorbance at 590 nm and 690 nm is measured with a plate spectrophotometer 
(PerkinElmer 2104 EnVision®), where A590 relates to the metabolic activity, and A690 is used as a 
reference wavelength.  
Statistical analysis. 
Statistical tests were performed in IBM® SPSS® Statistics version 22. Normality of all triplicates was 
verified with a Shapiro-Wilks test. Average values were further compared by means of an 
independent samples t-test or Welch’s t-test, based on the outcome of the Equality of Variances 
Levene test. The mean difference was considered significant at the p < 0.05 level. 
Ex vivo evaluation of intravitreal lipoplex mobility by single particle tracking microscopy. 
Intravitreal mobility of nanoparticles in vitreous humor was evaluated with single particle tracking 
microscopy in an ex vivo model as previously described 10. In short, fresh bovine eyes were obtained 
from a local slaughterhouse, subsequently disposed of extraocular material and incised along the 
limbus. Then, the cornea and lens were removed, exposing the anterior part of the hyaloid 
membrane that holds the vitreous body. For all vitreous experiments, the sclera was punctured 
laterally with a 21 G guard needle (BD Microlance, BD Biosciences Benelux N.V., Erembodegem, 
Belgium), after which 10-20 µl of nanoparticle suspension was injected in the vitreous humor with 
the help of a syringe and 25 G spinal needle (BD Microlance, BD Biosciences Benelux N.V., 
Erembodegem, Belgium). A MatTek glass bottom dish (35 mm, No. 1.5, MatTek Corporation, MA, 
USA) was positioned against the hyaloid membrane, thus permitting visualization by fluorescence 
microscopy within the vitreous humor. The nanoparticles were expunged from the syringe as close as 
possible to the anterior hyaloid membrane and coverslip to allow visualization within the working 
distance of the objective lens, though far enough to avoid punctuation of the anterior hyaloid 
membrane and subsequent outflow of vitreous liquid. Finally, to avoid drift of the eye inside the glass 
bottom dish, the eye was gently fixed with parafilm. Next, the sample was stored overnight  at room 
temperature before performing the microscopy experiments, thus allowing the nanoparticles to 
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diffuse from the injection site into the surrounding vitreous and within the working range of the 
objective lens. The microscope was always focused at 5 to 10 µm above the cover slip and for each 
sample, typically 20 movies of 250 frames each were recorded at different locations within the 
sample, at a frame rate of 31 fps. All fluorescence video imaging of diffusing nanoparticles was 
performed on a custom-built laser wide field fluorescence microscope setup. Diffusion analysis of the 
videos was performed off-line using in-house developed software, as described before 22, providing a 
distribution of apparent diffusion coefficients. For a more detailed description of both the SPT 
microscope and the trajectory analysis, the reader is referred elsewhere 10. 
In vivo intravitreal injections and evaluation of retinal permeability by immunohistochemistry of 
retinal slices. 
All experiments with live animals were performed in compliance with the German Law on Animal 
Protection and the Institute for Laboratory Animal Research Guide for the Care and Use of 
Laboratory Animals (1999) and the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research. C57Bl6/J mice were kept  in an air-conditioned environment on a 12-hour light–dark 
schedule at 20–22°C and had free access to food and water. Before the intravitreal injections, mice 
were anesthesized by intraperitoneal injection of a mixture of Ketamine hydrochloride (100 mg/kg 
body weight, Ketavet, Pfizer Animal Health, New York, NY) and Xylazinhydrochlorid (5 mg/kg body 
weight, 2% Rompun, Bayer Health Care, Leverkusen, Germany) in 0.9% NaCl. After anesthesia, the 
mice were injected intravitreally with 3µl solution containing either uncoated or covalently coated 
HA-lipoplexes, prepared as described before with pCAG-GFP pDNA. The sclera was incised at the pars 
plana with a 21G-needle, followed by insertion of the blunt end injection needle (32G) (Hamilton, 
Switzerland). After the injection procedure, eyes were rinsed with antibiotic eyedrops to avoid any 
ocular inflammation and covered by 2% Methocel (Omni Vision) to avoid over-drying of the cornea. 
24 and 72 hours after the injection, retinas were sliced and frozen at -80 °C for analysis by 
immunohistochemistry. Before staining, slices were dried at room temperature for 10-15 minutes 
and washed in PBS twice. Retinal slices were blocked with 10% bovine serum albumin (BSA, Sigma), 
5% goat serum (Invitrogen) and 0.1% Triton-X-100 for 20-30 minutes. Subsequently, retinal sections 
were incubated overnight at 4°C with a monoclonal anti-glutamine synthetase (1:200, Millipore) 
primary antibody, to stain for Müller cells. Slices were washed 3 times with PBS and then incubated 
with  Alexa488 (green) or Alexa594(red)-antibodies (Jackson) for 4 hours at room temperature. After 
3 washing steps in PBS, slices were counterstained with DAPI for 15 minutes at room temperature 
and mounted with Moviol. Retinal slices were further imaged on a Zeiss Axio Imager M2 equipped 
with an Apotome 2. Objective lenses used were 20x and 40x Zeiss EC Plan-NeoFluar.   
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R E S U L T S  
CHARACTERIZATION OF HA-COATED LIPOPLEXES 
Lipoplexes were composed of pDNA and cationic DOTAP:DOPE liposomes, to which HA was coated 
electrostatically or covalently. PEGylated DOTAP:DOPE lipoplexes were also included in the 
experiments. Size, polydispersity index and zeta potential of gene lipoplexes was determined with 
dynamic light scattering (Table 5.2 and Figure 3A-B). Uncoated lipoplexes were formed by 
spontaneous complexation of DOTAP:DOPE liposomes and pDNA at an N/P ratio of 4/1 (see 
Materials & Methods section), resulting in monodisperse (PDI < 0.3) nanoparticles with a net cationic 
surface charge. PEGylated lipoplexes at similar N/P ratio had a similar size, though more 
Table 5.2 | Physical characterization of different lipoplexes. Shown are averages and standard 
deviations of 3 measurements by dynamic light scattering. 
 
 
N/P/C 
ratio 
Z-
averaged 
diameter 
(nm) 
PDI 
Zeta 
potential 
(mV) 
Uncoated lipoplexes 4/1/0 140 ± 2 0.288 ± 0.017 40 ± 3 
5%PEG lipoplexes 4/1/0 142 ± 2 0.113 ± 0.017 11 ± 1 
Electrostatic 10 mol% 
HA- lipoplexes 
4/1/0.4 127 ± 5 0.179 ± 0.006 38 ± 1 
Electrostatic 25 mol% 
HA- lipoplexes 
4/1/1 677 ± 49 0.417 ± 0.030 10 ± 1 
Electrostatic 50 mol% 
HA- lipoplexes 
4/1/2 185 ± 3 0.201 ± 0.009 -27 ± 1 
Electrostatic 100 mol% 
HA- lipoplexes 
4/1/4 176 ± 1 0.264 ± 0.025 -31 ± 3 
Electrostatic 200 mol% 
HA- lipoplexes 
4/1/8 159 ± 1 0.256 ± 0.021 -36 ± 1 
Covalent 10 mol% HA- 
lipoplexes 
4/1/0.4 115 ± 1 0.187 ± 0.010 40 ± 1 
Covalent 25 mol% HA- 
lipoplexes 
4/1/1 194 ± 11 0.222 ± 0.019 21 ± 1 
Covalent 50 mol% HA- 
lipoplexes 
4/1/2 1091 ± 48 0.457 ± 0.143 -10 ± 0 
Covalent 100 mol% 
HA- lipoplexes 
4/1/4 472 ± 25 0.398 ± 0.023 -20 ± 1 
Covalent 200 mol% 
HA- lipoplexes 
4/1/8 204 ± 4 0.151 ± 0.009 -20 ± 4 
 
  Chapter 5 
 
  Page 133 
monodisperse and with a more neutral zeta potential due to the shielding of the surface charge by 
the PEG-chains. HA-coated lipoplexes were prepared with either an electrostatic or a covalent HA-
coating, in gradually increasing N/P/C ratios (Table 5.2 and Figure 5.4). From these data, it is clear 
that the surface charge of lipoplexes inverts from a positive charge to a negative charge upon 
increasing HA-content. Aggregation can be observed when the zeta potential becomes near neutral.  
  
 
Figure 5.4 | Physical characterization of different lipoplexes in HEPES buffer pH 7.2 by dynamic 
light scattering. Shown are the average values (bars) and standard deviations (error bars) of 3 
measurements. (A) Z-averaged hydrodynamic diameter and PDI are shown for uncoated and 
PEGylated lipoplexes. Additionally, these parameters are shown for covalently HA-coated 
lipoplexes in N/P/C-ratios ranging from 4/1/0.4 to 4/1/8. (B) Zeta potential is shown for uncoated 
and PEGylated lipoplexes, as well as covalently HA-coated lipoplexes in N/P/C-ratios ranging from 
4/1/0.4 to 4/1/8. (C) Z-averaged hydrodynamic diameter and PDI are shown for electrostatically 
HA-coated lipoplexes in N/P/C-ratios ranging from 4/1/0.4 to 4/1/8. (B) Zeta potential is shown 
for uncoated and PEGylated lipoplexes, as well as electrostatically HA-coated lipoplexes in N/P/C-
ratios ranging from 4/1/0.4 to 4/1/8.  
PDI: polydispersity index; PEG: 5% PEGylated lipoplexes; Uncoated: uncoated lipoplexes; cov: 
covalently coated HA-lipoplexes; Elect: electrostatically coated lipoplexes 
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To verify the complexation efficiency of the HA-coated lipoplexes compared to uncoated lipoplexes, 
the samples were loaded on a 1% agarose gel (Figure 5.5). Upon preparing electrostatically coated 
HA-lipoplexes, no significant decrease in complexation efficiency was noted. For the covalent HA-
coated lipoplexes, on the other hand, pDNA complexation appears to be insufficient at those N/P/C-
ratios where the HA-coated lipoplexes are not yet colloidally stable (judged by the increased size and 
PDI for 4/1/4-ratios). A bright fluorescent band is visible below the wells, where only little 
fluorescence is spotted within the wells. Upon increasing HA-content, pDNA complexation efficiency 
appears to increase (increase in fluorescence within the well and less fluorescence in the band with 
free pDNA).  
INTRAVITREAL MOBILITY 
From the characterization results obtained by DLS and gel electrophoresis, we opted to continue with 
covalent and electrostatic HA-coated lipoplexes with an N/P/C-ratio of 4/1/8 for the following 
experiments. To evaluate if HA-coating would prevent immobilization in the vitreal matrix, we 
determined their intravitreal mobility with our previously optimized ex vivo eye model 10. This model 
is based on excised bovine eyes from which the anterior segment is removed. By placing a cover slip 
in the exposed anterior hyaloid membrane, an optical window is created allowing us to visualize 
movement of nanoparticles in intact vitreous. By using high-resolution fluorescence microscopy and 
single particle tracking analysis, the intravitreal diffusional mobility profile of a nanoparticle 
population can be accurately measured. Figure 5.6 shows the distributions of diffusion coefficients of 
 
Figure 5.5 | Gel electrophoresis showing complexation efficiency of HA-coated lipoplexes. For 
higher N/P/C-ratios, the covalent HA-coated lipoplexes are slightly less efficient at retaining the 
pDNA up to an N/P/C-ratio of 4/1/4 (evident from decreased fluorescence in the well and 
increased fluorescence in the lower band). Nonetheless, a higher complexation efficiency is seen 
for the covalent 4/1/8 ratio. 
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lipoplexes in the vitreous humor as measured by SPT. First of all, it can be seen that uncoated, 
cationic lipoplexes (black solid line) show a bimodal diffusion behavior, indicative of a large 
immobilized fraction. A PEGylation degree of 5% greatly diminishes this immobilization (purple solid 
line), resulting in a large population of mobile lipoplexes. Electrostatic (green solid line) and covalent 
(red solid line) HA-coating of lipoplexes both show a similar mobility improvement , where covalently 
coupled HA-lipoplexes shows the least amount of immobilized lipoplexes.  
UPTAKE AND TRANSFECTION EFFICIENCY 
Having determined that both electrostatic and covalent HA-coupling to lipoplexes provides the 
nanoparticles with improved intravitreal mobility, it now has to be verified that these nanoparticles 
can be taken up and transfect retinal target cells. Similarly to the intravitreal experiments, we only 
evaluate HA-coated lipoplexes in an N/P/C-ratio of 4/1/8. Uptake and transfection efficiencies were 
determined in vitro in an ARPE-19 cell line with flow cytometry, the results of which are shown in 
Figure 5.7A-D. Furthermore, the cytotoxicity of a 2 hour incubation period was evaluated with an 
MTT assay, 24 hours after addition of the particles (Figure 5.7E). In terms of uptake of YOYO1-labeled 
lipoplexes (Figure 5.7A-B), we notice that HA-lipoplexes are taken up very efficiently, even compared 
to the uncoated lipoplexes. PEGylation however, results in significantly less uptake. Interesting to 
 
Figure 5.6 | Distributions of diffusion coefficients of different lipoplexes in an ex vivo vitreous 
humour model, obtained by single particle tracking. Higher diffusion coefficients relate to higher 
mobility. All HA-coated lipoplexes have an N/P/C-ratio of 4/1/8. 
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Figure 5.7 | Uptake, transfection and cytotoxicity of the different lipoplexes in ARPE-19 cells. (A) 
Mean YOYO-1 fluorescence intensity of the ARPE-19 cell population, measured by flow cytometry 
and normalized against uncoated lipoplexes, comparing uptake efficiency between uncoated, 
PEGylated and covalent HA-lipoplexes. (B) Mean YOYO-1 fluorescence intensity of the ARPE-19 
cell population, measured by flow cytometry and normalized against uncoated lipoplexes, 
comparing uptake efficiency between uncoated, PEGylated and electrostatic HA-lipoplexes. (C) 
Mean GFP-fluorescence intensity of the ARPE-19 cells population, measured by flow cytometry 
and normalized against uncoated lipoplexes, comparing the level of transgene expression 
between uncoated, PEGylated and covalent HA-lipoplexes. (D) Mean GFP-fluorescence intensity 
of the ARPE-19 cells population, measured by flow cytometry and normalized against uncoated 
lipoplexes, comparing the level of transgene expression between uncoated, PEGylated and 
electrostatic HA-lipoplexes. (E) Metabolic activity of ARPE-19 cells after incubation with different 
kinds of lipoplexes, measured by an MTT assay and normalized against an untreated cell 
population. 
All values are the mean of 3 repetitions and the error bars represent the standard deviation. 
(*) p < 0.05 with respect to uncoated lipoplexes (independent samples t-test). 
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note are the differences in transfection efficiency between the different HA-coated lipoplexes, 
evaluated by the amount of GFP expression in the ARPE-19 cells (Figure 5.7C-D). First of all, we 
confirmed that a 5% PEGylation degree significantly decreases the transfection potential of the 
lipoplexes, resulting in almost no transgene expression. When using an electrostatic coating of HA, 
no significant differences in transfection efficiency are noted compared to the uncoated lipoplexes 
(Figure 5.7D). Remarkably, a covalent coating with HA shows a significant increase in transgene 
expression, over eight-fold when compared to uncoated lipoplexes (Figure 5.7C). Finally, cytotoxicity 
of all lipoplexes was evaluated with an MTT assay (Figure 5.7E), from which can be concluded that, 
even though covalently coupled HA-lipoplexes appear to be slightly more cytotoxic, the HA-
lipoplexes are well tolerated by ARPE-19 cells. 
IN VIVO RETINAL PERMEABILITY OF LIPOPLEXES 
Previous results show that HA-lipoplexes, regardless of their coating strategy, remain mobile in 
bovine vitreous humor and that covalently coated HA-lipoplexes are most adept at inducing GFP 
expression in vitro in an ARPE-19 cell line. Based on these observations, we decided to evaluate the 
in vivo transfection efficiency of covalent HA-lipoplexes after intravitreal injection in mice in 
comparison to uncoated lipoplexes (Figure 5.8). Lipoplexes were prepared as described before with 
pDNA encoding the CAG-promoter and GFP. 24 hours after injection, HA-lipoplexes were shown to 
induce GFP expression in the inner nuclear layer (INL), whereas uncoated lipoplexes were only able 
to transfect cells in the ganglion cell layer (GCL) and inner retina (ganglion cells, astrocytes). Also, the 
efficiency of GFP expression was overall higher for HA-lipoplexes than uncoated lipoplexes as can be 
seen from an increased amount of cells and a generally brighter fluorescent appearance, though this 
has not been quantified. After 72 hours, HA-lipoplexes appeared to have advanced towards the outer 
retina and were shown to induce GFP expression in cells surrounding the subretinal space. The 
uncoated lipoplexes on the other hand, remained localized in the inner retina and ganglion cell layer. 
Note that the green fluorescence that can be seen in this retinal section is not GFP expression but 
rather autofluorescence caused by the photopigments contained in photoreceptors and RPE cells.  
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Figure 5.8 | Fluorescence images of transverse retinal sections after intravitreal injection in rat 
eyes. CAG-GFP expression was evaluated 24 hours and 72 hours after intravitreal injection of 
(DOTAP:DOPE)/(pCAG-GFP)-lipoplexes, either uncoated or covalently coated with hyaluronic acid. 
GFP expression is shown in green, cell nuclei were counterstained with DAPI (shown in blue) and 
Müller cells were visualized by antibody-staining against glutamine synthetase (GS, red). 24 hours 
after injection, HA-lipoplexes induce GFP expression as far as the outer plexiform layer, whereas 
GFP expression by uncoated lipoplexes remains restricted to the inner retina and ganglion cell 
layer. After 72 hours, HA-lipoplexes were able to induce expression in cells surrounding the 
subretinal space. GFP expression induced by uncoated lipoplexes, however, remained limited to 
the ganglion cell layer. Highly likely, the green fluorescence noted in this section is 
autofluorescence caused by the photopigments contained in photoreceptors and RPE cells.  
un-lplxs = uncoated lipoplexes; HA-lplxs (cov) = covalently HA-coated lipoplexes; ONL = outer 
nuclear layer; OPL = outer plexiform layer; INL = inner nuclear layer; GCL = ganglion cell layer; GS = 
glutamine synthetase  
(*) GFP-positive cells are highlighted in the micrographs by an asterisk. 
(!) Suspected unspecific staining, usually by autofluorescence of the retinal vessels, is denoted by 
an exclamation mark.   
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D I S C U S S I O N  
While retinal gene therapy is advancing in several clinical trials and clinical application might soon 
become reality, questions have been raised about the feasibility on a larger scale using current 
methodologies based on subretinal injection of viral vectors. While intravitreal injection of nonviral 
gene nanoparticles promises to be less costly and invasive, their therapeutic efficacy to date remains 
rather low. This can be attributed to the low expression of the transgene in the target cells, though 
efficient delivery to these target cells after intravitreal injection also poses a major problem. We have 
previously determined that cationic and hydrophobic surfaces are detrimental to intravitreal mobility 
of the nanomedicines 10. By using a PEG-coating, we have shown that immobilization in the vitreal 
matrix can be drastically decreased. However, as it is known that PEGylation also affects cellular 
interactions 11, 12, we have recently proposed HA as an alternative coating strategy for improved 
intravitreal mobility while retaining the ability to transfect retinal target cells 13. HA has known a 
recent surge in popularity in the field of drug delivery due to its inherent biocompatibility and 
versatile nature 23. Since it is a known ligand for the CD44-receptor, it has been especially 
investigated for the targeted delivery of chemotherapeutics to CD44-overexpressing tumor tissues 15. 
It has been previously shown that targeting and uptake efficacy of HA-coated nanoparticles towards 
CD44-expressing cell types is dependent on the MW of HA, with increasing affinity towards the 
hyaladherins with increasing MW 24, 25. For this reason, the experiments in this study were performed 
with high MW HA (1600 kDa). Next to MW, grafting density is also an important factor for CD44 
affinity, as has been demonstrated by Qhattal et al. 26. As the reasoning behind these differences in 
CD44 affinity is thought to be due to HA presentation, we hypothesized that the manner in which HA 
is coupled to the nanoparticle surface can also have an effect on the affinity towards hyaladherins.  
In our study, two different approaches of coating lipoplexes with HA were compared in terms of their 
suitability for intravitreal injection (Figure 5.3). In the first method, HA was electrostatically 
complexed on pre-formed cationic lipoplexes until a negative surface charge was obtained, indicating 
surface decoration with HA. The second approach entails the random conjugation of DOPE-lipids on 
the HA polymer, after which liposomes will be formed with an HA-coating attached via insertion of 
the conjugated DOPE-lipids in the lipid membrane. Covalently coated HA-lipoplexes were formed by 
adding nucleic acids to these HA-coated liposomes. By increasing the amount of HA added to the 
lipoplexes, we determined that both approaches delivered nanosized, monodisperse HA-coated 
lipoplexes with an anionic surface charge, once the amount of HA reached a certain threshold at an 
N/P/C-ratio of 4/1/8, where N, P and C represent the amine groups in the cationic lipid, the 
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phosphate groups in the NAs and the carboxylgroups in the HA-monomers, respectively (Table 5.2 
and Figure 5.4).  
The first barriers nanoparticles will encounter after intravitreal injection is the vitreous humor itself. 
We have previously shown that PEGylation could drastically increase the mobility throughout the 
vitreal matrix of CBA-ABOL polyplexes10 and DOTAP:DOPE lipoplexes 9. We further showed that an 
electrostatic coating of HA on these CBA-ABOL polyplexes also improved intravitreal mobility, though 
this was limited to the use of LMW HA (22kDa and 137 kDa) 13. In the present study, HA-lipoplexes at 
a 4/1/8-ratio were shown to have markedly increased intravitreal mobility compared to the uncoated 
lipoplexes, even reaching that of the PEGylated lipoplexes (Figure 5.5). We must highlight that even 
the population of PEGylated lipoplexes is not 100% mobile, as can be seen from the small fraction of 
immobile lipoplexes. Nevertheless, this is in agreement with the findings of Peeters et al. 9, who 
showed that a PEGylation degree of 5% indeed improved the mobility of DOTAP:DOPE lipoplexes in 
vitreous humor, though even there some immobilization was still seen. This small immobilized 
fraction is also noticed in the distribution of diffusion coefficient of the electrostatically coated HA-
lipoplexes, whereas a covalent HA-coating appears to render nearly all nanoparticles mobile. We 
conclude that both approaches endow the lipoplexes with additional intravitreal mobility compared 
to the uncoated lipoplexes, where a covalent HA-coating slightly outperforms the electrostatic 
coating. 
We subsequently investigated whether the HA-lipoplexes maintained their ability to transfect retinal 
target cells. In this study, ARPE-19 cells were used to verify in vitro uptake and transfection efficiency 
by flow cytometry (Figure 5.6). Whereas PEGylation decreased uptake of lipoplexes, HA-coated 
lipoplexes at a 4/1/8-ratio were taken up to the same extent or even more than uncoated lipoplexes. 
More importantly, the transgene expression in ARPE-19 cells was nearly eight-fold higher for 
covalent HA-lipoplexes compared to the uncoated lipoplexes (Figure 5.6B). Electrostatic HA-
lipoplexes, on the other hand, did not induce a significant improvement in transgene expression. 
(Figure 5.6D). We conclude from these experiments that a covalent coupling of HA to the lipoplexes 
appears to be most beneficial for cellular uptake and subsequent transgene expression. Though 
influence of HA MW on targeting and uptake has been investigated before, our results show that the 
method of HA attachment also has a profound influence on the efficacy of HA-coated 
nanomedicines. Our findings are supported by data from Toriyabe and colleagues 27, who noticed 
that HA-coated liposomes targeted to liver endothelial cells only accumulated at the target site when 
the HA was covalently attached to the surface of the liposomes, not when it was presented as an 
electrostatic coating.  
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As highlighted before, we believe these differences between electrostatic and covalent coating can 
be related to the presentation of HA binding monomers to the HA-receptors. Avidity of HA to 
hyaladherins is dependent on multivalent interactions and several HA-monomers should be 
available, estimated between 20 and 38 for optimal avidity through divalent binding 28. Decreased 
affinity, and possibly decreased cellular uptake, has been proposed to result from a decrease in the 
degree of freedom the HA molecule experiences when attached to the surface of nanoparticles, thus 
limiting the amount of potential reaction sites available for binding by the hyaladherins 24. 
Alternatively, the electrostatic coating could result in free HA polymers competing for the binding 
sites at hyaladherins, and thus limiting cellular uptake of electrostatic HA-lipoplexes. Covalent HA-
lipoplexes, on the other hand, do not have free HA polymers competing with binding sites, as the 
conjugated DOPE-lipids will preferentially accumulate in the lipid bilayers.  Taking the putative 
differences in avidity between electrostatic and covalent HA-lipoplexes in consideration, and even 
though uptake of covalent HA-lipoplexes is indeed noticeably higher than that of the electrostatic 
counterparts, we feel this does not solely account for the eight-fold increase in transfection 
efficiency. We hypothesize that the differences in HA presentation and hyaladherins avidity bring 
about a different entry pathway, and a more efficient subsequent intracellular processing. Indeed, it 
is a well-known fact that efficiency in transgene expression is not exclusively determined by the 
amount of cellular uptake 29, and different barriers have yet to be overcome (e.g. endosomal escape, 
see Chapter 6). Furthermore, it has been hypothesized that HA influences uptake pathway and 
intracellular processing, bypassing the lysosomal pathway and therefore avoiding degradation 30.  
Finally, the ability of lipoplexes to cross the vitreoretinal barrier and permeate the retina after 
intravitreal injection was evaluated with in vivo experiments in mice (Figure 5.7). Indeed, the inner 
limiting membrane is considered to be a formidable barrier for nanoparticle penetration in the retina 
from the vitreous, limiting transfection to the inner retinal cells at best 31, 32. Uncoated lipoplexes and 
covalent HA-coated lipoplexes were compared in terms of their ability to induce GFP expression in 
the retinal cell layers 24 hours and 72 hours after intravitreal injection. We noticed that transfection 
efficiency of uncoated lipoplexes was indeed limited to the inner retina, even after 72 hours. 
Surprisingly, covalent HA-lipoplexes were able to induce expression as far as the outer plexiform 
layer already after 24 hours. The permeation of HA-lipoplexes appeared to continue, as we observed 
that after 72 hours GFP expression was induced in cells surrounding the subretinal space. As the 
retina looks slightly perturbed and these cells stained positive for glutamine synthetase, these are 
likely dedifferentiated Müller cells instead of RPE cells. Gan and colleagues 16 have recently shown 
that core-shell liponanoparticles covalently modified with HA were also able to cross the ILM and 
penetrate the retina. However they could only observed this effect in an experimental autoimmune 
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uveitis model, while in healthy retinas, the authors found that the nanoparticles remain trapped at 
the ILM, even up to 7  days after intravitreal injection. The same observation was made by Iezzi et al. 
for uncoated poly(amido amine) dendrimers 33. Nevertheless, our results are in line with other 
studies where intravitreally injected nanoparticles could overcome the ILM barrier and penetrate 
into the retina 34-36. Most notably, self-assembled amphiphilic polymeric nanoparticles with a 5β-
cholanic core and HA-shell were shown to efficiently penetrate the healthy retina of rats 6 hours and 
24 hours after intravitreal injection 17. The authors further postulated that intravitreal nanoparticles 
(either with HA-shell or human serum albumin) crossed the ILM by endocytosis in the Müller cells, 
based on previously published results from this group with human serum albumin-based 
nanoparticles 36. Seeing as particles in the 100 nm size range are able to cross the ILM in a healthy 
retina, this does indeed suggest endocytosis by Müller cells, especially as the Müller cell endfeet are 
thought to protrude through the ILM in the vitreous. This could offer a possible explanation for 
selective transport of nanoparticles across the retina by the Müller cells, depending on which ligands 
on the Müller cell surface are targeted. As Müller cells have been shown to express CD44 on their 
surface 37, HA could be a viable targeting strategy in case the presentation of HA ligands to the Müller 
cell receptors is sufficient (dependent on MW, grafting density and coupling strategy). 
C O N C L U S I O N  
In conclusion, we document the differences in behavior of two different approaches used for HA-
coating of lipoplexes intended for retinal gene therapy. HA-lipoplexes were prepared either by an 
electrostatic attachment of HA to preformed lipoplexes, or by the formation of HA-liposomes using a 
preformed HA-DOPE conjugate. Both approaches resulted in anionic, monodisperse HA-lipoplexes at 
an N/P/C-ratio of 4/1/8, which markedly improved their intravitreal mobility compared to uncoated 
lipoplexes in an ex vivo vitreal model. Furthermore, we noticed that the HA-lipoplexes were very well 
tolerated in vitro and that in vitro transfection efficiency in ARPE-19 cells was not hampered by the 
HA-coating. On the contrary, a covalent HA-coating provided a eight-fold increase in transgene 
expression compared to the uncoated cationic lipoplexes. Preliminary in vivo data in mice further 
suggests that covalent HA-lipoplexes were able to induce GFP expression in cells surrounding the 
subretinal space, 72 hours after intravitreal injection. Taken together, our data suggest that a 
covalent coupling of HA to lipoplexes promises to be more suitable for gene nanomedicines. While 
both approaches increased intravitreal mobility, the advantages of covalent HA-coating were more 
pronounced at the level of transgene expression.  
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A B S T R A C T  
Successful cytosolic delivery of nanomaterials is becoming more and more important, given the 
increase in intracellular applications of quantum dots, gold nanoparticles, liposomal drug 
formulations and polymeric gene delivery vectors. Most nanomaterials are taken up by the cell via 
endocytosis, yet endosomal escape has long been recognized as a major bottleneck in cytosolic 
delivery. Although it is essential to detect and reliably quantify endosomal escape, no consensus has 
been reached so far on the methods to do so. This review will summarize and discuss for the first 
time the different assays used to investigate this elusive step to date. 
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I N T R O D U C T I O N  
Cytosolic delivery of nanomaterials has gained a lot of interest. Recent developments in nanoscience 
and nanotechnology have created a library of nanomaterials with potential applications in the 
visualization of subcellular structures and dynamics, intracellular delivery of therapeutics, gene 
therapy and the treatment or diagnostics of organelle-specific diseases 1-4. Importantly, efficient 
delivery to the intracellular environment is necessary for exerting their intended function. Though 
 
Figure 6.1 | Most nanoparticles, organic and inorganic ones, for drug delivery as well as for 
imaging,  are usually taken up by target cells via endocytosis, leading to sequestration of the 
cargo in the endocytic vesicles (blue interior denotes neutral pH). Acidification of the endosomes 
typically will trigger a destabilization of the endosomal membrane by the delivery vector (orange 
interior denotes acidified pH). After destabilization of the endosomal membrane, depending on 
the delivery vector, the cargo will be released by a bursting effect if an osmotic gradient is 
established by endosomal buffering, through pores formed in the endosomal membrane by 
persistent destabilization, or by membrane fusion if the cargo was packaged in an enveloped 
delivery vector. Different assays are available to investigate these endosomal escape 
mechanisms, as indicated in red. Also the efficiency of endosomal escape can be quantified with a 
variety of techniques, as indicated in blue.  
IFP = intracellular fluorescence profile. 
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physical techniques are sometimes used to force the nanoparticles across the plasma membrane 
(microinjection, electroporation, …) 4, uptake of foreign nanomaterials usually relies on the cell’s 
innate endocytic uptake mechanism. This results in the cargo residing in endosomes (Figure 6.1), thus 
being physically separated from the cytosol by the endosomal limiting membrane 5, 6. Furthermore, 
maturation of most types of endosomes to multivesicular late endosomes is coupled with a decrease 
in intravesicular pH and fusion with lysosomes, potentially resulting in destruction of the functional 
nanomaterials by degradative lysosomal enzymes 7. This endolysosomal sequestration and hydrolytic 
degradation of the nanoparticulate cargo implies that they should escape from the endosomes in a 
timely manner to exert or preserve their intended function.  
For instance, semiconductor nanocrystals, or quantum dots (Qdots), are being explored to be used 
for labeling intracellular structures and molecules both in vitro and in vivo 8-10. Not only does 
sequestration prevent their access to the cytosol, it also results in toxicity as a result from ion 
leaching by degradation in the endolysosomal environment, especially in the case of Cd2+-containing 
Qdots 11. For cellular labeling and in vivo cell tracking, MRI contrast agents can be delivered to the 
cell interior in the form of paramagnetic Gadolinium-nanoparticles (Gd3+) 12 or superparamagnetic 
iron oxide (SPIO) nanoparticles 13, 14. It has been shown that sequestration of such contrast agents in 
intracellular vesicles could result in quenching of the MRI signal 12, 13. Therefore, it is often strongly 
preferred that nanoparticles for imaging applications should escape from the endolysosomal 
pathway to the intracellular environment 12. 
Intracellular drug delivery, for instance adaptive immunotherapy and gene therapy, is made possible 
by packaging therapeutic (macro)molecules in nanomedicine particles such as polymer micelles or 
dendrimers, nanogels, liposomes, mesoporous silica particles etc., that should provide protection to 
and mediate intracellular delivery of these therapeutics 2, 15, 16. However, therapeutic nucleic acids 
exert their effect in the cytosol or nucleus of the cell. MHC-I dependent antigen presentation to CD8+ 
T-cells also relies on antigenic protein or peptide delivery to the cytosol of antigen presenting cells 
(APCs) such as dendritic cells or macrophages 17. Endolysosomal sequestration and hydrolytic 
degradation drastically decreases the efficiency of drug delivery systems and should be countered by 
efficient endosomal escape of the therapeutic cargo to the cytosol.  
A wide variety of approaches have been developed to facilitate release of nanoparticles and 
molecules from endosomes before lysosomal degradation, such as fusogenic peptides and 
photochemical internalization (PCI), which have been the topic of numerous reviews 1, 2, 4, 6, 8, 16, 18, 19. 
Despite decades of research, however, endosomal escape is still recognized as a very inefficient 
process and a major bottleneck in cytosolic delivery of nanomaterials 2, 16, 18. In order to improve on 
  Chapter 6 
  Page 153 
those methods, it is quite essential being able to detect and reliably quantify endosomal escape 18, 20. 
Although different assays have been proposed to date, there is no consensus yet on how to evaluate 
this critical step in the intracellular delivery process.  
In this review, we aim to provide an exhaustive overview of methodologies used to evaluate 
endosomal escape, and to discuss the usefulness and limitations of each. First, a brief overview is 
presented of the different mechanisms and compounds to enhance endosomal escape. Next, an 
overview of reported endosomal escape assays is given, with exemplary applications and discussion 
on the underlying assumptions and limitations inherent to each technique. Specifically, a distinction 
is made between assays investigating the mechanism of endosomal escape (relating to membrane 
fusion or membrane integrity), and those that aim to visualize or quantify cargo release in the 
cytosol, regardless of the mechanism of endosomal escape. 
E N H A N C I N G  E N D O S O M A L  E S C A P E  
Most manmade materials to enhance endosomal escape have been inspired by viral and bacterial 
infection pathways in the cell, which rely on endocytosis followed by cleverly evolved ways of 
escaping towards the cytosolic compartment 21, 22. Typically, the endosomal membrane is initially 
destabilized, after which endosomal escape can occur through either pore formation, rupture or 
membrane fusion, depending on the nanoparticle’s characteristics (Figure 6.2). We will briefly discuss 
these endosomal escape mechanisms, though the reader is referred to several recent reviews on this 
topic for a more detailed overview 1, 2, 4, 18. 
ENDOSOMAL DESTABILIZATION AND PORE FORMATION 
Endosomal escape is characterized by an initial membrane destabilization (Figure 6.2B), which is 
confined to the endosomes as a result of the inherent acidification during endosomal maturation 
(Figure 6.2A). The most frequently proposed mechanisms for causing endosomal membrane 
destabilization, cationic charge and membrane-destabilizing peptides,  are discussed below. 
Furthermore, persistent membrane destabilization can lead to pore formation in the endosomal 
membrane, resulting in leakage of molecules and smaller particles from the endosomal compartment 
to the cytosol (Figure 6.2C). 
Since the outer layers of endosomal membranes are typically thought to be composed of 
phospholipids with an overall negative charge, the interaction of endosomally trapped cationic 
nanoparticles with the endosomal membrane is thought to induce a “flip-flop” mechanism, where  
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anionic phospholipids from the cytosolic leaflet will flip to the intraluminal side of the endosome 23-25. 
This charge-neutralized ion pair will result in non-lamellar phase changes and subsequent membrane 
destabilization 25. A permanent cationic charge can result from quaternary amine groups, as is the 
case with cationic lipids such as N[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium (DOTMA) 
chloride or 1,2-dioleyl-3-trimethylammonium-propane (DOTAP). Alternatively, protonable amine 
groups on the nanoparticle surface can also provide a cationic charge, i.e. for materials such as 
poly(ethylene imine) (PEI), poly(L-lysine) (PLL) and chitosan. Importantly, since the cationic charge 
can sometimes be enhanced along with the acidification of the endosomal compartment, membrane 
destabilization will then primarily occur in acidic endosomes.  
Membrane-destabilizing peptides, inspired by natural viral entry peptides such as the HA-2 subunit of 
the influenza virus hemagglutinin, are usually called fusogenic peptides since their conformational 
change exposes hydrophobic (α-helical) domains, allowing them to interact with the lipid membrane 
of the endosome. They can typically be divided in three different classes based on the amino acid 
residues present in the peptide and a slightly different mechanism of action 21, 26: 1. anionic 
amphiphilic peptides, such as INF7 and E5WYG, which contain glutamate residues and undergo a 
conformational change from a random coil to an alpha-helix under acidic conditions (pH 5 – 5.5); 2. 
histidine rich peptides such as H5WYG that protonate under mildly acidic conditions and destabilize 
membranes due to cationic interactions and an osmotic buffering effect (see section ‘Endosomal 
rupture’); 3. cationic amphiphilic peptides with lysine amino acids, such as K5 and KALA that can bind 
anionic nucleic acids and induce a pH-independent membrane destabilization by cationic interactions 
(previous page) Figure 6.2 | Different proposed mechanisms for endosomal escape. (A.) Normal 
acidification of the endosomes during maturation to late endosomes. ATP-driven transport of H+-
ions across the endosomal membrane by V-type ATPases produces an electrical gradient, which is 
balanced in part by the influx of counter-ions, presumably Cl--ions. (B.) Upon acidification, cationic 
particles induce negatively charged phospholipids on the outer endosomal leaflet to flip to the 
luminal side of the endosome by a flip-flop effect, resulting in a charge-neutral pair and causing 
membrane destabilization. Alternatively, fusogenic or lysogenic peptides will undergo 
conformational changes in acidic environments, resulting in a triggered destabilization of the 
endosomal membrane. (C.) Persistent membrane destabilization by cationic nanoparticles or by 
fusogenic peptides can result in pore formation. (D.) When buffering compounds are found in the 
endolysosomal lumen, acidification will be buffered by their proton-absorbing characteristics. The 
increased cationic charge and swelling of the compound, as a result of the ongoing protonation of 
free protonable amines, will result in membrane destabilization. A continued influx of chloride 
ions will create an osmotic gradient and internal pressure, leading to rupture of the endosomes 
and bursting of the contents into the cytosol. (E.) When an enveloped nanoparticle comes in close 
contact with an already destabilized membrane, e.g. by cationic charge, fusion between 
nanoparticle and endosomal membrane can result in cargo release in the cytosol. 
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with the endosomal membrane. GALA is also widely known and contains both glutamate residues for 
pH dependence and histidine amino acids for cationic charge and buffering 27. A different approach 
to achieve membrane destabilization, without relying on acidification, entails the interaction of the 
endosomal membrane with the lysogenic peptide L-leucyl-L-leucine methyl ester (Leu-Leu-OMe). 
This dipeptide is converted into a membrane-lysing compound, not by an acidic environment, but by 
the lysosomal enzyme dipeptidyl peptidase I 25, 28. 
ENDOSOMAL RUPTURE 
Whereas persistent membrane destabilization can result in gradual leakage of small nanomaterials 
through pore formation, bursting of endosomes has also been proposed as a mechanism for 
endosomal escape (Figure 6.2D). Likely the best-known mechanism to enhance endosomal escape is 
the “proton sponge effect” 29, which is based on cationic polymers or lipids with excess uncharged 
protonable amine groups that can buffer endosomal acidification by absorbing protons in the 
endolysosomal compartment. As long as ATP is present in the cytosol, V-type ATPases will keep 
pumping protons against their electrochemical gradient across the endolysosomal membrane, with 
an associated influx of counter-ions to balance the transmembrane voltage difference (Figure 6.2A) 7, 
30. Endolysosomal rupture is currently believed to result from a combination of three effects 
(Figure 6.2D). First, the buffering compounds will induce an initial membrane destabilization by the 
flip-flop effect induced by the cationic charge of the protonated amine groups. Second, electrostatic 
repulsion of the protonated amine groups results in swelling of the buffering agent, also referred to 
as the “umbrella effect” 16, further contributing to membrane destabilization 10. Third, the constant 
influx of counter-ions to balance the electric potential creates an osmotic gradient between vesicle 
and cytosol, leading to an influx of H2O to restore the osmotic balance. With an already destabilized 
endolysosomal membrane, the swelling of the intracellular vesicles results in bursting of the 
endosome and release of the cargo in the cytosol. Typical examples of proton sponge compounds are 
PEI 31, poly-amido amines 32 and imidazole-containing polymers (e.g. histidine) 2, 18. They are typically 
incorporated into the nanoparticles as the delivery vector, although in some cases the buffering 
compounds are either co-incubated with the nanoparticles (e.g. monensin) or added afterwards (e.g. 
chloroquine). Similar to chloroquine, ammonium chloride and methyl-amine are lipophilic in the 
unprotonated form and will penetrate cellular and vesicular membranes. Upon protonation in 
acidifying endosomes, these compounds become trapped and can act as proton sponges 18.  
In contrast to membrane destabilization triggered by the endolysosomal compartment only, certain 
physical techniques allow (spatio)-temporally controlled disruption of intracellular vesicles. A well-
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known strategy to induce rupture without the need for acidification is PCI 33, 34, which involves the 
use of amphiphilic photosensitizers, e.g. ethyl eosin 35 or TPPS2a (mesotetraphenylporphine carrying 
two sulfonate groups on adjacent phenyl rings) 33. After pulse-chased administration of the 
photosensitizer to the cells in vitro, they will accumulate in intracellular membranes, amongst which 
the endosomal membranes. Upon illumination with a specific light source, excitation of the 
photosensitizers induces the formation of reactive oxygen species (ROS), primarily singlet oxygen. 
Due to a short lifetime, the damage caused by this highly reactive intermediate will be mainly 
confined to the proximate membranes 33. Light has also been used as a trigger for heat-induced 
endosomal destabilization or rupture, for example by NIR irradiation of reduced graphene oxide 36 or 
by the generation of vapor nanobubbles through pulsed-laser irradiation of gold  nanoparticles 37. An 
alternative method to induce bursting of the endosomal vesicles in a temporally controlled manner is 
the so-called “osmolytic shock”. This is attained by loading the intracellular vesicles with a hypertonic 
solution via endocytosis and afterwards incubating the cells with a hypotonic solution, causing the 
intracellular vesicles to swell and burst 28, 38, 39. Similarly, carrier materials have been developed which 
exhibit swelling upon a decrease in temperature 40, 41, thereby disrupting intracellular vesicles 
containing the particles after a “cold shock” treatment. 
ENDOSOMAL MEMBRANE FUSION 
Fusion of a nanocarrier with the endosomal membrane can result in escape of the nanocarrier’s 
cargo into the cytosol (Figure 6.2E). Endosomal escape through fusion only occurs when the 
nanoparticle itself is enveloped by a membrane. It is beneficial if the endosomal membrane is already 
destabilized. This is the case for cationic liposomes, whose charge ensures close interaction with and 
destabilization of the endosomal membrane, resulting in fusion and release of the encapsulated 
cargo. Incorporation of fusogenic “helper” lipids (e.g. 1,2-dioleoyl-sn-glycerol-3-phosphatidyl-
ethanolamine or DOPE) further enhances endosomal fusion and escape, by undergoing a 
conformational change upon acidification and promoting a non-lamellar lipid phase change 42. 
Cholesterol has also been integrated in liposomal particles to enhance fusogenicity in a pH-
independent way, both at the plasma membrane and after endocytosis 43.  
S T U D Y I N G  E N D O S O M A L  E S C A P E  M E C H A N I S M S  
As previously highlighted, endosomal escape involves an initial membrane destabilization, followed 
by pore formation, endosomal rupture or membrane fusion. Typically, the mechanisms for 
endosomal escape are assayed by investigating the integrity of the endosomal membrane. Though 
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these assays can be performed in cells, a more controlled environment can be created ex cellulo by 
using artificial endosomes. These artificial endosomes are frequently modeled by creating liposomes 
with membranes of a known phospholipid composition, which then interact with the compound 
under investigation. 
VERIFYING PH-INDUCED MEMBRANE DESTABILIZATION 
The initial membrane destabilization of endosomal escape is usually triggered by an acidic pH, 
leading to conformational changes of fusogenic compounds or a flip-flop effect by cationic particles. 
The effect of pH on this membrane destabilization is investigated by comparing endosomal escape 
scenarios where pH either does or doesn’t affect the cationic or fusogenic compounds. The 
difference in endosomal escape between the normal and the pH-irrelevant scenario is then 
evaluated using the different endosomal escape assays which will be discussed further, and have 
been summarized in Figure 6.1. Removing the influence of pH on endosomal escape is done by either 
altering the compound under investigation so it is no longer pH-reactive 44, or the pH of the 
endosomal compartment itself is altered. In a controlled ex cellulo environment, the pH can be 
modeled by using buffers with different pH 45, 46. In cellular assays, acidification can be blocked by the 
use of inhibitors. Several studies report the inhibition of endosomal acidification by using a higher 
buffering capacity in the extracellular medium 47 or co-incubation with buffering agent such as 
ammonium chloride 48, 49, chloroquine 50 and monensin 48. However, it is important to take into 
account that these buffering agents might enhance endosomal escape due to the proton-sponge 
effect, rather than block it through inhibiting acidification.  Therefore, it would make more sense to 
block the acidification process altogether, which is done by the addition of ion channel inhibitors 
(ionophores) 51 or more importantly, V-type proton-pumping ATPase inhibitors such as bafilomycins 
or concanamycins 52. 
(next page) Table 6.1 | Overview of the different assays used to investigate pore formation by 
leakage of tracer compounds, with their use in cellulo or ex cellulo. Most assays are based on 
fluorescence, though alternatives are also listed. 
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ASSAYS FOR STUDYING PORE FORMATION  
Pore formation can be investigated by measuring the leakage of tracer compounds into the 
extravesicular environment (see Table 6.1). Typically, though not always, these tracers are 
fluorescent molecules that are quenched inside the vesicles and become (more) fluorescent upon 
their escape. This increase in fluorescence intensity can be measured with spectrofluorimetry in ex 
cellulo assays, or with fluorescence microscopy or flow cytometry in cellular assays. Flow cytometry is 
convenient in that it can provide a high-throughput quantification of the fluorescence intensity per 
cell. Fluorescence microscopy has lower throughput but has the advantage of providing additional 
information on the intracellular fluorescence profile (IFP). A punctate fluorescence pattern is often 
considered an indication of the tracer compound being entrapped in endosomes, while a diffuse 
 
Figure 6.3 | (A) The intracellular fluorescence profile (IFP) of 3 kDa dextrans (green fluorescence), 
illustrating the difference between a punctate pattern (sequestered cargo; left) and diffuse 
staining (cytosolic cargo; right). Scale bar 10 µm. Reprinted from 53, © 2012, with permission from 
Elsevier.  (B) IFP of Qdots (green fluorescence), visually classified as a punctate pattern, moderate 
release and a high amount of release. Blue color indicates the nucleus. Scale bar 50 µm. Reprinted 
with permission from 54. © 2013 American Chemical Society 
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cytosolic staining implies leakage from the endosomal vesicles (Figure 6.3). It must be noted 
however, that such a tracer leakage assay cannot distinguish between endosomal escape by pore 
formation, or by bursting (see section ‘Assays for studying membrane rupture’). 
8-Aminonaphthalene-1,3,6-Trisulfonic Acid (ANTS) and 8-Hydroxypyrene-1,3,6-Trisulfonic Acid  
(HPTS) are polyanionic fluorescent molecules that are quenched by the cationic quencher p-Xylene-
Bis-Pyridinium Bromide (DPX). Both ANTS/DPX 53 and HPTS/DPX 53, 54 have been used in ex cellulo 
assays to investigate the membrane integrity of artificial endosomes, where leakage and dilution of 
both compounds results in dequenching of the fluorescent signal. Fluorescein-labeled cell-
penetrating peptides (CPPs) have been used in a similar manner with potassium iodide as quencher 
55. Otherwise, rather than using a quencher molecule, self-quenching of certain fluorophores can be 
achieved when used at a sufficiently high concentration, which is relieved upon leakage resulting in 
increased fluorescence. For instance, calcein 56, 57, carboxyfluorescein (CF) 45 and sulforhodamine B 
(SulfoB) 58 have been used in ex cellulo leakage assays to investigate membrane integrity of artificial 
endosomes by spectrofluorimetry. In cellular assays, these tracer molecules are loaded in the 
endosomes by constitutive endocytosis. Especially calcein has been used for this, since the acidic pH 
in endolysosomes will further quench its fluorescence so that the increase in fluorescence intensity 
after leakage is even more pronounced. Scoring pore formation in cellular assays using calcein has 
been achieved both by microscopy 47, 59 and flow cytometry 60. 
Whereas an increased calcein fluorescence does not disclose from which intracellular vesicle leakage 
occurred, the use of other tracer molecules such as DQ-ovalbumin 38 and acridine orange (AO) 38, 47, 51 
relate specifically to endolysosomal membrane integrity. DQ-ovalbumin is a 45 kDa protein to which 
a high number of BODIPY-FL (8-chloromethyl-4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-
sindacene) is conjugated, quenching its fluorescence. Before this protein is proteolytically processed 
into peptides in the endolysosomal compartment, pore formation will lead to release of the 
quenched DQ-ovalbumin protein. However, after proteolytical degradation, pore formation will lead 
to release and dilution of the quenched BODIPY-FL-labeled peptides and an increase in fluorescence.  
Another interesting approach to specifically investigate lysosomal integrity that doesn’t involve a 
dequenching of highly concentrated dye, relies on acidotropic dyes like AO that accumulate at a high 
concentration in the lysosomal lumen, forming fluorescent dimers in acidic environments. Upon 
lysosomal membrane damage its fluorescence decreases because the lysosomal acidic pH can no 
longer be maintained in combination with AO leaking out in the cytosol. Quantification of this 
decreased fluorescence is then related to damage to the lysosomal membrane 38, 47, 51. 
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Endosomal membrane integrity can also be evaluated in cells without the use of fluorescent tracers. 
For instance, the leakage of certain toxins from endosomes is known to inhibit protein synthesis. In 
such a way, Pseudomonas exotoxin 61, ribotoxin α-sarcin 62 and saporin 63 were used as tracer 
molecules to investigate membrane destabilization by different viruses. The influence on protein 
synthesis was evaluated either with radio-actively labeled [3H]-leucine 61 or [35S]-methionine 62, or by 
using an MTT assay 63. Though these assays were used in a viral setting, they could easily be applied 
for manmade materials as well. 
As already highlighted, the leakage assay is frequently used to evaluate the effectiveness of certain 
compounds to induce pore formation, such as viral nanoparticles 58, 61-63  and CPPs 53, 55-57, 60. 
Nonetheless, these assays were also used to verify the effectiveness of polymeric gene delivery 
complexes, composed of cationic polymers such as PEI 51, 59 or  poly(2-alkylacrylic acid) 47, and pDNA. 
A limitation of detecting leakage of small molecules, however, is that it may not directly relate to the 
release of larger macromolecules or nanoparticles. Therefore, radioactive labeled proteins were used 
instead of small molecule tracers in an ex cellulo assay, where the radioactivity of leaked proteins in 
the extravesicular environment was visualized after agarose gel electrophoresis 56. Fluorescent 
dextrans of various molecular weights are interesting for use in cellular assays as well since they are 
efficiently taken up by cells without spontaneous leakage from the endocytic vesicles, and they can 
be labeled with different fluorophores 38, 60, 64. However, as leakage of dextrans into the cytosol will 
not lead to fluorescence dequenching, it requires visualization of the IFP with fluorescence 
microscopy. Of course, to distinguish punctate from diffuse staining, it is essential that these large 
tracer compounds are still able to diffuse throughout the cytosol, which can be checked e.g. by 
microinjection.  
ASSAYS FOR STUDYING MEMBRANE RUPTURE 
Aside from pore formation, endosomal escape can also occur through the rupture or bursting of the 
endosomal vesicles when an already destabilized membrane is perturbed by an outward force, e.g. 
osmotic pressure (see section ‘Endosomal rupture’). The leakage assays discussed in section ‘Assays 
for studying pore formation’ can also be applied here since rupture is also associated with membrane 
damage. However, they cannot distinguish between pore formation and rupture, seeing as the latter 
is a transient event. Instead, direct visualization of the bursting event can be accomplished with live-
cell video microscopy. For instance, calcein release from light-responsive polymersomes and 
endosomes was imaged by Vasdekis and colleagues as a burst of fluorescence towards the cytosol 
(Figure 6.4A), which is indicative of endosomal rupture rather than gradual leakage after pore 
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formation 35. Leakage of fluorescent dextrans after PCI treatment was visualized in real-time by De 
Bruin and coworkers, who noted a disappearance of the amount of labeled endosomes, indicating 
fast release of the compounds (Figure 6.4B) 34. High-speed video acquisition was able to document an 
asymmetric release of tracer molecules from the endosomes, representative for a burst-like 
mechanism (Figure 6.4C). Furthermore, the authors investigated release kinetics after PCI of different 
pDNA-polyplexes composed of PEI, PLL and poly-D-lysine (PDL), and noticed a distinct influence of 
buffering on the bursting effect. Similarly, fluorescently labeled oligodeoxynucleotides (ODNs) were 
used as self-quenching tracer molecules for the visualization of PEI-induced endosomal rupture 65. 
 
Figure 6.4 | Examples of the visualization of endosomal rupture by video microscopy. (A.) Light-
induced release of calcein in macrophages by bursting of the endosomes, which is noticeable as a 
burst of calcein fluorescence in the cytosol. Reprinted with permission from 35, © 2012 American 
Chemical Society. (B.) A fast decrease in the amount of dextran-filled endosomes is seen, together 
with an increase in cytoplasmic fluorescence, indicative of endosomal bursting. Scale bar 5 µm. 
Reprinted with permission from 34, © 2008, with permission from Elsevier. (C) High-speed video 
microscopy shows the asymmetric release of dextrans from an endosome, indicative of bursting. 
Scale bar 2 µm. Reprinted with permission from 34, © 2008, with permission from Elsevier. (D.) 
Real-time visualization of endosomal escape of fluorescently labeled oligodeoxynucleotides (FITC-
ODNs). A sudden release of quenched FITC-ODNs can be seen as a burst of green fluorescence, 
accumulating quickly in the nucleus after endosomal release. Reprinted with permission from 66, 
© 2013 American Chemical Society. 
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With a spinning disk confocal microscope, the release of ODNs was clearly visible as a burst of 
fluorescence filling the cytosol, followed by an accumulation of fluorescent ODNs in the nucleus 
(Figure 6.4D). These measurements are a particularly nice confirmation of the proton sponge 
hypothesis of buffering cationic polymers like PEI. 
Though it has not been proven explicitly, one could argue that when visualizing endosomal rupture of 
small tracer molecules, the co-incubation of small tracer molecules might alter the actual osmotic 
pressure within endosomes, leading to a bursting event where there normally isn’t one. An 
alternative rupture assay not troubled by this limitation is proposed by Maier and colleagues 66, 
making use of a cell line stably expressing the lectin galectin-3 (Gal-3) fused to an mCherry 
fluorophore. Gal-3 binds galactose residues, which under physiological conditions are present 
exclusively on the extracellular or intraluminal domains of membrane glycoproteins. Using live-cell 
video microscopy they could detect membrane rupture by viral nanoparticles in real-time based on 
the accumulation of cytosolic mCherry-Gal-3 on intraluminal galactose residues in ruptured 
endosomal structures. Even though this assay was coined in a viral setting, the authors confirmed 
that this was only possible in case of fully disrupted membranes, and not in case of pore formation, 
extending the usefulness of this assay to all kinds of man-made nanomaterials.  
ASSAYS FOR STUDYING MEMBRANE FUSION 
When nanomaterials are delivered by enveloped nanoparticles, e.g. liposomal formulations, 
endosomal escape is hypothesized to occur via fusion with the endosomal membrane. The fusion of 
lipid bilayers is usually assayed by a dye dilution assay, where fluorescent markers are diluted over an 
increased surface area (Table 6.2). This will result in a change in fluorescence intensity, which can be 
monitored with fluorescence techniques such as spectrofluorimetry or fluorescence microscopy. As a 
control, lipid membranes are typically lysed by a detergent for complete dilution of the fluorophores. 
The fluorophores used are either lipophilic in nature or coupled to lipid compounds such as 
phosphatidylethanolamine (PE), so that they can be efficiently incorporated in the lipid bilayer.  
For example, when pyrene is loaded into a lipid membrane in a sufficiently high concentration, 
excitable pyrene dimers, or “excimers” will be formed. However, upon dye dilution over a larger 
surface area, these dimers will break apart, leading to a loss in fluorescence 57. A more frequently 
used technique to monitor fluorophore dilution is Förster resonance energy transfer (FRET). FRET is a 
distance-dependent interaction between a pair of fluorophores, a donor (D) and acceptor (A), if the 
emission spectrum of the donor fluorophore overlaps with the excitation spectrum of the acceptor 
fluorophore. If both fluorophores are in close proximity, typically 1 – 10 nm, the excited donor 
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fluorophore can (non-radiatively) transfer its energy to the acceptor fluorophore. This results in an 
increase of acceptor fluorescence at the expense of donor fluorescence 44. A frequently used FRET 
pair is NBD  (4-chloro-7-nitrobenz-2-oxa-1,3-diazole) as a donor and rhodamine as an acceptor dye 17, 
44, 67. Liposomal particles are double-labeled in a high concentration so that the distance between 
Table 6.2 | Successful lipid-lipid fusion leads to a dilution of the incorporated fluorophores over a 
larger surface area. Dye dilution can be detected in a number of ways: dimer quenching, resulting 
in loss of fluorescence; FRET, resulting in a shift in fluorescence ratio of two fluorophores; dye 
dequenching, resulting in an increase in fluorescence due to dequenching of a self-quenching 
fluorophore. 
 
Dimer  
quenching 
 
PyrPC 
λexc=345 nm; 
λem=480 nm 
Ex cellulo [59] 
FRET 
 
NBD (D) 
λexc=465 nm; 
λem=535 nm 
 
Rhodamine (A) 
λexc=545 nm; 
λem=576 nm 
Ex cellulo [17, 44] 
In cellulo [68] 
Dye  
dequenching 
 
Rhodamine 
λexc=545 nm; 
λem=576 nm 
Ex cellulo [55] 
DiD 
λexc=633 nm; 
λem=650 nm LP 
In cellulo [69, 70] 
DiI 
λexc=549 nm; 
λem=565 nm 
In cellulo [71] 
FRET: Förster resonance energy transfer; F = fluorophore; D = donor; A = acceptor; NBD = 4-chloro-7-nitrobenz-2-oxa-
1,3-diazole; PE = phoshpatidylethanolamine; DiD = 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocyanine; DiI = 1,1’-
dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine; PyrPC = 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-
phosphocholine; 
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donor and acceptor allow FRET. Upon successful lipid fusion however, both fluorophores will be 
diluted over a larger surface area and the distance between donor and acceptor will increase, 
resulting in a decreased FRET efficiency. In an ex cellulo setting, this double-labeling can be applied to 
either the liposomal vector 17 or the artificial endosome 44, and FRET efficiency can be monitored by 
spectrofluorimetry. FRET has been used in cellular experiments as well, where the donor and 
acceptor fluorophores are incorporated in the lipid envelop of the nanoparticulate cargo and FRET 
efficiency is monitored by live cell spectral imaging microscopy 67. A third alternative for dye dilution 
relies on the self-quenching characteristics of specific fluorophores when they are loaded above a 
certain concentration in a lipid membrane. Upon fusion, the fluorophores are diluted below their 
self-quenching concentration and the increase in fluorescence intensity can be monitored 53, 68-70.  
Fluorophore dilution in lipid membranes is frequently used to investigate membrane fusion, either 
induced by CPPs 53, 57, 67, viral nanoparticles 68-70 or liposomal delivery vectors of proteins 17 or pDNA 
44, 67. Nevertheless, it should be emphasized that the major limitation of this assay is the inability to 
distinguish between lipid fusion and lipid mixing (Figure 6.5A) 71.Whereas both fusion and mixing 
denotes the interaction between lipid bilayers and will lead to dilution of the incorporated 
fluorophores over a larger surface area, lipid mixing will not result in the intended displacement of 
the cargo. Therefore, complementary assays have to be included to distinguish lipid mixing from lipid 
fusion. As an additional confirmation in an ex cellulo assay, it was suggested to measure the 
hydrodynamic size by dynamic light scattering. If fusion of lipid nanoparticles and artificial 
endosomes occurs, this should lead to an increase in average particle size 44. Alternatively, content 
transfer from the enveloped nanoparticle has also been used to prove fusion instead of mixing 
(Figure 6.5A). For instance, the transfer of fluorescently labeled ODNs to giant unilamellar vesicles 
was visualized by fluorescence microscopy 72, though this assay lacked high-throughput. Content 
displacement of tracer compounds has also been employed to verify lipid fusion, both towards 
artificial endosomes ex cellulo 57, and to the cytosol in cellulo 68. However, such content displacement 
could be an indication of both membrane fusion and pore formation 71. Therefore, both content 
displacement and dye dilution assays should be combined to ascertain lipid fusion. Miyauchi and 
coworkers proposed such a combination of dye dilution and content transfer assays, where a dual-
color fluorescence labeling of an enveloped virus could distinguish lipid fusion from lipid mixing at 
the plasma membrane or the endosomes 68 (Figure 6.5B). Though this assay was used in a viral 
setting, the same technique could be applied to manmade enveloped nanoparticles. Basically, both 
the content and the envelope are labeled in fluorophores with different spectra (green and red, 
respectively) resulting in a yellow signal when the viral particle is intact outside of the 
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 cell or inside of the endosome. To ascertain if the particle interacts with the plasma membrane or 
the endosomal membrane, the dilution of the membrane dye will lead to complete loss of the red 
signal when infinitely diluted over the plasma membrane, or the signal will still be visible when 
diluted over the smaller, finite surface of the endosomes. Nevertheless, this dye dilution assay, 
though informative about where interaction occurs, does not distinguish lipid mixing from lipid 
fusion. The fluorescent content marker is incorporated to this end, as a loss of its fluorescence 
indicates fusion instead of mixing, regardless of the location. 
BIOLOGICALLY RELEVANT ARTIFICIAL MEMBRANES 
Artificial membranes mimicking the endosomal membrane are frequently used in ex cellulo assays to 
evaluate endosomal escape in a controlled environment. The major constituents of the endosomal 
membrane are PC (phosphatidylcholine), PE and PSer (phosphatidylserine), that are present at a ratio 
of 55%, 25% and 10% of total lipid content, respectively 72, 73. Although often artificial membranes are 
simplified versions consisting only of PC and sometimes cholesterol, more and more studies try to 
mimic the endosomal membrane as accurately as possible 44. The importance of lipid composition on 
(previous page) Figure 6.5 | Combining membrane dye dilution and content transfer assays to 
verify lipid fusion.  
(A) A single color membrane dye dilution assay (1) cannot distinguish between lipid mixing and 
lipid fusion, as the increase in red fluorescence resulting from dequenching after dye dilution 
could be attributed to both cases. A content transfer assay (2) can be used as a complementary 
assay, where fluorescence of the content marker will be lost upon dilution only after membrane 
fusion. Both assays can be combined when using two-color fluorescence microscopy (3), where a 
sub-resolution particle will appear green, yellow or red, depending on whether there is no 
interaction, lipid mixing or lipid membrane fusion respectively.   
(B) By using two color fluorescence microscopy, Miyauchi and colleagues proposed an assay to 
distinguish lipid mixing from lipid fusion at the plasma membrane and in endosomes. Labeling 
both the envelope with a membrane marker (red fluorescent) and the core with soluble NC-GFP 
(green fluorescent), the viral particles outside of the cells and inside of the endosomes will emit 
fluorescence from both fluorophores (appearing yellow). Lipid mixing at the plasma membrane 
will result in almost infinite dilution of the red label and loss of the red signal. Since lipid mixing 
does not result in cargo displacement, the green content signal is still visible. Lipid mixing with the 
endosomal membrane on the other hand will still result in the presence of yellow particles in the 
image, as the red membrane marker will still emit fluorescence after negligible dilution in the 
finite endosomal membrane, and the content signal will also remain the same. When lipid fusion 
occurs however, either at the plasma or endosomal membrane, the content marker signal will be 
lost due to infinite dilution in the cell cytoplasm. Fusion at the plasma membrane, therefore, will 
result in loss of both signals, whereas fusion with the endosomal membrane can be ascertained 
by loss of green fluorescence and emission of red fluorescence from the endosomal membrane. 
Adapted from 69, © 2009, with permission from Elsevier. 
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membrane interactions was proven for example in a study by Berezhna and coworkers 72. Lipid fusion 
was evaluated between lipoplexes and giant unilamellar vesicles (GUVs) consisting of different 
compositions of PC, PE, PSer and sphingomyelin (SM). Remarkably, the authors find that fusion of the 
cationic lipoplexes with the artificial membrane and subsequent release of nucleic acids is 
predominantly mediated by the negatively charged PSer and PE, while PC and SM are supposedly 
inert in this process. Similarly, a study by Yang et al. 53 showed that TAT-mediated fusion was 
dependent on the anionic lipid bis(monoacylglycero) phosphate (BMP), highly enriched in the 
intraluminal vesicles of late endosomes. Thus, these studies clearly show that the lipid composition 
of the artificial membrane used in the ex cellulo assay is of utmost importance.  
Another key aspect of endosomes is the shift in pH compared to the extravesicular environment. To 
recreate the endosomal acidic environment, a buffer with similar pH can be used to resuspend the 
artificial endosomes 26. A different approach by Madani et al. involves preparing artificial large 
unilamellar vesicles (LUVs) with bacteriorhodopsin (BR) integrated in the lipid layer. Upon 
illumination, BR will act as a proton-pumping V-type ATPase, hence acidifying the LUV’s interior and 
mimicking the late endosomal environment in a controlled manner 55. 
Nevertheless, liposomes will always be a simplification of actual endosomal membranes, given the 
lack of proteins and lipid asymmetry 74. In an attempt to investigate interactions with an artificial 
endosomal membrane with as high a biological relevance as possible, red blood cells (RBCs) have 
been frequently used as a model. A dye dequenching assay with RBCs as a model membrane has 
been used by Lakadamyali et al. 69 to study fusion in a viral context. Similar to leakage assays, RBC 
integrity is frequently employed to evaluate pore formation by endosomal escape enhancing 
compounds, such as CPPs 26, PEI 46 or other drug delivery vectors 47, 54, 75. Damage to the RBC 
membrane will lead to leakage of hemoglobin, which can be quantified by absorption measurements 
at 450 nm after removal of intact erythrocytes. An even more representative model membrane was 
used in a leakage assay by Prchla et al. 76. HeLa cells were previously loaded with a high 
concentration of biotin-dextrans, after which endosomes were isolated from the cells. Afterwards, 
leakage of biotin-dextrans ex cellulo could be detected in the extravesicular environment with an 
ELISA assay. Interestingly, Le Blanc and coworkers adopted a similar method 70, though elaborated by 
incubating the pre-loaded isolated endosomes in a cytosol-mimicking solution containing buffers and 
ATP for continuous acidification of the purified late endosomes. Though this assay was used in a viral 
setting, the mimicking of the cytosolic environment can be extrapolated for use in any ex cellulo 
assay. 
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S T U D Y I N G  E N D O S O M A L  E S C A P E  E F F I C I E N C Y  
Of even greater practical use than elucidating the mechanism of endosomal escape, is determining if 
and to which extent endosomal escape occurs. Instead of investigating the membrane integrity or 
fusion, these (mostly cellular) assays actually monitor the amount of cytosolic cargo. Therefore, these 
assays are not influenced as much by the type of delivery vector as they are by the type of cargo. In 
this section an overview is provided of the different methods that have been reported to determine 
successful cytosolic delivery of nanoparticulate cargo (Table 6.3). 
BIOLOGICAL ACTIVITY 
When the aim is to deliver biologically active molecules, e.g. therapeutic molecules in drug delivery, 
successful cytosolic delivery can be easily assessed by the biological activity. For instance in case of 
gene therapy, a model mRNA or pDNA is used encoding for a reporter protein such as luciferase 46 or 
eGFP 77. The extent of reporter protein expression is then a measure for successful delivery to the 
cytosol for mRNA and further to the nucleus in the case of pDNA, which only could have happened if 
endosomal escape has occurred. For siRNA, a mutant cell line can be used that (stably) expresses a 
reporter protein. The extent to which the delivered siRNA silences the reporter protein expression is 
then again a measure for successful cytosolic delivery of siRNA 78. Alternatively, knockdown of a 
housekeeping gene can be quantified by RT-PCR 79. For protein delivery, one can make use of model 
enzymes, such as the β-galactosidase enzyme, whose biological activity can be measured as the 
intensity of blue color after cleavage of X-Gal substrate 80. When dealing with antigen delivery, the 
unique properties of APCs allow different antigen presentation assays as biological read-out. When 
using ovalbumin (OVA) as a model antigenic protein, the extent of OVA-delivery to APCs can be 
related to either the proliferation of and IL-2 secretion by OVA-peptide specific CD8+ T-cells 17, or to 
the amount of MHC-I dependent SIINFEKL presentation by APCs as measured by 
immunohistochemical analysis 35. It is clear that the nanomaterials investigated with these assays 
should consist of cargo with biological activity (such as pDNA, siRNA or proteins), regardless of 
whether this cargo is delivered by liposomes 17, polymersomes 35 or cationic polymers such as PEI 46 
or chitosan 77. It must be noted however that the biological activity is usually the end-point of an 
intracellular cascade, from which endosomal escape is only one aspect. Nanoparticle uptake, 
dissociation of the cargo from its carrier, cytosolic translocation to the nucleus (for pDNA), 
transcription, translation, etc. can all influence the final outcome. Therefore, the biological assays are 
only an indirect measure for endosomal escape, warranting the use of other more specific assays, as 
described further on. 
  
Table 6.3 | Overview of different techniques used to monitor cargo displacement to the cytosol. 
Distinguish cytosolic 
fraction from 
sequestered fraction 
Measuring technique Use Reference Pro’s Con’s 
Biological activity 
in cytosol 
reverse transcriptase 
quantitative PCR 
- Knockdown  of reporter or house-
keeping gene by siRNA 
[80] - In vivo measurements 
- Easy high-throughput quantification 
- Indirect measure 
- Fixed end time-point 
- Limited to siRNA 
Spectro / luminometer 
- Expression or knockdown of 
reporter gene 
[46, 79] 
- Applicable to different cargo 
- Easy read-out 
- Easy high-throughput quantification 
- Indirect measure 
- Population average 
- Fixed end time-point - Enzyme activity 
[81] 
Flow cytometry - Expression or knockdown of 
reporter gene 
[78] 
- Applicable to different cargo 
- Fast and easy read-out 
- Easy high-throughput quantification 
- Single-cell measurements 
- Indirect measure 
- Fixed end time-point 
ELISA - Detection of IL-2 secretion as 
antigen presentation assay 
[17] - Live-cell measurement 
- Easy high-throughput quantification 
- Indirect measure 
- Limited to antigen delivery 
to APCs 
Immunofluorescence 
microscopy 
- Immunostaining of SIINFEKL as 
antigen presentation assay 
[35] 
- Easy high-throughput quantification 
- Indirect measure 
- Limited to antigen delivery 
to APCs 
- Fixed end time-point 
Cellular fractionation 
Quantitative PCR 
- Amount of DNA 
[82, 83] 
- Cytosol <> endosomes 
- Easy high-throughput quantification 
- In vivo measurements 
- Labor-intensive cellular 
fractionation 
- Carrier-bound DNA? 
- Fixed end time-point 
Stem-loop PCR - Amount of biologically active siRNA 
bound to RISC 
[84] 
- Cytosol <> endosomes 
- Easy high-throughput quantification 
- In vivo measurements 
- Only active cargo 
- Labor-intensive cellular 
fractionation  
- Immunoprecipitation step 
necessary 
- Fixed end time-point 
- Limited to siRNA 
Radio-activity - Amount of DNA 
[50] - Cytosol <> endosomes 
- Easy high-throughput quantification 
- In vivo measurements 
- Labor-intensive cellular 
fractionation 
- Amount of proteins [86] 
(Table continued on next page) 
  
(continued from previous page) 
Intracellular fluorescence 
profile 
Wide field epi-
fluorescence or 
confocal microscopy 
- Visual scoring [53, 65, 81] - Cytosol <> endosomes 
- Easy read-out 
- Specific labeling 
- Limited to small cargo 
- Difficult quantification 
- Fluorescent labeling - Quantification 
[47, 87, 88] 
Fluorescent 
microenvironment 
sensors 
Fluorescence 
microscopy 
- Measure reductive environment 
[89] 
- Easy read-out 
- Specific labeling 
- Live cells 
- Indirect measure 
- Standard curve necessary 
- No quantification 
- Fluorescent labeling 
- Measure difference in pH 
[26, 51, 71, 
90-92] 
Real-time visualization of 
endosomal escape 
Live-cell video 
microscopy 
- Visualize bursting of endosomes 
[66, 84, 93] - Cytosol <> endosomes 
- Mechanism of endosomal escape 
- Live cells 
- Specific labeling 
- Limited to small cargo 
- Low throughput 
quantification 
- Fluorescent labeling 
- Visualize fusion with endosomes 
[69-71] 
Colocalization Confocal microscopy 
- Visual scoring 
[10, 96-98] 
- Cytosol <> endosomes 
- Easy read-out 
- Specific labeling 
- All cargo 
- Difficult quantification 
- Fluorescent labeling 
- Limited temporal resolution 
- Fixation sometimes 
necessary 
- Quantification 
[51, 79, 82, 
100] 
Visual assessment Electron microscopy 
- Visual scoring 
[14, 49, 54, 
84, 105, 108, 
109] 
- Very high resolution 
- Labeling not always necessary 
- Fixation artifacts 
- Low throughput 
quantification 
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CELLULAR FRACTIONATION 
To distinguish nanoparticulate cargo in the cytosol from that sequestered in the endolysosomal 
compartment, a frequently used assay involves fractionation of the cells and measuring the cargo in 
the cytosolic and endosomal fractions with in vitro assays. For example, the amount of nucleic acids 
81, 82 in cytosol and endosomes was quantified with quantitative PCR after fractionation. To measure 
the amount of biologically active siRNA in the cytosol, the Ago-protein of the RISC-complex was 
immunoprecipitated from tissue lysates, followed by stem-loop PCR quantification of the amount of 
target siRNA present in the RISC-complex 83. Instead of PCR quantification, it is also possible to use 
fluorescently labeled cargo and quantify the fluorescence in different cellular 
fractions/compartments. For example, fluorescently labeled dextrans and PEG-particles have been 
quantified this way after cellular fractionation 84. Radio-active labeling has been used for both pDNA 
50 and proteins 85 as well. It was even shown that radio-active labeled proteins can be quantified in 
cellular fractions from tissue lysates after in vivo administration 85.  
We would like to highlight that for investigating endosomal escape, cellular fractionation is merely a 
means of distinguishing cytosolic from endosomal cargo, and should always be complemented with 
in vitro assays to measure to amount of cargo in each fraction. Though the nanomaterials which can 
be investigated by this endosomal escape assay are therefore only limited to whether the cargo can 
be measured or not, typical concerns about cellular fractionation are the labor-intensiveness of the 
assay, as well as the uncertainty of collecting all the fractions whilst avoiding contamination from the 
endolysosomal fraction in the cytosolic fraction 82. Also, questions have been raised about the 
fractionation process, where uptake of macromolecules or nanomaterials might alter the vesicle 
buoyant density and therefore necessitate an adapted purification protocol for each nanoparticle 84. 
Therefore it seems advisable to confirm findings by the cellular fractionation assay with other assays, 
as the ones described below. 
FLUORESCENCE MICROSCOPY 
Since most nanoparticles for intracellular delivery can be fluorescently labeled, or in some cases have 
intrinsic fluorescent properties, the most frequently used technique for discriminating cytosolic from 
endosomal cargo is via fluorescence microscopy. Given that the cargo is small enough so it can 
diffuse throughout the cytosol, a diffuse or punctate IFP can be related to the efficiency of 
endosomal escape (see section ‘Assays for studying pore formation’). This has been used to assess 
endosomal escape of peptides 60, 64, siRNA 86, Qdots 8 and smaller proteins 47, 87. In most studies, the 
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diffuse or punctate fluorescence pattern is scored visually, so that these experiments remain rather 
qualitative 60, 64, 80. Yet, in some studies it was attempted to quantify the IFP. For example, the median 
fluorescence value of complete confocal images was proposed as a simple parameter to distinguish a 
punctate pattern from a diffuse intracellular distribution 87. Alternatively, the average fluorescence 
intensity in regions of interest belonging to the diffuse and punctate staining can be quantified and 
compared 47, 86. 
Fluorescent probes have also been used in a different approach to sense a change in the nanoparticle 
microenvironment. For example, by attaching a quencher via a disulfide bond to fluorescently tagged 
proteins, transfer to the cytosol of these proteins triggered an increase in fluorescence due to 
reduction of the disulfide bonds by cytosolic glutathione and release of this quencher 88. Otherwise, 
the change in microenvironment pH between acidic endosomes and cytosol has been sensed by 
using fluorophores with a pH-dependent fluorescence emission 70, 89. These fluorophores can be 
either attached to the nanoparticle, or be used as a nanosensor itself. To increase sensitivity to a 
broader pH range, these sensors are made of a pH-independent reference fluorophore and one 26, 51, 
90 or two 91 dyes whose emissions are affected differently by the pH. These ratiometric fluorescent 
sensors have been employed on several occasions, and more specifically to investigate the 
endosomal escape of proton sponge-based PEI-delivery vectors 51, 90, 91. Nevertheless, when using 
such nanosensors, it should be noted that a standard curve is always required to relate fluorescence 
emission ratio to pH (Figure 6.6A). The pH obtained by these nanosensors can then be visualized in 
the acquired images by means of color-coding, as demonstrated in Figure 6.6B. 
Endosomal escape can also be investigated by live-cell video microscopy. For instance, the transfer of 
small nanoparticulate cargo such as ODNs 65, ribozymes 92 and siRNA 83 towards the cytosol by PEI-
mediated endosomal rupture was visualized by video microscopy as a burst of fluorescence from the 
endosomes to the cytosol. The release of pDNA, however, cannot be directly visualized since it has 
very limited mobility in the cytoplasm 34, 65. The same also applies to aggregates of cargo delivered to 
the cytosol, as has been observed for Qdots delivered by lipofectamine, polymers, CPPs and physical 
techniques such as electroporation 9, 93. This problem was circumvented by Rehman and colleagues, 
who prepared PEI-pDNA complexes containing in addition self-quenched fluorescently labeled ODNs 
as tracer compounds 65. This allowed to detect bursting of endosomes by dequenching of the small 
ODNs, in a similar way as calcein could be used. Interestingly, in this way they could actually count 
the number of endosomal escape events per cell. Furthermore, by visualizing the rate of ODN 
accumulation in the nucleus (Figure 6.4D), they could confirm that PEI induces sudden endosomal 
bursting and immediate release of cargo in the cytosol, while a more gradual leakage of ODNs was 
observed when lipid carriers were used. Likewise, Remaut et al. made use of FRET-ODNs that could 
  Chapter 6 
 
  Page 175 
 
estimate both the cytosolic delivery of the ODNs based on the nuclear accumulation, and the 
integrity of the delivered ODNs based on the FRET signal 94. It was found that the composition of the 
poly-beta-aminoester carrier can greatly influence the amount and integrity of ODNs that are 
delivered to the cytosol. 
Dual-color fluorescence microscopy and colocalization analysis is widely used to distinguish cytosolic 
nanoparticles from those that are still sequestered in the endolysosomal compartments, especially 
those too large to diffuse throughout the cytosol, such as pDNA polyplexes and lipoplexes. Often, 
 
Figure 6.6 | (A) Example of a standard curve obtained in vitro, where fluorescence emission 
intensity ratio is related to pH of buffers and fitted to a theoretical model. (B) Color coded 
microscopic image of the intracellular pH following incubation with a three-fluorophore 
nanosensor. The top row shows the images as acquired by fluorescence microscopy, while the 
bottom row are color coded images according to the pH standard curve in A.  
Scale bar 10 µm. N = nucleus. Reprinted by permission from Macmillan Publishers Ltd: Molecular 
Therapy 92, © 2012. 
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(the lack of) colocalization between nanoparticles and endosomes is regarded as a measure for 
endosomal escape. Although colocalization is frequently visually scored 10, 95-97, it can be very well 
quantified by different approaches 98. The most rudimentary way is to quantify colocalization on a 
per-pixel basis, where the percentage of overlapping pixels in both channels is taken as a measure for 
colocalization 78, 81. Other frequently used parameters to quantify colocalization between pixels are 
the Pearson’s 99 and Manders’ correlation coefficient 51. In our group, we have recently optimized a 
dual-color dynamic colocalization technique, which allows quantifying the amount of colocalization 
between two fluorescent labels based on their movement during a certain timeframe, in this case the 
colocalization between labeled endosomes and labeled pDNA-polyplexes 100, 101. In theory, this 
method should also be capable of detecting correlated trajectories which diverge over time, as could 
be the case for endosomes and their released macromolecular cargo.  
Given the widespread use of fluorescence microscopy and colocalization analysis for assaying 
endosomal escape, it is instructive to highlight some of the well-acknowledged technical challenges 
and limitations of the technique 102. Firstly, due to the limited optical resolution of the microscope, 
care should be taken when evaluating diffuse vs. punctate staining, as out-of-focus light might falsely 
give the impression of a diffuse staining or apparent colocalized pixels. Furthermore, sub-resolution 
objects that are located closer together than the microscope’s resolution will always appear to be 
colocalized, which can be especially problematic in the perinuclear region that typically contains a 
high density of endosomes. Confocal microscopy certainly is preferred over wide field epi-
fluorescence microscopy as it eliminates out-of-focus fluorescence to a large extent. However, due to 
a relatively low sensitivity, confocal microscopy can easily miss dim features like small endosomes 
and nanoparticles. This can be mitigated to some extent by using slow scanning speeds to collect 
more photons, if the fluorescent molecules do not bleach too quickly. Another frequently 
encountered problem is crosstalk of different fluorophores between detection channels which again 
may lead to false colocalization. This can be limited by recording each channel separately with 
sequential excitation of each of the different fluorophores 99, though the general guideline is to use 
fluorophores that have a minimal spectral overlap. Nevertheless, confocal microscopy is usually 
associated with poor temporal resolution and hence the need for fixation, which importantly has 
been shown to lead to artifacts concerning the endosomal sequestration 103, 104. Nonetheless, fast 
confocal image acquisition in live cells is now made possible using spinning disk confocal microscopes 
equipped with the newest generation of sensitive CCD cameras, like the electron-multiplying CCDs or 
scientific CMOS cameras 65, 83. 
Of equal importance for proper fluorescence microscopy is the choice of fluorescent endosomal 
markers. Dextrans 96 or transferrins 104 that are added to the cell medium are considered to be a non-
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specific endosome labeling method. Alternatively, one can pulse-chase lipophilic carbocyanine dyes 
in the plasma membrane 10 or use plasma-membrane specific dyes such as PKH67 67, which will end 
up in most endocytic vesicles. On the other hand, specific labeling of lysosomes can be attained by 
using lysosome-specific markers such as lysosomal-associated membrane protein 1 (LAMP1), for 
example by immunofluorescence staining against LAMP1 86 or transgene expression of an eGFP-
LAMP1-construct 100. Also acidotropic dyes can be used such as Lysotracker Blue 9, 92, Lysotracker 
Green 78, 79, Lysotracker Red 17, 95 and LysoSensor Green 99, which have been shown to label about 
70% of the intracellular vesicles 81. On a cautionary note, it is important to keep in mind that most 
acidotropic dyes are considered weak bases and might influence endosomal acidification after long 
incubation times. Therefore, it is recommended to follow the manufacturer’s instructions. 
Furthermore, combining acidotropic dyes with “proton sponge”-nanoparticles for particle-lysosome 
colocalization has been shown to influence the outcome 105. Indeed, though PEI-particles showed a 
lack of colocalization with an acidotropic dye, colocalization was in fact noticed with fluorescently 
labeled LAMP1. This was attributed to the fact that PEI has a buffering effect on the endolysosomes, 
thereby inhibiting staining by acidotropic dyes, a conclusion that is also confirmed by Mo and 
coworkers 97. 
Regarding labeling of the nanoparticle of interest, one has the choice of either labeling the carrier 
molecules or the cargo. On the one hand it can be argued that it is best to label the cargo since it will 
typically be incorporated into the carrier and have the least influence on uptake and intracellular 
processing of the nanoparticle. Also, labeling the carrier might give rise to false conclusions, seeing as 
carrier dissociation is shown to already occur in the endosomes for PEI 65. On the other hand, 
fluorescent labels are typically hydrophobic and might interact with the endosomal membrane and 
influence the displacement 65, 106. A consensus on this has not been reached, however, warranting 
further studies on this topic.   
 
ELECTRON MICROSCOPY 
Even though samples need to be fixed and require extensive preprocessing, transmission electron 
microscopy (TEM) is still frequently used for assaying endosomal escape due to its unparalleled 
resolution. It allows to visually distinguish if the nanoparticles are located freely in the cytosol, or 
sequestered in membranous vesicles. For inorganic nanoparticles like Qdots 104, gold nanoparticles 107 
and superparamagnetic iron oxide NP’s 14, 108, labeling steps are usually not necessary (Figure 6.7A 
and 6.7C). However, organic nanoparticles cannot always be easily distinguished from the cellular 
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structures, though for polymeric nanoparticles, opinions vary. Bieber and coworkers did not label 
PEI-based delivery vectors, arguing that the electron dense PEI would give sufficient contrast in the 
TEM images (Figure 6.7B) 105. On the other hand, osmium tetroxide is frequently used to label 
polymeric delivery vectors such as poly(lactic-co-glycolic acid) (PLGA) and PEI to enhance their 
 
Figure 6.7 | (A) Visualization of gold nanoparticles (GNPs) by transmission electron microscopy. 
Red arrows indicate cytosolic GNPs, blue arrows indicate sequestered particles. Scale bar 500 nm. 
Adapted with permission from 107, © 2010 American Chemical Society. (B) Visualization of PEI-
particles by TEM  as electron-dense spots (white arrows). PEI-particles are seen associated with 
the endosomal membrane (black arrow), leading to membrane damage (arrowhead). Reprinted 
from 105, © 2002, with permission from Elsevier. (C) TEM-visualization of superparamagnetic iron 
oxide nanoparticles. Adapted with permission from 108, © 2010 John Wiley & Sons, Inc. 
(D) Quantification of endosomal escape by Gilleron and colleagues (left) Automatic detection of 
GNPs coupled to siRNA. (middle) A visual distinction was made between early endosomes, late 
endosomes and lysosomes, based on vesicular morphology. (right) Gradual release and 
compartment-specific release were plotted over time (respectively a linear curve and a sigmoidal 
curve), and experimental data was found to correlate to a compartment-specific release. Adapted 
by permission from Macmillan Publishers Ltd: Nature Biotechnology 84, © 2013. 
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contrast 49, 109. Gold can also be employed as contrast agent, as used for instance by Gilleron and 
colleagues to visualize siRNA in the cytosol or in membranous vesicles 83 (Figure6. 7D). 
Draw-backs of TEM include the necessity for fixation and that both sample preparation and analysis 
is very labor intensive. Usually, endosomal escape is scored visually by assessing if the majority of the 
nanoparticulate cargo resides in membranous vesicles, or freely in the cytosol 14, 49, 104, 105, 109. Imelli 
and coworkers presented quantitative data on the amount of viral nanoparticles at the plasma 
membrane, in the cytosol and in the endosomal vesicles, based on data from 8 – 10 cells and 23 – 45 
particles per cell 110. The most advanced use of TEM in this context was arguably presented by 
Gilleron and colleagues who proposed a semi-automatic quantification of TEM images, by which 
siRNA coupled to 6 nm colloidal gold nanoparticles (siRNA-GNP’s) are automatically detected in TEM 
images after setting a certain threshold (Figure 6.7D, left). Manual assignment of the particles to 
either the cytosolic or vesicular location was still required (Figure 6.7D, middle). Interestingly, to 
assess if endosomal escape of siRNA-GNP’s occurred through a burst-like mechanism in a specific 
compartment or via gradual release, Gilleron and co-authors plotted the amount of particles in the 
cytosol over time 83. Mathematical modeling showed that a gradual release of particles should lead 
to a linear trend, whereas a burst-like mechanism should give rise to a sigmoidal curve. Experimental 
data showed a sigmoidal curve in both cell lines, indicating a burst-like mechanism (Figure 6.7D, 
right). 
ASSESSING THE ENDOSOMAL DEPOT OF NON-DELIVERED CARGO 
Additional verification of the efficiency of endosomal escape is assayed by checking the amount of 
cargo still sequestered in the endolysosomal compartments using previously discussed methods. By 
deliberately disrupting the remaining lysosomes and comparing the amount of cargo in the cytosol 
with normal circumstances, one can get an idea of the cargo which is inefficiently delivered. The 
techniques used for this endosomal disruption, e.g. proton sponge 50, Leu-Leu-OMe 38, PCI 12, 77, 
osmotic shock 28 etc. have previously been mentioned and the reader is referred to this section for 
more detail (see section ‘Enhancing endosomal escape’). 
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COMPUTATIONAL MODELING OF ENDOSOMAL ESCAPE 
Experimental results from different assays are frequently combined in a mathematical model in order 
to estimate those parameters that are difficult to measure directly. For example, computational 
modeling allowed Vargas et al. 111 to estimate cell binding, uptake, endosomal escape, vector 
unpackaging and nuclear import by combining quantitative experimental results on vector uptake, 
amount of pDNA in the nucleus and transfection efficiency. Similarly, Moore and colleagues 26 were 
able to determine the endosomal escape rate constant (k_escape) by fitting a mathematical model to 
experimental data obtained by ratiometric nanosensors measuring the intracellular pH with 
fluorescence microscopy. A study by Dinh and coworkers 112 further emphasizes the importance and 
usefulness of mathematical modeling, but also highlight the limitation that most mathematical 
models approach cellular transport mechanisms by first-order kinetics between well-defined 
compartments only. According to the authors, their study improves on previous mathematical 
models by incorporating the spatial structure of the cell, as well as taking into account the 
continuous movement of nanoparticles based on single-particle tracking experiments. Alternatively, 
computational models have been used as so-called “computational microscopy”, demonstrated by 
Tian et al. 113. By coarse-grain molecular dynamics modeling in the MARTINI force field, the authors 
investigate the mechanism of endosomal escape of pH-responsive dendrimers. By computational 
modeling, the authors could obtain a high-resolution simulation of how the endosomal membrane is 
destabilized by the protonated dendrimers. 
C O N C L U S I O N S  A N D  F U T U R E  P E R S P E C T I V E S  
Nanomaterials for intracellular drug delivery or cell imaging applications require an efficient cytosolic 
delivery mechanism. Up until now, the escape from endosomal sequestration and subsequent 
degradation remains a major bottleneck. In order to design improved nanomaterials, reliable assays 
for detecting and quantifying endosomal escape are necessary. In this review we have given an 
overview of assays that are currently available. Given the strengths and weaknesses of each 
approach, a combination of complementary methods is preferred, depending on which aspect of 
endosomal escape is investigated.  
Not only the mechanism or the efficiency of endosomal escape is of importance. It would be of 
interest in future studies to try and relate endosomal escape to the time and location at which it 
happens in the cell. Such information could be relevant for avoiding premature degradation by the 
acidic environment of the late endosomes or the harsh hydrolytic conditions of the lysosomes. It is 
therefore expected that live cell imaging will only gain in importance. A current limitation, however, 
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is that this is mostly based on fluorescently labeled cargo or carrier materials. As it may be that this 
influences the intracellular processing mechanisms or kinetics, it is of special interest to look into the 
capabilities of label-free microscopy techniques, such as Raman imaging, to follow up on endosomal 
escape.   
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O U T L O O K  A N D  F U T U R E  P E R S P E C T I V E S  
Retinal gene therapy continues to advance in research and clinical trials and promises to offer relief 
to millions of patients suffering from blinding disorders. Such dystrophies can be severely debilitating, 
and since they are not life-threatening, diagnosed patients are affected for the remainder of their 
lives. This places an immense burden on global resources, which has led to increasing advances in the 
diagnosis and classification of (hereditary) visual disorders by genetic screening 1. In part because of 
this, the eye is especially suited for gene therapy. Furthermore it is a small isolated compartment, 
facilitating localized delivery of novel therapeutics while minimizing the risk of systemic immunogenic 
responses. The promising results obtained in increasing numbers of clinical trials further encourage 
researchers and clinicians to pursue the realization of retinal gene therapy in a clinical setting. 
However, to conclude this thesis, we would like to highlight some of the remarks and pitfalls that 
cannot be overlooked when hoping to translate retinal gene therapy from bench to clinic on a large 
scale. 
As we have highlighted in the course of this dissertation, most promising clinical results of retinal 
gene therapy have been achieved by subretinal injection of viral vectors. We, however, have looked 
into intravitreal administration, as it is likely safer and more feasible on a large scale. Nonetheless, 
even here attention should be given to the following aspects. We (and others 2-5) have suggested that 
nanoparticles injected in the vitreous humour, granted they are mobile, will cross the vitreoretinal 
interface (i.e. the inner limiting membrane) via uptake by the Müller cells, after which they can be 
exocytosed in the neural retina or the subretinal space. This could be advantageous for delivery of 
gene nanomedicines to the foveal photoreceptors, as it is known that a high number of Müller cells is 
present at the fovea 6, 7. Targeting foveal photoreceptors via subretinal injection remains very 
precarious and challenging due to the temporary bleb-formation 8. Nonetheless, intravitreal injection, 
though promising in the near future, also entails some risks of increased intraocular pressure and 
endophthalmitis. Moreover, some reports suggest that intravitreal injection influences the activation 
state of microglia and Müller cells, causing phenotypic changes for short periods of time 9. Ocular 
inflammation has also been linked to swelling and functional alterations in Müller cells 10. One can 
imagine that such changes influence the vitreoretinal transport of nanomedicines, assuming that 
Müller cells are indeed the determining pathway. Ultimately, the ideal administration route to the 
retina should be noninvasive and risk-free. A recent report describes the ability of annexin A5-
associated liposomes to traverse the corneal epithelial barrier via transcytosis, and successfully 
delivering anti-VEGF antibodies to the retina in vivo 11. These results indicate delivery of gene 
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nanomedicines to the retina via topical administration could be realized in the years to come, 
renouncing the need for intraocular injections altogether. 
Aside from intravitreal injection, we also strongly motivate the use of nonviral gene carriers for 
retinal gene therapy, as they are cheaper and easier to produce on a large scale, and are less prone 
to induce immunogenic responses. Their cargo capacity is much larger than the typically used AAV-
vectors for retinal gene therapy, expanding the therapeutic window to include those dystrophies 
with large mutated genes such as Stargardt disease (ABCA4) and Usher syndrome (MYO7). 
Unfortunately, up until now nonviral vectors date are struggling to achieve a similar therapeutic 
efficacy and specificity as the viral vectors. Viral vectors have evolved over millions of years to infect 
certain cell types, and have become adept at bypassing nearly every extracellular and intracellular 
barrier. Nonviral vectors, however, are still catching up. For example, the tropism of viral vectors 
determines the specificity with which they are able to infect a certain cell type, a desirable attribute 
for gene therapy, where a transgene has to be delivered and expressed only in the target cells 12. 
Specificity of nonviral vectors, on the other hand, is attempted by means of two distinct approaches. 
Targeting ligands can be coupled on the surface of nonviral gene nanocarriers to trigger cell-type 
specific attachment and uptake. Secondly, cell-type specific promoter regions are incorporated in 
therapeutic nucleic acids to limit gene transcription to target cells only. Nevertheless, both 
approaches are still under development and off-target expression can never be completely avoided 12, 
indicating further research is needed to optimize nonviral expression specificity. Next to specificity, 
major advances are needed to bring transgene expression to the same levels as viral vectors. 
Endosomal escape, as we have discussed in Chapter 6, remains a challenging barrier for nonviral 
vectors, limiting the amount of therapeutics delivered at the target site. Furthermore, once in the 
cytosol, the therapeutic nucleic acids have to reach the cell nucleus (in the case of pDNA), a 
formidable challenge with the double-layered nuclear membrane as a barrier. Finally, transcription 
and translation have to be optimized to drive transgene expression to its maximal capacity. Indeed, 
the episomal nature of the used pDNA and the presence of bacterial elements used for the 
manufacturing promote the transient nature of nonviral gene expression. Fortunately, this 
shortcoming has been identified and an entire field dedicated to vector engineering attempts to 
increase transgene expression efficiency and duration by the incorporation of enhancers, CpG 
depletion, scaffold matrix attachment regions (S/MARs), etc. 13. As such, a recent publication by the 
group of Muna Naash documented that compacted DNA nanoparticles could drive transgene 
expression in vivo on a comparable scale and longevity as AAV vectors, with the additional advantage 
that nanoparticles did not leave the eye 14. On a final note, though usually persistent transgene 
expression is necessary, at times transient expression could be sufficient. Vector engineering has 
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been used to design inducible expression systems, where transgene expression can be driven upon 
delivery of pharmacological substances, such as rapamycin or tetracyclin, or as a response to 
environmental changes, such as hypoxia 15. 
In addition to the administration route and nucleic acid vector used, we would like to conclude with 
some final remarks concerning the potential applications of retinal gene therapy itself. Gene therapy 
entails the treatment of dystrophies by supplementing functional genes or silencing certain toxic 
genetic defects. This implies that the mutated gene should be identified and a functional transgene is 
available for delivery. Most known mutations affect proteins in either the photoreceptor cells or the 
retinal pigment epithelial (RPE) cells (see Chapter 1), though it has been proposed that gene therapy 
can only successfully restore vision if photoreceptors are still intact and functional. Indeed, loss of 
vision is usually attributed to the degeneration of photoreceptor cells resulting from inflammatory 
responses of the immune system to aberrant physiological or morphological situations in the retina. 
Therefore, to prevent or rescue loss of vision, gene supplementation of a dysfunctional gene is not 
always sufficient and in most cases should be complemented by strategies to prevent further retinal 
degeneration 16, e.g. by controlling or managing the retinal immune responses. If retinal 
degeneration has progressed too far and functional photoreceptors are lost, an alternative 
therapeutic strategy entails the implementation of novel photosensors in the neural retina. To this 
end, gene therapy has been proposed to convert RPE cells or other cells from the visual circuitry 
(bipolar, amacrine, …) to photosensors by expression of transgenic photosensitive proteins 12, 17. 
Considering what has been mentioned, should we conclude that retinal gene therapy will prove to be 
the promised cure for all dystrophies resulting from identified monogenic aberrations, wherever 
photoreceptor degeneration has not progressed too far? Not necessarily. Retinitis pigmentosa is 
known to be caused by monogenic mutations, however these can be very diverse. The cost of 
personalized treatment (genetic screening and vector engineering) for a very small group of patients 
could limit the incentive to produce gene therapeutics for these so-called ‘orphan disorders’. 
Conversely, age-related macular degeneration is an acquired visual disorder, not necessarily caused 
by genetic aberrations and therefore at first glance not a suitable candidate for retinal gene therapy. 
Nevertheless, as the most common form of AMD is associated with neovascularization, treatment 
strategies comprising persistent delivery of anti-VEGF compounds (monoclonal antibodies and 
soluble VEGF receptors) by gene therapy have been proposed, and have even reached clinical trials.  
In conclusion, though retinal gene therapy is steadily advancing towards clinical applications, a lot of 
limitations remain to be optimized. This dissertation aims at providing insight in some of these 
difficulties.  
Chapter 7 
 
Page 196 
R E F E R E N C E S  
1. Swaroop, A.; Sieving, P. A. The golden era of ocular disease gene discovery: race to the finish. 
Clin Genet 2013, 84, 99-101. 
2. Bourges, J. L.; Gautier, S. E.; Delie, F.; Bejjani, R. A.; Jeanny, J. C.; Gurny, R.; BenEzra, D.; 
Behar-Cohen, F. F. Ocular drug delivery targeting the retina and retinal pigment epithelium 
using polylactide nanoparticles. Invest Ophth Vis Sci 2003, 44, 3562-9. 
3. Bejjani, R. A.; BenEzra, D.; Cohen, H.; Rieger, J.; Andrieu, C.; Jeanny, J. C.; Gollomb, G.; Behar-
Cohen, F. F. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005, 
11, 124-32. 
4. Kim, H.; Robinson, S. B.; Csaky, K. G. Investigating the Movement of Intravitreal Human 
Serum Albumin Nanoparticles in the Vitreous and Retina. Pharm Res-Dord 2009, 26, 329-337. 
5. Koo, H.; Moon, H.; Han, H.; Na, J. H.; Huh, M. S.; Park, J. H.; Woo, S. J.; Park, K. H.; Kwon, I. C.; 
Kim, K.; Kim, H. The movement of self-assembled amphiphilic polymeric nanoparticles in the 
vitreous and retina after intravitreal injection. Biomaterials 2012, 33, 3485-93. 
6. Burris, C.; Klug, K.; Ngo, I. T.; Sterling, P.; Schein, S. How Muller glial cells in macaque fovea 
coat and isolate the synaptic terminals of cone photoreceptors. The Journal of comparative 
neurology 2002, 453, 100-11. 
7. Gass, J. D. Muller cell cone, an overlooked part of the anatomy of the fovea centralis: 
hypotheses concerning its role in the pathogenesis of macular hole and foveomacualr 
retinoschisis. Arch Ophthalmol 1999, 117, 821-3. 
8. Boye, S. E.; Boye, S. L.; Lewin, A. S.; Hauswirth, W. W. A Comprehensive Review of Retinal 
Gene Therapy. Molecular therapy : the journal of the American Society of Gene Therapy 2013. 
9. Seitz, R.; Tamm, E. R. Muller cells and microglia of the mouse eye react throughout the entire 
retina in response to the procedure of an intravitreal injection. Adv Exp Med Biol 2014, 801, 
347-53. 
10. Pannicke, T.; Uckermann, O.; Iandiev, I.; Wiedemann, P.; Reichenbach, A.; Bringmann, A. 
Ocular inflammation alters swelling and membrane characteristics of rat Muller glial cells. J 
Neuroimmunol 2005, 161, 145-54. 
11. Davis, B. M.; Normando, E. M.; Guo, L.; Turner, L. A.; Nizari, S.; O'Shea, P.; Moss, S. E.; 
Somavarapu, S.; Cordeiro, M. F. Topical delivery of Avastin to the posterior segment of the 
eye in vivo using annexin A5-associated liposomes. Small 2014, 10, 1575-84. 
12. Sahel, J. A.; Roska, B. Gene therapy for blindness. Annual review of neuroscience 2013, 36, 
467-88. 
13. Koirala, A.; Conley, S. M.; Naash, M. I. A review of therapeutic prospects of non-viral gene 
therapy in the retinal pigment epithelium. Biomaterials 2013, 34, 7158-67. 
14. Han, Z.; Conley, S. M.; Makkia, R.; Guo, J.; Cooper, M. J.; Naash, M. I. Comparative Analysis of 
DNA Nanoparticles and AAVs for Ocular Gene Delivery. PLoS One 2012, 7, e52189. 
15. Bainbridge, J. W.; Tan, M. H.; Ali, R. R. Gene therapy progress and prospects: the eye. Gene 
Ther 2006, 13, 1191-7. 
16. Cideciyan, A. V.; Jacobson, S. G.; Beltran, W. A.; Sumaroka, A.; Swider, M.; Iwabe, S.; Roman, 
A. J.; Olivares, M. B.; Schwartz, S. B.; Komaromy, A. M.; Hauswirth, W. W.; Aguirre, G. D. 
Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal 
degeneration despite enduring visual improvement. P Natl Acad Sci USA 2013, 110, E517-25. 
17. Wang, S. Z.; Yan, R. T. The Retinal Pigment Epithelium: a Convenient Source of New 
Photoreceptor cells? J Ophthalmic Vis Res 2014, 9, 83-93. 
 
  
  Chapter 7 
 
  Page 197 
  
Chapter 7 
 
Page 198 
 
Summary and general 
conclusions 
 
  
Summary and general conclusions 
Page 200 
  
  Summary and general conclusions 
 
  Page 201 
S U M M A R Y  
With the continued advances in molecular biology and the advent of fast and high-throughput 
sequencing methods, a multitude of hereditary disorders have been uncovered as possible targets 
for gene therapy. Gene therapy offers the possibility to cure those disorders which, up until know, 
were merely treated by symptomatic management. In Chapter 1, a short history and general 
introduction to gene therapy is provided, highlighting the different uses of the viral and nonviral 
vectors for nucleic acid delivery. The chapter continues with highlighting why the eye is such an 
attractive organ for gene therapy. The complex anatomy of the eye is briefly discussed in relation to 
the different possible targets for gene therapy, as well as the different barriers that need to be 
overcome for efficient nucleic acid delivery. Finally, the use of intravitreal administration of nonviral 
gene delivery vectors is motivated for retinal gene therapy applications on a larger scale.  
Once administered in the vitreous humor, the gene nanomedicines have to migrate towards the 
retinal target cells, located at the periphery of the eye. In order to reliably study intravitreal mobility 
of gene nanomedicines, we have developed a robust ex vivo eye model compatible with high-
resolution fluorescence microscopy, as described in Chapter 2. The ex vivo model was based on 
excised bovine eyes from which the anterior segments were removed without disrupting the fragile 
vitreal structure, thus providing an optical window for the visualization of nanoparticle diffusion. 
With this model, we set out to evaluate the relationship between nanoparticle characteristics, such 
as size and surface charge, and their intravitreal mobility by using an array of fluorescent polystyrene 
model beads. Nanoparticles up to 1 µm in size did not exhibit hindered diffusion in the vitreous 
humor, which is a positive finding for nonviral gene nanomedicines that are typically 100 – 200 nm in 
size. Whereas anionic nanoparticles were mobile for the most part, cationic nanoparticles exhibited a 
bimodal profile, with a large fraction of the nanoparticle population being immobilized. As most 
nonviral gene nanomedicines have a cationic surface charge for improved cellular attachment, this 
immobilization would mean a drastic decrease in therapeutic efficacy in case of intravitreal injection. 
In order to alleviate this immobilization, nanoparticle surfaces were functionalized with polyethylene 
glycol (PEG), resulting in increased intravitreal mobility. We applied our findings to a novel class of 
nonviral polymeric gene nanomedicines, composed of p(CBA-ABOL) and plasmid DNA (pDNA). As 
expected, these cationic polyplexes were found to be highly immobilized upon intravitreal injection. 
However, in accordance with our hypothesis, PEGylation of the polymeric vector resulted in a 
remarkable increase in intravitreal mobility of the polyplexes.  
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In spite of their improved mobility in the vitreous humor, it is well-known that PEGylated 
nanomedicines are less efficiently taken up in cells and have (highly) reduced transfection efficiency. 
In search for an alternative for PEG, we were inspired by the heterogeneous intravitreal mobility of 
the cationic nanoparticles. Though the majority appeared to be immobilized, a small fraction of 
nanoparticles remained mobile, almost equally mobile as the PEGylated nanoparticles. We 
hypothesized that these cationic nanoparticles were electrostatically coated with anionic 
components of the vitreous humor, effectively shielding their interactions with other vitreal 
components. The major anionic component in the vitreous humor is hyaluronic acid (HA), a 
ubiquitously found glycosaminoglycan which has caught the attention of the drug delivery 
community in recent years due to its intrinsic biocompatible and non-immunogenic characteristics. 
Chapter 3 is dedicated to providing a general introduction of HA and an overview of its uses as a drug 
and gene delivery additive.  
In Chapter 4 we have employed HA to electrostatically coat the cationic p(CBA-ABOL)/pDNA 
polyplexes (cfr. Chapter 2). We hypothesized that HA will provide the nanocarriers with a negatively 
charged hydrophilic surface, consequently endowing the nanocarriers with improved intravitreal 
mobility. Simultaneously, their ability to enter and transfect the retinal target cells was expected to 
be maintained, as HA is a known ligand for the CD44-receptor, expressed on several retinal cell types. 
Additionally, since it is well-documented that native HA has many different biological functions 
depending on its molecular weight (MW), we investigated the possible effect of MW on the 
electrostatically coated HA-polyplexes by using HA with MWs of 22 kDa, 137 kDa and 2700 kDa. We 
found that, regardless of the MW used, an electrostatic coating of the cationic polyplexes was 
possible. More importantly, the size of these ternary polyplexes remained in the submicron range, 
and pDNA complexation efficiency was not compromised. Intravitreal mobility of the HA-coated 
ternary polyplexes was evaluated with the ex vivo model presented in Chapter 2. Interestingly, the 
mobility of polyplexes coated with 22 kDa and 137 kDa HA in the vitreal matrix was markedly 
improved, supporting our hypothesis, while those coated with 2700 kDa did not show any significant 
improvement. Cellular uptake and transgene expression in ARPE-19 cells was evaluated in vitro with 
flow cytometry. Since higher MW of HA has been shown to have a higher affinity for CD44-receptors, 
we were surprised to find that HA-coated polyplexes coated with 137 kDa HA appeared to be less 
efficient at transgene expression than those coated with 22 kDa HA. These results highlight that, 
even though the use of HA as a drug delivery additive is growing exponentially, the effects of 
different MWs are not yet clearly understood, warranting further research. 
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Our previous results show that electrostatic HA-coating of cationic polymeric gene nanomedicines 
can result in improved mobility in the vitreous humor without drastically affecting in vitro 
transfection efficiency. However, the stability of these electrostatically coated complexes in 
extracellular matrices and tissues in vivo, such as the retina, remain questionable. In Chapter 5, we 
compare the suitability of two different HA-coating approaches for lipid gene nanocarriers composed 
of DOTAP:DOPE/pDNA. HA was either coated electrostatically on pre-formed lipoplexes, or HA-
liposomes were formed by inclusion of an HA-DOPE conjugate. Both electrostatic and covalent 
attachment of HA to the lipoplexes resulted in small, monodisperse nanoparticles with negative 
surface charge, while maintaining the ability for pDNA complexation. After intravitreal injection, HA-
lipoplexes remained highly mobile regardless of the coating strategy used. The main differences 
between coating strategies were noted at the cellular level. Whereas electrostatic HA-lipoplexes did 
not significantly affect in vitro transfection efficiency, the covalent HA-coupling resulted in an 8-fold 
increase in transgene expression. One final barrier that remained to be investigated was the 
permeation across the vitreoretinal interface. We could show with in vivo data in mice that 
intravitreal injection of covalent HA-coated lipoplexes resulted in transgene expression in cells as far 
as the subretinal space after 72 hours, while transfection efficiency of uncoated lipoplexes was 
limited to the inner retina. As the vitreoretinal interface is assumed to form a barrier against passive 
transport of nanoparticles towards the retina, we support the hypothesis that the lipoplexes are 
transported from the vitreous to the retinal layers by selective uptake and transcytosis of Müller glial 
cells. 
As highlighted before, upon intravitreal injection, gene nanomedicines encounter different barriers: 
(i) they have to remain mobile in the vitreous humor, (ii) they have to able to permeate the retinal 
layers and (iii) they have to be taken up in the target cells. One of the biggest hurdles for nonviral 
gene therapy is encountered after cellular uptake. In Chapter 5, we noticed a remarkable difference 
in in vitro transfection efficiency between covalent HA-lipoplexes and electrostatic HA-lipoplexes. We 
believe this dissimilarity is not merely a consequence of differences in uptake efficiency, but rather 
due to variations in intracellular trafficking and subsequent endosomal escape. Indeed, when 
particles are taken up by the cell, typically via endocytosis, the therapeutic cargo is trapped inside 
the endosomes. To exert their therapeutic effect, they have to escape from these intracellular 
vesicles into the cytosol. To overcome this barrier, several different approaches have been 
documented, though as of yet there is no consensus on how to accurately and reproducibly measure 
the efficiency of this escape. As an incentive for future research, in Chapter 6 we provide an overview 
of the different assays used to date to evaluate endosomal escape. We begin by introducing the 
endosomal barrier for the intracellular delivery of nanomaterials in general, and continue with 
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several methods used to overcome this barrier. Afterwards, we provide an exhaustive overview of 
different assays and methodologies employed to evaluate either (i) the mechanism of endosomal 
escape or (ii) the quantity of endosomal escape. 
Finally, in Chapter 7, we provide an outlook of where the field of retinal gene therapy might evolve 
towards, and what research will have to focus on for the improvement and advancement of retinal 
gene therapy towards the clinic.  
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G E N E R A L  C O N C L U S I O N  
The primary aim of this dissertation was to optimize the delivery of therapeutic nucleic acids to the 
retina via intravitreal administration. As the vitreous humor is a formidable barrier for nanoparticle 
transport, optimization of intravitreally injected nanomedicines requires a methodology to accurately 
determine the mobility in intact vitreous humor. With this method, it was found that optimal 
intravitreal mobility could be achieved by endowing nanoparticles with an anionic, hydrophilic 
surface coating, e.g. hyaluronic acid (HA). HA was evaluated in this dissertation as a coating strategy 
for both polymeric and lipid gene nanocarriers. Though HA is being used extensively in the drug 
delivery community, we urge future studies to account for both the differences in HA molecular 
weight and attachment approaches used, e.g. electrostatic or covalent. As a coating strategy for 
intravitreally injected nanomedicines, we have concluded that HA can provide nanoparticles with the 
necessary characteristics to (i) overcome the vitreal barrier and move towards the retina, (ii) cross 
the vitreoretinal barrier and permeate the neural retina, presumably via entry in the Müller cells and 
(iii) maintain the ability to enter the target cells, possibly through CD44-receptor mediated 
endocytosis, and induce transgene expression. A final hurdle for nonviral gene nanomedicines is 
found in their inefficiency to escape towards the cytosol after cellular uptake. If nonviral carriers are 
to reach the same therapeutic efficacy as their viral counterparts, research will have to be focused on 
optimizing the escape of this intracellular barrier. 
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S A M E N V A T T I N G  
De aanhoudende vooruitgang in het domein van de moleculaire biologie en de opkomst van snelle 
sequeneringsmethodes met hoge doorvoercapaciteit hebben een resem aan erfelijke aandoeningen 
als mogelijke kandidaten voor gentherapie blootgelegd. Gentherapie biedt de mogelijkheid tot 
genezing van ziektes waarvoor tot op heden slechts een symptomatische behandeling mogelijk was. 
Hoofdstuk 1 bevat een korte geschiedenis en algemene inleiding tot gentherapie, waarin de 
verschillen in toepassing van virale en niet-virale aflevering van nucleïnezuren worden aangekaart. 
Verder in dit hoofdstuk wordt gemotiveerd waarom het oog een geschikt orgaan is voor gentherapie. 
De complexe anatomie van het oog wordt beschreven en gerelateerd aan de verschillende potentiële 
doelwitten voor gentherapie, alsook de mogelijkse barrières die efficiënte aflevering van 
nucleïnezuren in de weg kunnen staan. Ten slotte motiveren we het gebruik van intravitreale injectie 
van niet-virale gentherapeutica voor het toepassen van retinale gentherapie op grote schaal. 
Eenmaal de gen nanomedicijnen toegediend worden in het glasachtig lichaam van het oog (corpus 
vitreum of glasvocht), moeten deze nog de retinale doelwitcellen kunnen bereiken, gesitueerd aan 
de achterkant van het oog. Om de intravitreale mobiliteit van nanomedicijnen betrouwbaar te  
kunnen onderzoeken, beschrijven we in Hoofdstuk 2 de ontwikkeling van een robuust ex vivo 
glasvocht model dat compatibel is met hoge resolutie fluorescentie microscopie. Dit ex vivo model is 
gebaseerd op ontlede ogen afkomstig van recent geslachte koeien. Het anteriore gedeelte van deze 
ogen werd verwijderd zonder de fragile structuur van het glasvocht aan te tasten, waardoor een 
optisch raamwerk gecreëerd werd voor het visualiseren van de diffusie van nanopartikels. Aan de 
hand van dit model werd getracht de relatie te bepalen tussen enerzijds de karakteristieken van 
inerte, fluorescente nanopartikels, zoals grootte en oppervlakte lading, en anderzijds hun 
intravitreale mobiliteit. De diffusie in het glasvocht van nanopartikels met een grootte tot 1 µm werd 
niet gehinderd, dit betekende een positieve bevinding voor niet-virale gentherapeutica aangezien 
deze zich meestal in de grootte-orde van 100 – 200 nm bevinden. Nanopartikels met een negatieve 
oppervlaktelading bleken voor het grootste deel mobiel. Positief geladen nanopartikels echter, 
vertoonden een bimodaal profiel waarbij een groot deel van de nanopartikels geïmmobiliseerd 
werden. Aangezien de meerderheid van niet-virale gentherapeutica een positieve oppervlaktelading 
hebben voor efficiënte cellulaire opname zou dit een groot verlies in therapeutische efficiëntie 
betekenen na intravitreale injectie. Om deze immobilisatie te verminderen werd de oppervlakte van 
de nanopartikels gefunctionaliseerd met polyethylene glycol (PEG) met een verhoogde intravitreale 
mobiliteit tot gevolg. Deze bevindingen werden toegepast op een nieuw type niet-virale 
polymerische gentherapeutica, bestaande uit CBA-ABOL polymeren en plasmide DNA (pDNA). Zoals 
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verwacht bleek een grote fractie van deze kationische polyplexen geïmmobiliseerd na intravitreale 
injectie. Desalniettemin resulteerde PEGylatie van de polyplexen in een uitzonderlijke verhoging van 
hun intravitreale mobiliteit, overeenkomstig  met onze hypothese.  
Niettegenstaande hun verhoogde intravitreale mobiliteit is geweten dat gePEGyleerde 
nanomedicijnen minder efficiënt worden opgenomen in cellen en bijgevolg een verminderde 
transfectie efficiëntie vertonen. In de zoektocht naar een alternatief voor PEG werden we 
geïnspireerd door de heterogene intravitreale mobiliteit van kationische nanopartikels. Hoewel de 
meerderheid geïmmobiliseerd leek, bleef een kleine fractie bijna even mobiel als de gePEGyleerde 
nanopartikels. We leidden hieruit af dat deze kationische nanopartikels elektrostatisch omhuld 
werden met negatief geladen componenten uit het glasvocht. Het voornaamste anionische 
component in glasvocht is hyaluronzuur (HA), een glycosaminoglycaan dat alomtegenwoordig in het 
lichaam kan gevonden worden. Door de intrinsieke biocompatibiliteit en het niet-immunogene 
karakter heeft HA in de voorbije jaren de aandacht van de wetenschappelijke gemeenschap 
getrokken voor aflevering van geneesmiddelen. Hoofdstuk 3 is gewijd aan een algemene introductie 
van HA en een overzicht van diens gebruik in het afleveren van geneesmiddelen en nucleïnezuren.  
In Hoofdstuk 4 gebruiken we HA om de kationische p(CBA-ABOL)/pDNA polyplexen (cfr. Chapter 2) 
elektrostatisch te omhullen. We postuleerden dat HA de nanomedicijnen een hydrofiele, negatief 
geladen oppervlakte zou toebrengen, waarmee hun intravitreale mobiliteit verhoogd wordt. 
Bovendien werd verwacht dat hun cellulaire opname en transfectie efficiëntie zou behouden blijven, 
aangezien HA een gekend ligand is voor de CD44 receptor die in vele retinale celtypes tot expressie 
komt. Aangezien reeds voldoende beschreven is hoe lichaamseigen HA verschillende biologische 
functies uitoefent afhankelijk van diens moleculaire gewicht (MW), onderzochten we vervolgens het 
mogelijke effect van MW op elektrostatische omhulde HA-polyplexen door HA te gebruiken met een 
MW van 22 kDa, 137 kDa en 2700 kDa. We ondervonden dat een elektrostatische omhulling van HA 
op polyplexen mogelijk was, ongeacht het gebruikte MW. Belangrijker nog, de grootte-orde van deze 
ternaire poyplexen bleef gelijk en hun mogelijkheid tot complexatie van pDNA werd niet in het 
gedrang gebracht. De intravitreale mobiliteit van de bekomen nanopartikels werd beoordeeld met 
het ex vivo model, voorgesteld in Hoofdstuk 2. Polyplexen omhuld met HA van 22 kDa en 137 kDa 
vertoonden een sterk verhoogde mobiliteit in het glasvocht, terwijl een omhulling van  2700 kDa 
geen significante verbetering van intravitreale mobiliteit teweeg bracht. Cellulaire opname en 
transfectie efficiëntie in ARPE-19 cellen werd in vitro geëvalueerd met flowcytometrie. Aangezien 
aangetoond werd dat een hoger MW van HA overeenkomt met een hogere affiniteit voor de CD44-
receptoren, waren we verrast te ontdekken dat een omhulling met 137 kDa HA resulteerde in een 
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lagere expressie van transgenen dan wanneer 22 kDa HA gebruikt werd. Niettegenstaande de 
exponentiële toename van het gebruik van HA bij geneesmiddelenaflevering, wijzen deze resultaten 
erop dat de effecten van verschillen in MW nog niet volledig doorgrond zijn en moedigen ze verder 
onderzoek aan.  
Onze voorgaande resultaten toonden aan dat een elektrostatische HA-omhulling op kationische, 
polymerische gentherapeutica leidde tot een verhoogde intravitreale mobiliteit zonder drastische 
invloed op de in vitro transfectie efficiëntie. Niettegenstaande kan de in vivo stabiliteit van deze 
elektrostatische complexen in vraag getrokken worden, voornamelijk in extracellulaire matrices en 
weefsels zoals de retina. In Hoofdstuk 5 vergelijken we de geschiktheid van twee verschillende 
manieren van HA-omhulling op gentherapeutica opgebouwd uit pDNA en DOTAP:DOPE liposomen. 
HA werd ofwel elektrostatisch omhuld op reeds gevormde lipoplexen, ofwel opgenomen in de lipide 
dubbellaag met behulp van een covalent conjugaat van HA en DOPE-lipiden. Zowel de 
elektrostatische als covalente koppeling van HA aan de lipoplexen resulteerde in kleine, 
monodisperse nanopartikels met een negatieve oppervlaktelading, waarbij de mogelijkheid tot 
complexeren van pDNA behouden bleef. Na intravitreale injectie bleven HA-omhulde lipoplexen 
mobiel ongeacht de koppelingsstrategie. Verschillen tussen deze strategieën werden voornamelijk 
opgemerkt op het cellulaire niveau: waar elektrostatische omhulling geen significante invloed had op 
in vitro transfectie efficiëntie, werd een achtvoudige verhoging in transgen expressie vastgesteld 
voor de covalent gekoppelde HA-lipoplexen. Een laatste barrière die in deze studie onderzocht wordt 
is de permeatie doorheen het vitreoretinale raakvlak. We konden aantonen met in vivo data in 
muizen dat intravitreale injectie van covalent gekoppelde HA-lipoplexen resulteerde in transgen 
expressie in cellen zo ver als de subretinale ruimte na 72 uur. Transfectie efficiëntie van 
elektrostatische HA-lipoplexen daarentegen bleef beperkt tot de binnenste lagen van de retina. Het 
vitreoretinale raakvlak wordt algemeen gezien als een barrière tegen passief transport van 
nanopartikels naarheen de retina. Daarom ondersteunen wij de hypothese dat de lipoplexen 
getransporteerd worden vanuit het glasvocht tot in de retinale cellagen door selectieve opname en 
transcytose door Müller cellen.  
Zoals reeds werd toegelicht zullen gentherapeutica na intravitreale injectie op verschillende barrières 
stuiten: (i) zij moeten mobiel blijven in het glasvocht, (ii) zij moeten in staat zijn doorheen de retinale 
cellagen te migreren en (iii) zij moeten opgenomen worden door de doelwitcellen. Eén van de 
grootste barriéres voor niet-virale gentherapie bevindt zich na cellulaire opname. In Hoofdstuk 5 
merkten we een duidelijk verschil op in transfectie efficiëntie tussen covalente en elektrostatische 
HA-lipoplexen. We nemen aan dat dit verschil niet louter te wijten is aan verschillen in de opname 
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efficiëntie, maar veeleer door variaties in intracellulaire transportprocessen en de daaropvolgende 
endosomale ontsnapping. Nadat partikels opgenomen worden door de cel, meestal via endocytose, 
bevinden zij zich inderdaad ingesloten in de endosomen. Alvorens zij hun therapeutisch effect 
kunnen uitoefenen moeten ze eerst vanuit deze intracellulaire vesikels kunnen ontsnappen naar het 
cytosol. Verschillende methodes om dit te bewerkstelligen zijn reeds gedocumenteerd, maar tot op 
heden heerst nog geen consensus over hoe de efficiëntie van deze ontsnapping accuraat en 
representatief te meten.  Als aanzet voor toekomstig onderzoek, geven we in Hoofdstuk 6 een 
overzicht van de verschillende testen die tot dusver gebruikt worden endosomale ontsnapping te 
evaluaren. We beginnen met een inleiding tot het endosoom als barriére voor de intracellulaire 
aflevering van nanomaterialen in het algemeen en halen de verschillende methoden aan om deze 
barrière te doorbreken. Vervolgens wordt een uitgebreid overzicht aangeboden van de verschillende 
testen en methodes die toegepast worden ter evaluatie van ofwel (i) het mechanisme achter de 
endosomale ontsnapping, ofwel (ii) de kwantiteit van endosomale ontsnapping.  
Ter afsluiting bespreekt Hoofdstuk 7 de mogelijke vooruitzichten en evoluties van het veld van 
retinale gentherapie en waarop onderzoek voornamelijk gericht zal worden ter verbetering en 
vooruitgang van retinale gentherapie naar een klinische setting.  
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A L G E M E N E  C O N C L U S I E  
Dit proefschrift richt zich op de optimalisatie van de aflevering van therapeutische nucleïnezuren 
naar de retina via intravitreale injectie. Het corpus vitreum vormt een niet te onderschatten barrière 
voor transport van nanopartikels, en optimalisatie van nanomedicijnen voor intravitreale injectie 
vereisen een methode om accuraat hun mobiliteit in intact glasvocht te bepalen. Aan de hand van 
dergelijke methode vonden we dat een optimale intravitreale mobiliteit kon bereikt worden door 
nanopartikels te omhullen met een hydrofiele, anionische oppervlaktelaag, bvb. met behulp van 
hyaluronzuur (HA). In dit proefschrift werd HA geëvalueerd als dergelijke strategie op polymerische 
en lipide gentherapeutica. Hoewel HA veelvuldig gebruikt wordt in het veld van geneesmiddelen-
aflevering, dringen we er op aan dat toekomstig onderzoek rekening moet houden met de verschillen 
in gebruikt moleculair gewicht en koppelingsstrategie (bvb. elektrostatisch of covalent). Wij besloten 
dat het gebruik van HA als omhullingsstrategie resulteerde in de mogelijkheid van nanopartikels om 
(i) het corpus vitreum als barriére te omzeilen en te migreren naar de retina, (ii) de vitreoretinale 
barriére te doordringen en te verspreiden doorheen de retina, vermoedelijk door opname door de 
Müller cellen en (iii) transgen expressie te induceren na opname in de doelwitcellen, vermoedelijk 
door CD44-receptor gemedieerde endocytose. Een laatste hindernis voor niet-virale gentherepautica 
wordt aangetroffen in hun inefficiëntie om te ontsnappen naar het cytosol na cellulaire opname. Als 
de therapeutische efficiëntie van niet-virale nanomedicijnen ooit het niveau van de virale varianten 
moet halen, zal onderzoek ook gericht moeten worden op het optimaliseren van deze intracellulaire 
ontsnapping. 
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EVER SCIENCE FOR SIGHT, Nice, France (October 10 – 13, 2012) 
 
Published abstract: Martens, T.F., et al., An ex vivo assay to measure the intravitreal mobility of nanomedicines for 
retinal gene therapy. 2012 Acta Ophthalmologica Special Issue: Abstracts from the 2012 European Association for 
Vision and Eye Research Conference: Volume 90, Issue Supplement s249, page 0, September 2012 (DOI: 
10.1111/j.1755-3768.2012.4261.x) 
 
- “Measuring the intravitreal mobility of nanoparticles with single particle tracking 
microscopy”, Martens TF, Vercauteren D, Forier K, Deschout H, Remaut K, Demeester J, De 
Smedt SC, Braeckmans K 
BIOPHARMACY DAY, Utrecht, The Netherlands (November 09, 2012) 
 
- “Measuring the intravitreal mobility of nanoparticles to aid in the rational design of gene 
nanomedicines for retinal disorders”, Martens TF, Vercauteren D, Forier K, Deschout H, 
Remaut K, Demeester J, De Smedt SC, Braeckmans K 
10TH ISOPT CONFERENCE, Paris, France (March 07 – 10, 2013) 
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- “Single particle tracking to measure the mobility of retinal gene therapeutics after injection 
in the vitreous humor of the eye”, Martens TF, Vercauteren D, Forier K, Deschout H, Remaut 
K, Demeester J, De Smedt SC, Braeckmans K 
FOCUS ON MICROSCOPY, Maastricht, The Netherlands (March 24 – 27, 2013) 
 
- “Evaluating hyaluronic acid as a coating strategy for intravitreally injected nanomedicines 
for retinal gene therapy”, Martens TF, Remaut K, Demeester J, De Smedt SC, Braeckmans K 
EVER SCIENCE FOR SIGHT, Nice, France (September 17 – 19, 2013) 
 
- “Bio-compatible Hyaluronic acid as a Coating Strategy to Improve Intravitreal Delivery of 
Gene Nanomedicines to the Retina”, Martens TF, Remaut K, Demeester J, De Smedt SC, 
Braeckmans K 
ISOPT CLINICAL 11TH SYMPOSIUM, Reykjavik, Iceland (June 19 – 22, 2014) 
P O S T E R  P R E S E N T A T I O N S  
- Single Particle Tracking to Evaluate the Diffusive Properties of Nanoscopic Drug Carriers in 
Vitreous Humour, Thomas F Martens, Dries Vercauteren, Katrien Forier, Katrien Remaut, 
Stefaan C De Smedt, Kevin Braeckmans  
FOCUS ON MICROSCOPY 2011, Konstanz, Germany (April 17-20, 2011) 
 
- Evaluating Intravitreal Mobility of Nanomedicines in Ocular Gene Therapy  
Thomas F Martens, Dries Vercauteren, Katrien Forier, Katrien Remaut, Stefaan C De Smedt, 
Kevin Braeckmans  
ESF 3RD SUMMER SCHOOL IN NANOMEDICINE, Wittenberg, Germany (June 19-24, 2011) (1st poster 
prize) 
 
- Evaluating Intravitreal Mobility of Nanomedicines in Ocular Gene Therapy  
Thomas F Martens, Dries Vercauteren, Katrien Forier, Katrien Remaut, Stefaan C De Smedt, 
Kevin Braeckmans  
NB-PHOTONICS ANNUAL MEETING, Ghent, Belgium (September 23, 2011) 
 
- Hyaluronic acid as a coating strategy for nanomedicines in retinal gene therapy 
Thomas F Martens, Katrien Remaut, Laurent Hansen, Thomas De Beer, Jo Demeester, Stefaan 
C De Smedt, Kevin Braeckmans  
NB-PHOTONICS ANNUAL MEETING, Ghent, Belgium (September 21, 2012) 
 
- An ex vivo assay to measure the mobility inside the eye of nanomedicines for retinal gene 
therapy, Martens TF, Vercauteren D, Forier K, Deschout H, Remaut K, Demeester J, De 
Smedt SC, Braeckmans K  
XXTH ANNUAL ESGCT CONFERENCE, Versailles, France (October 26-29, 2012) 
 
Published abstract: Martens, T.F., et al., An ex vivo assay to measure the mobility inside the eye of nanomedicines 
for retinal gene therapy. Human gene therapy, 2012. 23(10): p. A81-A82. 
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- Gene therapeutics for retinal disorders: measuring nanomedicine mobility in the eye 
Thomas F Martens, Dries Vercauteren, Katrien Forier, Hendrik Deschout, Katrien Remaut, 
Stefaan C De Smedt, Kevin Braeckmans  
KNOWLEDGE FOR GROWTH, Ghent, Belgium (May 05, 2013) 
 
- Hyaluronic acid as a coating strategy for nanomedicines in retinal gene therapy 
Thomas F Martens, Katrien Remaut, Laurent Hansen, Thomas De Beer, Jo Demeester, Stefaan 
C De Smedt, Kevin Braeckmans  
NB-PHOTONICS ANNUAL MEETING, Ghent, Belgium (September 20, 2013) 
 
- Hyaluronic acid as a coating strategy for nanomedicines in retinal gene therapy 
Thomas F Martens, Katrien Remaut, Laurent Hansen, Thomas De Beer, Jo Demeester, Stefaan 
C De Smedt, Kevin Braeckmans  
BIOPHARMACY DAY, Ghent, Belgium (December 18, 2013) 
 
- Hyaluronic acid as a coating strategy for nanomedicines in retinal gene therapy 
Thomas F Martens, Katrien Remaut, Jo Demeester, Stefaan C De Smedt, Kevin Braeckmans 
ESCDD, Egmond-aan-Zee, The Netherlands (April 17 - 19, 2014) 
 
- Hyaluronic acid as a coating strategy for nanomedicines in retinal gene therapy 
Thomas F Martens, Katrien Remaut, Jo Demeester, Stefaan C De Smedt, Kevin Braeckmans 
KNOWLEDGE FOR GROWTH, Ghent, Belgium (May 08, 2014) 
 
- Hyaluronic acid as a coating strategy for nanomedicines in retinal gene therapy 
Thomas F Martens, Katrien Remaut, Jo Demeester, Stefaan C De Smedt, Kevin Braeckmans 
NB-PHOTONICS ANNUAL MEETING, Ghent, Belgium (September 08, 2014) 
 
- Hyaluronic acid as a coating strategy for nanomedicines in retinal gene therapy 
Thomas F Martens, Katrien Remaut, Jo Demeester, Stefaan C De Smedt, Kevin Braeckmans 
µFIBR, Hasselt, Belgium (October 03, 2014) 
G R A N T S ,  A W A R D S  A N D  H O N O R S  
- 1st poster prize at the 3rd Summer School in Nanomedicine by the European Science 
Foundation (ESF) 
- Facultaire Commissie Wetenschappelijk Onderzoek (FCWO) travel grant (Faculty of 
Pharmaceutical Sciences, Ghent) for Focus on Microscopy 2011 
- FWO travel grant for EVER Science for Sight 2012 
- Facultaire Commissie Wetenschappelijk Onderzoek (FCWO) travel grant (Faculty of 
Pharmaceutical Sciences, Ghent) for EVER Science for Sight 2013 
- 2014 FRO grant laureate (Shared  1st place) 
- Facultaire Commissie Wetenschappelijk Onderzoek (FCWO) travel grant (Faculty of 
Pharmaceutical Sciences, Ghent) for Knowledge for Growth 2014 
- Facultaire Commissie Wetenschappelijk Onderzoek (FCWO) travel grant (Faculty of 
Pharmaceutical Sciences, Ghent) for ISOPT Clinical 11th symposium  
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… kort en bondig, een ‘dank’-woord. Uiteraard volstaat één woord niet om mijn dankbetuigingen over 
te brengen aan iedereen die mij – op welke manier dan ook - geholpen heeft de eindmeet te behalen. 
Naar t schijnt is het dankwoord ook wel het meest gelezen hoofdstuk van een doctoraat, dus voel ik 
me ergens verplicht om toch wat meer neer te pennen dan ‘Dank’. 
Het is standaard dat de promotor eerst bedankt wordt, soms pro forma, soms met reden. Kevin, geloof 
me dat het in dit geval met reden is. In een doctoraat is zelfstandig leren werken een heel belangrijk 
aspect, maar dat kan vlug fout lopen zonder goede begeleiding. Ik was altijd, en ben nog steeds, 
verbaasd over hoe jouw kleine, to-the-point aanpassingen het verschil kunnen maken tussen een 
‘goede’ tekst, en een ‘uitstekende’ tekst (of abstract, of presentatie, …). Ik weet nog dat ik soms uren 
op bepaalde zinnen kon staren, en dagen over bepaalde paragrafen kon nadenken en geen zinvolle 
manier vond om ze coherent over te brengen. Enkele kleine woordjes hier en een komma daar van 
jouw kant, en alle puzzelstukjes vielen samen. Ondanks je drukke schema stond je deur ook altijd open 
voor feedback, of kon je last-minute nog een abstract of poster nakijken, of vond je ergens tóch nog 
een half uurtje voor even samen te zitten om het project te bespreken en me weer op het goede spoor 
te brengen. Katrien (Remaut, nvdr), ook jij kon altijd tijd vrijmaken voor onze doc-meetings en ook jij 
kon altijd de juiste vragen stellen en het project in de juiste richting laten verdergaan. Bij deze, Kevin 
en Katrien, zonder jullie was ik waarschijnlijk nog niet aan Hoofdstuk 2 geraakt. Bedankt om me de 
vrijheid te geven om mijn eigen doctoraatsproject te laten vormen, én vooral om waakzaam in te 
springen als ik het doel uit ogen begon te verliezen. 
Stefaan en Jo, bedankt ook aan jullie om tijd vrij te maken in de Monday meetings om jullie visies en 
ervaring te delen met mij en op die manier het project te laten groeien tot wat het uiteindelijk 
geworden is. Stefaan, ik heb altijd gerespecteerd hoe jij met één zin of vraag tot de kern van een project 
kan komen, en ons kan doen inzien wat de relevantie er van is. Een project moet een doel hebben, en 
daar werden we gelukkig door jou aan herinnerd! Trouwens, ongelooflijk hoe je aan zo’n tempo 
nieuwe ideeën kan blijven aanbrengen! Het woord ‘visionair’ komt even in me op. Nu je vermoedelijk 
weer wat meer tijd zal hebben voor het wetenschappelijke, vind je hopelijk de tijd om al (of alleszins 
een deel van) deze ideeën realiteit te laten worden. Jo, ook jij was essentieel voor de vorming van deze 
thesis. Ik herinner me nog goed de eerste maal toen we het idee van een hyaluronzuur-coating 
opperden: ‘Hyaluronzuur is mijn favoriete molecule’ zei je toen, en vanaf dan wist ik zeker dat dit 
project met jouw kennis ergens naartoe zou gaan. Bovendien, nog een speciale dankbetuiging naar jou: 
als ik kijk naar de groep hoe die nu is, en de instrumenten die wij tot onze beschikking hebben, en de 
kansen die we krijgen voor ons werk te presenteren op (inter)nationale congressen, en de 
werkmiddelen die we kunnen benuttigen voor reagentia en dergelijke, en alle andere dingen die ik nu 
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niet kan opnoemen… Ik besef maar al te goed dat ik gedurende 4 jaar het voorrecht gehad heb om te 
doctoreren in het labo biochemie. En dankzij jou is de groep geworden wat die nu is: een plezier om 
te doctoreren. Velen moeten het met minder doen. 
Dat brengt me bij de mensen ‘achter de schermen’. Katharine en Ilse, bedankt om alles te regelen, van 
inschrijvingen van congressen, tot de facturen van het slachthuis, tot de terugbetalingen van onkosten 
en al die andere talloze zaken die jullie doen die het labo doen draaien en ervoor zorgen dat wij niet 
stilvallen. Bart, dé go-to persoon voor … alles eigenlijk. Vanaf dag één kon ik je lastigvallen met 
allerhande praktische zaken (waar staat dit, hoe werkt dat, hebben we zoiets, kan je dat bestellen, …). 
En waar je de tijd vond, weet ik niet, maar je was altijd bereid om me onmiddellijk uit de nood te 
helpen. Zonder jou zou dit doctoraat waarschijnlijk dubbel zo lang geduurd hebben, dus ook aan jou 
een welgemeende dank je! 
Dries, Katrien F, Stephan en Karen, mijn bureaugenoten! Dries, Het was maar 1 jaar, maar het zal me 
altijd bijblijven. Samen werken aan het vitreum project was de basis voor de daaropvolgende 4 jaren, 
en het was mede jouw enthousiasme dat me gedreven heeft mijn doctoraat te vormen rond oculaire 
gentherapie. Katrien F, samen uit, samen thuis denk ik spontaan! 4 jaar samen gedoctoreerd, in 
hetzelfde bureau begonnen, samen naar een nieuwe bureau verhuisd, (ongeveer) samen eerste paper 
ingediend, (ongeveer) samen eerste review ingediend, en nu (ongeveer) samen ons doctoraat afgelegd. 
Het deed ongelooflijk veel dat we in die drukke periodes tenminste ons hart konden luchten aan elkaar, 
omdat we wisten dat we in exact hetzelfde schuitje zaten. Tel daar dan nog Stephan en Karen bij als 
bureaugenoten, en je gaat elke dag met plezier gaan werken! Karen, jij neemt nu het oculaire project 
over, waarvoor dank; ik hoop dat het je evenveel kan boeien als het mij geboeid heeft, maar dat hoop 
ik zelfs niet meer, dat weet ik gewoon zeker. Het moet ook niet altijd serieus zijn, onze 3D-bureau-
stressball-pong zal ik moeten missen, maar de gesprekken hopelijk niet! Stephan, gij ook, altijd naarstig 
aan t werk, maar chance dat we af en toe ook eens konden zeveren. Guy code en vuistjes en 
dergelijke… Ik kom wel nog eens langs om die Russische wijn soldaat te maken, for ol’ times sake. 
 All work and no play makes Jack a dull boy. Het heeft bijna 4 jaar geduurd, en bij momenten lange 
dagen en nachten werken, maar gelukkig waren de collega’s er om de sfeer er in te houden. Karen, 
Complex, Katrien, Eline, Lenny, Heleen, Joke, Laura, CPO, Lotte, Elisa, Freya, Ray Verbeek, Ine, Oliwia, 
3S, Barry G, Bacardi Broezer, George, Hua, Bart L, Koen Ra, Ine L, Katrien R, Hendrik, … té veel goede 
herinneringen om op de noemen. Talloze traktaties aan de koffietafel/lunchtafel; s middags met 15 
lunchen aan een tafel, binnen of buiten, waar het normaalgezien met 8 al krap zou zijn, en toch nog 
plaats vinden voor een collega die wat later toekomt; sayway of the day; vuistjes; op de Duitse 
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Autobahn in panne vallen, en Jean-Marie Pfaffs-gewijs duidelijk maken dat de motor broebelt; de 
metal-heads in Dessel laten horen wat echte muziek is (One night in Bangkok and the world’s your 
oyster), gekleed als Burger Kings; ternauwernood aan de dood ontsnappen op voorgenoemde 
Autobahn, al zingende in duet en – je kan het al raden – gekleed als een Burger King; laptops met 
belangrijke presentaties die vergeten worden in de euforie van een conference dinner; Ekiden-
marathons; s nachts ronddolen in Blankenberge op zoek naar het albekende en uiterst hippe “Riderz” 
café; Laser Karaoke in Versailes (“Qui est tu?”); vuistjes; de obligate vuurdoop van Spaanse Erasmus-
studentes in de nu al epic-housewarming-parties van de patron en eega; de finale van Battle of Talents, 
ik vind ons nog steeds beter dan spraakwaterval Hendrik V!; na het werk “eentje gaan drinken in t park” 
en 12 uur later op de Vlasmarkt belanden; iets met sigaren en batterijen; de teleurstelling van 
‘Generation aan Zee’; Rudimental; 80s feestjes, kinderdroomfeestjes, Geordie shore feestjes, thrift 
shop feestjes, … (dat er nog velen mogen volgen); vuistjes; bakken bier willen vervoeren met een go-
cart; Fine-tunen en dan spontaan een Beatles-cover band oprichten, en diezelfde avond tot inzicht 
komen dat het misschien toch niet dat is; Keizer Karel in De Drij Zinne (propere vloer hebben ze daar); 
La Chouffe en de perfecte fine-tuning; Complex met de wc-rol, natuurlijk; Mad Dogs, da we ze nog 
geire meuge meuge; Sosuke; testosteron-boosts met beef burgers en high-body-count-action movies; 
ondergedompeld worden in de wondere wereld van whiskey-tasting; Oude Vismijn; fietsen, met vallen 
en opstaan; De Kerstman met wiped cream; old-skool skaten aan den Aldi; … en talloze andere zaken 
waar ik nu even niet op kan komen. Het is me wat geweest, en hoewel dit doctoraatswerk er niet meer 
langer op zal worden, hoop ik dat de lijst met bovenstaande herinneringen dat wél zal. 
Over the course of 4 years, I had the privilege of meeting new colleagues from all over Europe. I’d really 
like to thank Prof. Johan Engbersen, Prof. Elias Fattal, Prof. Serge Picaud and Prof. Thomas Langmann 
for their time and allowing me in their lab to learn new methods. Thais, thanks for always finding the 
time to prepare the conjugate, I hope you will be happy with the result! I remember coming to Paris 
for just 1 week, but I was amazed at your hospitality (and Alice, Leticia and Sabrina of course) and I 
truly had a great time. If you’re ever in Ghent let me know! Marcus, it’s a pity we didn’t get the chance 
to explore Köln anymore. You’ve already shown me the culinary highlights, now the rest! Nog één 
person die zéker niet mag ontbreken in deze dankbetuiging is Ronny Poppe. Ronny, merci voor 
gedurende 4 jaar de ogen uit koeienkoppen te snijden zodat ik mijn onderzoek kon uitvoeren! Ik heb 
mijn opvolgers al het principe van de Ronny-guarantee uitgelegd: “Als Ronny Poppe de ogen uitsnijdt, 
is het gegarandeerd een geslaagd experiment”.  
Een doctoraat is uiteraard geen 9-to-5 job, en het loopt ook niet altijd van een leien dakje. Het is soms 
moeilijk om dat van je af te zetten, zelfs al ben je niet op het labo, maar ik ben toch blij dat ik de nodige 
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afleiding kon vinden op training, in de Newcastle, in Ledeberg, in de Ardennen, in Praag … of gewoon 
in Gent. Vooral een speciale dank naar mijn ouders, die mij altijd met trots gesteund hebben, en die 
altijd begrip hebben getoond al die keren dat ik geen tijd had om eens langs te komen. Bedankt! 
Save the best for last! Charlotte, ik zie je ongelooflijk graag. Ik zou nog 200 bladzijden moeten schrijven, 
moest ik alles willen neerpennen waarvoor ik u dankbaar ben. Zonder jou had ik het waarschijnlijk al 
opgegeven, jij kent mij het beste en kan me doen relativeren. Als ik alweer tegen de klok aan het 
werken was, hielp je mij waar nodig en kon je mij weer tot kalmte brengen. Ik herinner me nog in het 
begin van mijn doctoraat, nachtwerk om mijn eerste wetenschappelijk poster af te werken, en dankzij 
jouw creatieve hulp met de lay-out omstreeks 1u30 was die toch tegen de volgende dag klaar! Nu op 
het einde van mijn doctoraat, hetzelfde liedje voor de cover … De voorbije 4 jaar zijn we nog meer naar 
elkaar toe gegroeid, we zijn gaan samenwonen, we zijn verloofd! Met onze verbouwingen erbij is het 
een hectische periode geweest de voorbije 10 maanden, maar dankzij jou is dat allemaal goed 
gekomen. Je zag wanneer ik tegen de limiet aan dreigde te komen, en nam zonder verpinken de 
planningen en verbouwingen grotendeels over zodat ik mij op het doctoraat kon focussen. Bedankt 
om begrip te tonen, bedankt om mij te helpen, bedankt om er voor mij te zijn de voorbij 12+ jaren. Je 
bent nu ook bezig aan een PhD-avontuur, ik hoop dat ik hetzelfde kan betekenen voor jou als jij voor 
mij. Ik denk dat dat de enige manier zal zijn om mijn dank écht te tonen.  
Eén woord volstond inderdaad niet voor de dankbetuigingen, en na 3.5 bladzijden heb ik nóg het 
gevoel dat ik vrienden, collega’s, kennissen uit de boot heb laten vallen. Maar dat wil niet zeggen dat 
ik ze vergeten ben, aan iedereen die mij rechtstreeks of onrechtstreeks geholpen heeft de voorbije 4 
maanden: bedankt!  
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